Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof

ABSTRACT

Provided are an FGFR4 inhibitor having the structure of formula (1), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and can be widely used in the preparation of a drug for treating cancers, especially prostate cancer, liver cancer, pancreatic cancer, esophageal carcinomas, gastric cancer, lung cancer, breast cancer, ovarian carcinomas, colon cancer, skin cancer, glioblastomas or rhabdomyosarcomas, and is expected to be developed into a new generation of FGFR4 inhibitor drugs.

TECHNICAL FIELD

The present invention belongs to the field of medicament synthesis, and in particular relates to an FGFR4 inhibitor, preparation method and pharmaceutical use thereof.

TECHNICAL BACKGROUND

Fibroblast growth factor (FGF) is a family of 22 structurally related polypeptides with diverse biological activities that can regulate cell proliferation, differentiation and migration, and play a major role in the process of limb development, angiogenesis, tissue repair, tumor formation and the like. (Eswarakumar et al., 2005 Cytokine Growth Factor Rev 16: 139-149 Ornitz and Itoh 2001 Genome Bio 12: Reviews 3005).

The receptors for FGF (FGFR) belong to a family of RPTK of receptor tyrosine kinases. Four FGFRs, FGFR1, FGFR2, FGFR3 and FGFR4, have been identified to date (Ullrich and Schlessinger, 1990 Cell 61:203). The interaction between receptors and the corresponding ligands FGF leads to receptor dimerization and autophosphorylation, thereby initiating multiple downstream signaling cascades including MAPK and AKT (Powers et al., 2000 Endocr Relat Cancer 7: 165-197).

FGFR1-3 has been found to be overexpressed, mutated or translocated in a variety of tumors (including myeloma, breast cancer, stomach cancer, colon cancer, bladder cancer, pancreatic cancer, and hepatocellular carcinoma), and considered to be driver gene in cancer (Chesi et al., 2001 Blood 97:729-726; Gowardhan et al., 2005 Br J Cancer 92: 320-327; Jaakkola et al., 1993 Int J Cancer 54:378-282; Jang et al., 2001 Cancer Res 61: 3541-3543). Some FGFR inhibitors have also been developed in the clinical and preclinical development process. However, previous studies have shown that FGFR1 can regulate the level of phosphate, so pan-FGFR inhibitors may pose safety concerns.

Hepatocellular carcinoma (CC) is one of the leading causes of cancer-related deaths in China and is one of the fastest growing cancers every year (Shariff et al., 2009 Expert Rev Gastroenterol Hepato 13: 353-367). Currently, the first-line treatment option is sorafenib, there are no approved second-line treatment, and there is still a need for targeted therapy with anti-tumor agents.

Overexpression of FGF19 is present in 5-10% of hepatocellular carcinoma patients, whereas FGFR4 is a dominant FGFR present in human hepatocytes, and its high expression in hepatocytes is found to be associated with the aggressiveness of hepatocellular tumors. Therefore, FGFR4 plays a very important role in liver cancer. In addition, the interaction of FGF19 and FGFR4 is also considered to be related to the aggressiveness of other cancers (such as gastric cancer, prostate cancer, lung cancer, colorectal cancer, pancreatic cancer, and ovarian cancer) (Ye et al, 2011 Cancer 5304-5313; Xu et al, 2011 BMC Cancer 11:84; Fawdar et al, 2013 PNAS 110:12426-12431).

At present, some FGFR inhibitors have entered into the clinical research stage as anti-tumor drugs, but mostly inhibitors against FGFR1, 2 and 3, with weaker inhibition of FGFR4 activity. The inhibition of FGFR1-3 has on-target side effects such as hyperphosphatenia. Highly selective inhibitor of FGFR4 can effectively treat cancer caused by abnormal FGFR4 signaling, and can avoid the side effects caused by FGFR1-3 inhibition such as hyperphosphatemia. Highly selective small molecule inhibitors against FGFR4 have significant application prospects in the field of anti-tumor targeted therapy. Therefore, the development of a novel anti-tumor agent that can selectively target FGFR4 as a good drug candidate will meet the needs of domestic liver cancer and other anti-tumor target therapy, and have the advantages of better safety and higher selectivity.

SUMMARY OF THE INVENTION

An object of the present invention is to provide an FGFR4 inhibitor, preparation method and pharmaceutical use thereof.

The first aspect of the invention provides a compound of formula ( ), a stereoisomer or a pharmaceutically acceptable salt thereof:

wherein, X₁ is —C(R₇)— or N;

X₂, X₃, and X₅ are each independently selected from the group consisting of —(CR₈)_(n)—, —C(O)—, —N(R₉)—, N and S;

X₄ is C or N,

Z is selected from the group consisting of C₁₋₈ alkylene, C₂₋₈ alkenylene, C₂₋₈ alkynylene, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl and 5-10 membered heteroaryl, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₈ alky, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—OC(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R¹⁴, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁, above groups are further more optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ haloalkyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—OC(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁;

R₁ is selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₁₋₈ alkoxyC₁₋₈ alkyl, C₃₋₈ cycloalkyloxyC₁₋₈ alkyl, C₃₋₈ cycloalkylC₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl and C₁₋₈ alkanoyl;

R₂, R₃, R₄, R₅, R₆ and R₇ are each independently selected from the group consisting of H, deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈S(O)(NR₉)R₁₀, —C₀₋₈—P(O)(R₁₀)₂, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁, or R₂ and R₄, R₃ and R₅, R₄ and R₆, R₅ and R₆ are taken together with the directly attached carbon atoms to form a C₅₋₁₀ cycloalkyl, 5-10 membered heterocyclyl, 5-10 membered aryl or 5-10 membered heteroaryl,

above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ haloalkyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁;

R₈ is selected from the group consisting of H, deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—S(O)(NR₉)R₁₀, —C₀₋₈—P(O)(R₁₀)₂, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)R₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁,

above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ haloalkyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁, above groups are further more optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ haloalkyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(C)OR₁₁;

R₉ is selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl and C₁₋₈ alkanoyl, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ haloalkyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(C)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(C)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁;

R₁₀ is selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₁₋₈ haloalkyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, amino, mono-C₁₋₈ alkylamino, di-C₁₋₈ alkylamino and C₁₋₈ alkanoylamino;

R₁₁ is selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl and 5-10 membered heteroaryl, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ alkylthio, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₁₋₈ alkylsulfonyl, C₁₋₈ alkylsulfonylamino, amino, mono-C₁₋₈ alkylamino, di-C₁₋₈ alkylamino, ═O or hydroxyl;

R₁₂ is selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ alkoxy, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₅₋₁₀ aryloxy and 5-10 membered heteroaryloxy, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ alkylthio, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₁₋₈ alkylsulfonyl, C₁₋₈ alkylsulfonylamino, amino, mono-C₁₋₈ alkylamino, di-C₁₋₈ alkylamino, ═O or hydroxyl;

R₁₃ and R₁₄ are each independently selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀aryl, 5-10 membered heteroaryl, C₁₋₈ alkylsulfonyl and C₁₋₈ alkanoyl, or R₁₃ and R₁₄ are taken together with the directly attached nitrogen atom to form a 4-10 membered heterocyclyl,

above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ alkylthio, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₁₋₈ alkysulfonyl, C₁₋₈ alkylsulfonylamino, amino, mono-C-s alkylamino, di-C-s alkylamino, ═O or hydroxyl;

m is 0 or 1;

n is 0, 1 or 2;

r is 0, 1 or 2;

provided that, when X₃ is —(CR₈)_(n)—, X₂ is —C(O)—, X₄ is C, X₅ is selected from the group consisting of —N(R₉)— N, O and S; when X₃ is —C(O)—, X₂ is —N(R₉)—, and Z is selected from the group consisting of C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl and phenyl.

In a further preferred embodiment, in the compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof, Z is selected from the group consisting of C₁₋₄ alkylene, C₂₋₄ alkenylene, C₂₋₄ alkynylene, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl and 5-8 membered heteroaryl, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄—, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁, above groups are further more optionally substituted by one or more substituents selected from the group consisting of deuterium halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₁₀ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₁, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁;

R₁ is selected from the group consisting of H, deuterium, C₁₋₄ alkyl, C₁₋₄ alkoxyC₁₋₄ alkyl, C₃₋₆ cycloalkyloxyC₁₋₄ alkyl, C₃₋₆ cycloalkylC₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl and C₁₋₄ alkanoyl;

R₂, R₃, R₄, R₅, R₆ and R₇ are each independently selected from the group consisting of H, deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₁₋₄ alkenyl. C₂₋₄ alkynyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—S(O)(NR₉)R₁₀, —C₀₋₄—P(O)(R₁₀)₂, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁, or R₂ and R₄, R₃ and R₅, R₄ and R₆, R₅ and R₆ are taken together with the directly attached carbon atoms to form a C₅₋₈ cycloalkyl, 5-8 membered heterocyclyl, 5-8 membered aryl or 5-8 membered heteroaryl,

above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁.

In a further preferred embodiment, in the compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof, Z is selected from the group consisting of C₁₋₂ alkylene and the following structures:

above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁, above groups are further more optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido. C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁.

In a further preferred embodiment, in the compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof, R₁ is selected from the group consisting of H, deuterium, methyl, isopropyl, methoxyethyl, cyclopropyloxymethyl, cyclopropylmethyl, allyl, cyclopropyl and acetyl;

R₂, R₃, R₄ and R₅ are each independently selected from the group consisting of H, deuterium, halogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, —C₀₋₄—O—R₁₁ and —C₀₋₄—NR₁₃R₁₄, or R₂ and R₄, R₃ and R₅ are taken together with the directly attached carbon atoms to form a C₅₋₈ cycloalkyl, 5-8 membered heterocyclyl, 5-8 membered aryl or 5-8 membered heteroaryl, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁;

R₆ is H or deuterium.

In a further preferred embodiment, in the compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof, R₁ is selected from the group consisting of H, deuterium, methyl and cyclopropylmethyl;

R₂, R₃, R₄ and R₅ are each independently selected from the group consisting of H, deuterium, F, Cl, methyl, isopropyl, allyl, ethynyl, cyclopropyl, 3-oxacyclobutyl, trifluoromethyl, trideuteromethyl, —C₀₋₄—O—R₁₁ and —C₀₋₄—NR₁₃R₁₄, or R₂ and R₄, R₃ and R₅ are taken together with the directly attached carbon atoms to form a 5-8 membered heterocyclyl, the heteroatom is O or N, the 5-8 membered heterocyclyl is optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁;

R₆ is H or deuterium.

In a further preferred embodiment, the compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof is the compound of the following formula (IIa):

wherein X₃ is selected from the group consisting of —N(R₉)—, N, O and S;

Z is selected from the group consisting of C₁₋₂ alkylene and the following structures:

above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁, above groups are further more optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁;

R₂, R₃, R₄ and R₅ are each independently selected from the group consisting of H, deuterium, F, Cl, methyl, isopropyl, allyl, ethynyl, cyclopropyl, 3-oxacyclobutyl, trifluoromethyl, trideuteromethyl, —C₀₋₄—O—R₁₁ and —C₀₋₄—NR₁₃R₁₄, or R₂ and R₄, R₃ and R₅ are taken together with the directly attached carbon atoms to form a 5-8 membered heterocyclyl, the heteroatom is O or N, the 5-8 membered heterocyclyl is optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁;

R₇ is selected from the group consisting of H, deuterium, Cl, F, hydroxyl, allyl, ethynyl, cyclopropyl, 3-oxacyclobutyl, trifluoromethyl, trideuteromethyl, —C₀₋₄—O—R₁₁ and —C₀₋₄—NR₁₃R₁₄;

R₉ is selected from the group consisting of H, deuterium, C₁₋₄ alkyl, C₃₋₆ cycloalkyl and 3-8 membered heterocyclyl, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₁₋₄ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁;

X₁, X₂, X₅, R₈, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, m, n, and r are as described above.

In a further preferred embodiment, the compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof is selected from the group consisting of the following compounds of formula (IIIa-1), (IIIa-2), (IIIa-3) and (IIIa-4):

wherein Z is selected from the group consisting of C₁₋₂ alkylene and the following structures.

above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁, above groups are further more optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁;

R₂, R₃, R₄ and R₅ are each independently selected from the group consisting of H, deuterium. Cl, F, hydroxyl, methyl, isopropyl, cyclopropyl, 3-oxacyclobutyl, trifluoromethyl, trideuteromethyl and —O—R₁₁, or R₂ and R₄, R₃ and R₅ are taken together with the directly attached carbon atoms to form a 5-8 membered heterocyclyl, the heteroatom is N or O;

R₇ is selected from the group consisting of H, deuterium, Cl, F, hydroxyl, cyclopropyl and —O—R₁₁;

R₉ is selected from the group consisting of H, deuterium, C₁₋₄ alkyl, C₃₋₆ cycloalkyl and 3-8 membered heterocyclyl, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, —C₀₋₄—O—R₁₁, —C₀₋₄—NR₁₃R₁₄ and —C₀₋₄—C(O)NR₁₃R₁₄:

X₁, X₅, R₈, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, m, n and r are described in claim 1.

In a further preferred embodiment, the compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof is selected from the compound of the formula (IVa-1):

wherein X₅ is —CH— or N: Z is selected from the group consisting of C₁₋₂ alkylene and the following structures:

above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl. —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁, above groups are further more optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄. —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁;

R₂, R₃, R₄ and R₅ are each independently selected from the group consisting of H, deuterium, Cl, F, hydroxyl, methyl, isopropyl, cyclopropyl, 3-oxacyclobutyl, trifluoromethyl, trideuteromethyl and —O—R₁₁, or R₂ and R₄, R₃ and R₅ are taken together with the directly attached carbon atoms to form a 5-8 membered heterocyclyl, the heteroatom is N or O;

R₇ is selected from the group consisting of H, deuterium, Cl, F, hydroxyl, cyclopropyl and —O—R₁₁;

R₈ is selected from the group consisting of H, deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—S(O)(NR₉)R₁₀, —C₀₋₈—P(O)(R₁₀)₂, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁,

above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁, above groups are further more optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁;

X₁, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, m, n and r are as described above.

In a further preferred embodiment, in the compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof, R₈ is selected from the group consisting of H, deuterium, halogen, cyano, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀aryl, 5-10 membered heteroaryl, —C₀₋₈—O—R₁₁, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁,

above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁, above groups are further more optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁.

In a further preferred embodiment, the compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof is selected from the compound of the formula (IIb):

wherein X₃ is —(CR₈)_(n)— or —C(O)—;

Z is selected from the group consisting of C₁₋₂ alkylene and the following structures:

above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁;

R₂, R₃, R₄ and R₅ are each independently selected from the group consisting of H, deuterium, F, Cl, methyl, isopropyl, allyl, ethynyl, cyclopropyl, 3-oxacyclobutyl, trifluoromethyl, trideuteromethyl, —C₀₋₄—O—R₁₁ and —C₀₋₄—NR₁₃R₁₄, or R₂ and R₄, R₃ and R₅ are taken together with the directly attached carbon atoms to form a 5-8 membered heterocyclyl, the heteroatom is N or O, the 5-8 membered heterocyclyl optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁;

R₇ is selected from the group consisting of H, deuterium, Cl, F, hydroxyl, allyl, ethynyl, cyclopropyl, 3-oxacyclobutyl, trifluoromethyl, trideuteromethyl, —C₀₋₄—O—R₁₁ and —C₀₋₄—NR₁₃R₁₄;

R₉ is selected from the group consisting of H, deuterium, C₁₋₄ alkyl, C₃₋₆ cycloalkyl and 3-8 membered heterocyclyl, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁;

X₁, X₂, X₅, R₈, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, m, n and r are as described above;

provided that, when X₃ is —(CR₈)_(n)—, X₂ is —C(O)—, X₅ is —N(R₉)—, N, O or S; when X₃ is —C(O)—X₂ is —N(R₉)—, and Z is a C₁₋₄ alkyl or phenyl.

In a further preferred embodiment, the compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof is selected from the group consisting of the following compounds of the formula (IIIb-1) and (IIIb-2):

wherein Z is selected from the group consisting of C₁₋₂ alkylene and the following structures

above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁;

R₂, R₃, R₄ and R₅ are each independently selected from the group consisting of H, deuterium Cl, F, hydroxyl, methyl, isopropyl, cyclopropyl, 3-oxacyclobutyl, trifluoromethyl, trideuteromethyl and —O—R₁₁, or R₂ and R₄, R₃ and R₅ are taken together with the directly attached carbon atoms to form a 5-8 membered heterocyclyl, the heteroatom is N or O:

R₇ is selected from the group consisting of H, deuterium Cl, F hydroxyl, cyclopropyl and —O—R₁₁;

X₁, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, m and r are as described above.

In a further preferred embodiment, the compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof is selected from the compound of formula (IIIb-3):

wherein R₂, R₃, R₄ and R₅ are each independently selected from the group consisting of H, deuterium, Cl, F hydroxyl, methyl, isopropyl, cyclopropyl, 3-oxacyclobutyl, trifluoromethyl, trideuteromethyl and —O—R₁₁, or R₂ and R₄, R₃ and R₅ are taken together with the directly attached carbon atoms to form a 5-8 membered heterocyclyl, the heteroatom is N or O;

R₇ is selected from the group consisting of H, deuterium, Cl, F, hydroxyl, cyclopropyl and —O—R₁₁;

R₉ is selected from the group consisting of H, deuterium, C₁₋₄ alkyl, C₃₋₆ cycloalkyl or 3-8 membered heterocyclyl, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl 3-8 membered heterocycyl, —C₀₋₄—O—R₁₁, —C₀₋₄—NR₁₃R₁₄ and —C₀₋₄—C(O)NR₁₃R₁₄; X₁, R₈, R₁₀, R₁₁, R₁₃, R₁₄ and n are as described above.

In the most preferred embodiment, the compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof includes, but is not limited to, the following compounds:

The second aspect of the invention provides a process for preparing the above compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof, which is carried out by the following way according to the reaction steps of the allylamide group, when m=1:

or by the following way, when m=0:

optionally, a conversion reaction is further carried out between the different substituents according to the different substituent;

wherein, X is a leaving group, and is preferably selected from the group consisting of Cl, Br, methylthio, methylsulfonyl and methoxy; R is selected from the group consisting of nitro, cyano and azido; Pg is an amino protecting group, and is preferably selected from the group consisting of tert-butyloxycarbonyl, benzyloxycarbonyl, 2-biphenyl-2-propoxy carbonyl and p-toluenesulfonyl; and X₁, X₂, X₃, X₄, X₅, R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄ m, n and r are as described above.

In a further preferred embodiment, when X is methylsulfonyl, the corresponding compound can be produced by an oxidation reaction of the methylthio when R is with an oxidizing agent such as m-CPBA (m-chloroperoxybenzoic acid).

In a further preferred embodiment, the conversion reaction between the different substituents according to the different substituent means that, if necessary, the conversion of substituents can be carried out by the conventional experiment in the art under the conditions meeting chemical synthesis principle according to the different definitions of X₁, X₂, X₃, X₄, X₅, R₁, R₂, R₃, R₄, R₅, R₆, R⁷, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, and R₁₄, after the condensation reaction.

The third aspect of the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of the above compound of formula (I), stereoisomer or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carrier.

The fourth aspect of the present invention provides use of the above compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof or the aforementioned pharmaceutical composition for preparing a medicament as an FGFR4 inhibitor.

The fifth aspect of the present invention provides use of the above compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof or the aforementioned pharmaceutical composition for preparing a medicament for treating cancer.

Preferably, the cancer is prostate cancer, liver cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma.

The sixth aspect of the invention provides the above compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof or the aforementioned pharmaceutical composition for use as an FGFR4 inhibitor.

The seventh aspect of the invention provides the above compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof or the aforementioned pharmaceutical composition for use in the treatment of cancer.

Preferably, the cancer is prostate cancer, liver cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma.

The eighth aspect of the invention provides a method for inhibiting FGFR4, which comprises administering to a patient in need thereof a therapeutically effective amount of the above compound of formula (I), the stereoisomer or pharmaceutically acceptable salt thereof, or the aforementioned pharmaceutical composition.

The ninth aspect of the invention provides a method for treating cancer, which comprises administering to a patient in need thereof treatment a therapeutically effective amount of the above compound of formula (T), the stereoisomer or pharmaceutically acceptable salt thereof, or the aforementioned pharmaceutical composition.

Preferably, the cancer is prostate cancer, liver cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma.

The series of compounds developed by the present invention have strong inhibitory effects on FGFR4 kinase activity and very high selectivity, and can be widely used for preparing a medicament for treating cancer, especially prostate cancer, liver cancer, pancreatic cancer, esophageal cancer, stomach cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma. The compounds are expected to be developed into a new generation medicaments of FGFR4 inhibitor.

It is to be understood that within the scope of the present invention, the above various technical features of the present invention and the technical features specifically described hereinafter (as in the examples) may be combined with each other to constitute a new or preferred technical solution. Due to space limitations, they will not be described one by one.

DETAILED DESCRIPTION OF THE INVENTION

Based on a long-term and in-depth study, the inventors have developed for the first time an FGFR4 inhibitor with a structure of the formula (I), the series of compounds have very strong inhibitory effects on FGFR4 kinase activity and very high selectivity, and could be widely used for preparing a medicament for treating cancer, especially prostate cancer, liver cancer, pancreatic cancer, esophageal cancer, stomach cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma. These compounds will be expected to be developed into a new generation medicaments of FGFR4 inhibitor. On such basis, the present invention has been completed.

Detailed description: Unless otherwise stated, the following terms used in the specification and claims have the following meanings.

“Alkyl” means a straight or branched saturated aliphatic hydrocarbon group, for example, “C₁₋₈ alkyl” means a straight or branched alkyl having 1 to 8 carbon atoms, including but is not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl or various branched isomers thereof and so on.

Alkyl can be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, independently selected from the group consisting of deuterium halogen, cyano, nitro, azido C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁.

“Cycloalkyl” means a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, for example, “C₃₋₈ cycloalkyl” refers to a cycloalkyl having 3-8 carbon atoms, which may be a monocyclic cycloalkyl and a polycyclic cycloalkyl, wherein, monocyclic cycloalkyl includes, but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl and the like; and polycyclic cycloalkyl includes spiro, fused, and bridged cycloalkyls.

“Spirocycloalkyl” refers to a polycyclic group that shares a carbon atom (called a spiro atom) between the monocyclic rings. These groups may contain one or more double bonds, but none of the rings have a fully conjugated it-electron system. The spirocycloalkyl may be a monospirocycloalkyl, a bispirocycloalkyl or a polyspirocycloalkyl according to the number of common spiro atoms between the rings, spirocycloalkyl includes, but is not limited to:

“Fused cycloalkyl” means an all-carbon polycyclic group in which each ring shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain one or more double bonds, but none of the rings have a fully conjugated π-electron system. Depending on the number of rings, it may be bicyclic, tricyclic, tetracyclic or polycyclic, fused cycloalkyl includes but is not limited to:

“Bridged cycloalkyl” refers to an all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly bonded, which may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system. Depending on the number of rings, it may be bicyclic, tricyclic, tetracyclic or polycyclic, bridged cycloalkyl includes but is not limited to:

The ring of the cycloalkyl may be fused to a ring of aryl, heteroaryl or heterocycloalkyl, wherein the ring attached to the parent structure is a cycloalkyl, includes, but is not limited to indanyl, tetrahydronaphthyl, benzocycloheptyl and the likes.

The cycloalkyl can be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, and independently selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R ₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁.

“Heterocyclyl” means a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent wherein one or more of the ring atoms are heteroatoms selected from nitrogen, oxygen or S(O), (wherein r is an integer of 0, 1, 2), but excluding ring moiety of —O—O—, —O—S— or —S—S—, and the remaining ring atoms are carbon atoms. For example, “5-10 membered heterocyclyl” means a cyclic group containing 5 to 10 ring atoms, and “3-10 membered heterocyclyl” means a cyclic group containing 3 to 10 ring atoms.

Monocyclic heterocyclyl includes, but is not limited to pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl and the likes.

Polycyclic heterocyclyl includes a spiro, fused, and bridged heterocyclyl. “Spiroheterocyclyl” refers to a polycyclic heterocyclyl that shares a carbon atom (called a spiro atom) between the monocyclic rings, wherein one or more of the ring atoms are heteroatoms selected from nitrogen, oxygen or S(O)_(r) (wherein r is an integer of 0, 1, 2), and the remaining ring atoms are carbon atoms. These groups may contain one or more double bonds, but none of the rings have a fully conjugated π-electron system. The spiro heterocyclyl may be a monospiroheterocyclyl, a bispiroheterocyclyl or a polyspiroheterocyclyl according to the number of common spiro atoms between the rings, spiroheterocyclyl includes, but is not limited to:

“Fused heterocyclyl” means a polycyclic heterocyclyl in which each ring shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain one or more double bonds, but none of the rings have a fully conjugated π-electron system, wherein one or more of the ring atoms are heteroatoms selected from nitrogen, oxygen or S(O)_(r) (wherein r is an integer of 0, 1, 2), and the remaining ring atoms are carbon atoms. Depending on the number of rings, it may be bicyclic, tricyclic, tetracyclic or polycyclic, fused heterocyclyl includes, but is not limited to:

“Bridged heterocyclyl” refers to a polycyclic heterocyclyl in which any two rings share two carbon atoms that are not directly bonded, which may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system wherein one or more of the ring atoms are heteroatoms selected from nitrogen, oxygen or S(O)_(r) (wherein r is an integer of 0, 1, 2), and the remaining ring atoms are carbon atoms. Depending on the number of rings, it may be bicyclic, tricyclic, tetracyclic or polycyclic, bridged heterocyclyl includes, but is not limited to:

The ring of the heterocycyl may be fused to a ring of aryl heteroaryl or cycloalkyl wherein the ring attached to the parent structure is a heterocyclyl, includes but is not limited to:

The heterocycyl can be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups and independently selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R ₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁.

“Aryl” means an all-carbon monocyclic or fused polycyclic (ie, a ring that shares a pair of adjacent carbon atoms) group, and a polycyclic group having a conjugated n-electron system (i.e., a ring with adjacent pairs of carbon atoms), for example, “C₅₋₁₀ aryl” means an all-carbon aryl having 5-10 carbons, and “5-10 membered aryl” means an all-carbon aryl having 5-10 carbons, including but not limited to phenyl and naphthyl. The aryl ring may be fused to a ring of heteroaryl, heterocyclyl or cycloalkyl, wherein the ring attached to the parent structure is an aryl ring, includes, but is not limited to:

The aryl group can be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, and independently selected from the group consisting of halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ haloalkyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄. —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁.

“Heteroaryl” refers to a heteroaromatic system containing 1 to 4 heteroatoms including a hetero atom selected from nitrogen, oxygen or S(O)r (wherein r is an integer of 0, 1, 2), for example, 5-7 membered heteroaryl refers to a heteroaromatic system containing 5 to 7 ring atoms, and 5-10 membered heteroaryl refers to a heteroaromatic system containing 5 to 10 ring atoms, including but not limited to furyl, thiophenyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl group or the like. The heteroaryl ring may be fused to a ring of aryl, heterocyclyl or cycloalkyl wherein the ring attached to the parent structure is a heteroaryl ring, includes, but is not limited to

The heteroaryl can be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups and independently selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R ₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁.

“Alkenyl” refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, for example, C₂₋₈ alkenyl refers to a straight or branched alkenyl containing 2 to 8 carbons. Alkenyl includes, but is not limited to vinyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, and the likes.

The alkenyl group can be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, and independently selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₃, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁.

“Alkynyl” refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, for example, C₂₋₈ alkynyl refers to a straight or branched alkynyl containing 2 to 8 carbons. Alkynyl includes, but is not limited to ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, and the likes.

The alkynyl can be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, and independently selected from the group consisting of deuterium halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁.

“Alkoxy” means —O-(alkyl), wherein alkyl is as defined above, for example, “C₁₋₈ alkoxy” refers to an alkyloxy containing 1 to 8 carbons. Alkoxy includes, but is not limited to methoxy, ethoxy, propoxy, butoxy, and the likes.

The alkoxy can be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, and independently selected from the group consisting of deuterium halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R¹⁴, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁.

“Cycloalkyloxy” means —O-(unsubstituted cycloalkyl), wherein cycloalkyl is as defined above, for example, “C₃₋₈ cycloalkyloxy” refers to a cycloalkyoxy containing 3 to 8 carbon atoms. Cycloalkyloxy includes, but is not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the likes.

The cycloalkyloxy can be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, and independently selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocycyl-, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁.

“3-10 membered heterocyclyloxy” means —O-(unsubstituted 3-10 membered heterocyclyl), wherein 3-10 membered heterocyclyl is as defined above, 3-10 membered heterocyclyloxy can be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, and independently selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁.

“C₅₋₁₀ aryloxy” means —O-(unsubstituted C₅₋₁₀ aryl), wherein C₅₋₁₀ aryl is as defined above, C₅₋₁₀ aryloxy can be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, and independently selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁.

“5-10 membered heteroaryloxy” means —O-(unsubstituted 5-10 membered heteroaryl), wherein 5-10 membered heteroaryl is as defined above, 5-10 membered heteroaryloxy can be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, and independently selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁.

“C₁₋₈ alkanoyl” refers to a monovalent group obtained by removing hydroxyl from C-s alkyl acid, is also generally referred to as “C₀₋₇—C(O)—”, for example, “C₁—C(O)—” refers to acetyl; “C₂—C(O)—” refers to propionyl; and “C₃—C(O)—” refers to butyryl or isobutyryl.

“—C₀₋₈—S(O)_(r)R₁₀” means that the sulfur atom in —S(O)_(r)R₁₀ is bonded to C₀₋₈ alkyl, wherein C₀ alkyl means a bond, and C₁₋₈ alkyl is as defined above.

“—C₀₋₈—O—R₁₁” means that the oxygen atom in —O—R₁₁ is bonded to C₀₋₈ alkyl, wherein C₀ alkyl means a bond, and C₁₋₈ alkyl is as defined above.

“—C₀₋₈—C(O)OR₁₁” means that the carbonyl group in —C(O)OR₁₁ is bonded to C₀₋₈ alkyl, wherein C₀ alkyl means a bond, and C₁₋₈ alkyl is as defined above.

“—C₀₋₈—C(O)R₁₂” means that the carbonyl group in —C(O)R₁₂ is bonded to C₀₋₈ alkyl, wherein C₀ alkyl means a bond, and C₁₋₈ alkyl is as defined above.

“—C₀₋₈—O—C(O)R ₁₂” means that the oxygen atom in —O—C(O)R₁₂ is bonded to C₀₋₈ alkyl, wherein C₀ alkyl means a bond, and C-s alkyl is as defined above.

“—C₀₋₈NR₁₃R₁₄” means that the nitrogen atom in —NR₁₃R₁₄ is bonded to C₀₋₈ alkyl, wherein C₀ alkyl means a bond, and C₁₋₈ alkyl is as defined above.

“—C₀₋₈—C(O)NR₁₃R₁₄” means that the carbonyl in —C(O)NR₁₃R₁₄ is bonded to C₀₋₈ alkyl, wherein C₀ alkyl means a bond, and C₁₋₈ alkyl is as defined above.

“—C₀₋₈—N(R₁₃)—C(O)R₁₂” means that the nitrogen atom in —N(R₁₃)—C(O)R₁₁ is bonded to C₀₋₈ alkyl, wherein C₀ alkyl means a bond, and C₁₋₈ alkyl is as defined above.

“—C₀₋₈—N(R₁₃)—C(O)OR₁₁” means that the nitrogen atom in —N(R₁₃)—C(O)OR₁₁ is bonded to C₀₋₈ alkyl, wherein C₀ alkyl means a bond, and C₁₋₈ alkyl is as defined above.

“C₁₋₈ haloalkyl” means a alkyl group having 1 to 8 carbon atoms, wherein any hydrogen atom on which is optionally substituted with F, Cl, Br or I, and includes, but is not limited to difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, and the likes.

“C₁₋₈ haloalkoxy” means an alkoxy having 1 to 8 carbon atoms, wherein any hydrogen atom on which is optionally substituted with F, Cl, Br or I, and includes, but is not limited to difluoromethoxy, dichloromethoxy, dibromomethoxy, trifluoromethoxy, trichloromethoxy, tribromomethoxy, and the likes.

“Halogen” means F. Cl, Br or I. “THF” refers to tetrahydrofuran. “EA/EtOAc” refers to ethyl acetate. “MeOH” means methanol. “EtOH” refers to ethanol. “PivOH” refers to trimethylacetic acid. “DMSO” refers to dimethyl sulfoxide. “DIMF” means N,N-dimethylformamide. “DIPEA” refers to diisopropylethylamine. “CH₃CN” means acetonitrile. “PE” means petroleum ether. “DCM/CH₂Cl₂” means dichloromethane. “DCE” refers to dichloroethane. “DMA” refers to dimethylacetamide. “Et₃N” refers to triethylamine. “NH₄Cl” means ammonium chloride. “NMP” refers to N-methylpyrrolidone. “HOAc” refers to acetic acid. “TFA” refers to trifluoroacetic acid. “MeI” means methyl iodide. “K” means potassium iodide. “MsC” refers to methylsulfonyl chloride. “SO₂Cl₂” means sulfonyl chloride. “POCl₃” refers to phosphorus oxychloride. “MeONa” means sodium methoxide. “NaHCO₃” refers to sodium bicarbonate. “Na₂SO₄” means sodium sulfate. “K₂CO₃” means potassium carbonate. “NaN₃” refers to sodium azide. “NaH” refers to sodium hydride. “CuI” refers to cuprous iodide. “PPA” refers to polyphosphoric acid. “m-CPBA” refers to m-chloroperoxybenzoic acid. “MnO₂” means manganese dioxide. “LiAlH₄” means lithium aluminum hydride. “LiOH” refers to lithium hydroxide. “NaOAc” refers to sodium acetate. “NaNO₂” refers to sodium nitrite. “AgNO₃” means silver nitrate. “Boc₂O” refers to di-tert-butyl dicarbonate. “LiCl” means lithium chloride. “Zn(CN)₂” refers to zinc cyanide. “IBX” means 2-iodoxybenzoic acid. “Pd/C” means palladium carbon. “Pd(OAc)₂” means palladium acetate. “PPh₃” means triphenylphosphine. “Pd(PPh₃)₂Cl₂” means palladium bis(triphenylphosphine) dichloride. “Pd₂(dba)₃” means tris(dibenzylideneacetone) dipalladium. “Pd(dppf)Cl₂” means [1,1′-bis(diphenylphosphino)ferrocene] palladium dichloride. “Pd(PPh₃)₄” means tetrakis (triphenylphosphine) palladium. “brett-phos” refers to dicyclohexyl[3,6-dimethoxy-2′,4″-triisopropyl[1,1′-biphenyl]-2-yl]phosphine.

“Optional” or “optionally” means that the event or environment subsequently described may, but need not, occur, including where the event or environment occurs or does not occur. For example, “heterocyclyl optionally substituted by alkyl” means that an alkyl group may be, but is not necessarily, present, and the description includes the case where the heterocyclyl is substituted with an alkyl and the case where the heterocyclyl is not substituted with an alkyl.

“Substituted” means that one or more hydrogen atoms in a group are each independently substituted with a corresponding number of substituents. It goes without saying that a substituent is only in its possible chemical position, and those skilled in the art will be able to determine (by experiment or theory) possible or impossible substitution without undue efforts. For example, it may be unstable that an amino group or a hydroxyl group having a free hydrogen is attached with a carbon atom having an unsaturated bond (such as an olefin).

“Pharmaceutical composition” means a mixture comprising one or more of the compounds described herein, or a physiologically/pharmaceutically acceptable salt or pro-drug thereof, and other chemical components, for example physiological/pharmaceutically acceptable carriers and excipients. The purpose of the pharmaceutical composition is to promote the administration to an organism, which facilitates the absorption of the active ingredient thereby exerting biological activities.

The Present Invention Will be Further Described in Detail Below in Conjunction with the Embodiments which is not Intended to Limit the Present Invention. The Present Invention is Also not Limited to the Contents of the Embodiments.

The structure of the compound of the present invention is determined by nuclear magnetic resonance (NMR) or/and liquid chromatography-mass spectrometry (LC-MS). The NMR chemical shift (δ) is given in parts per million (ppm). The NMR is measured by a Bruker AVANCE-400 nuclear magnetic apparatus, and the solvent is deuterated dimethyl sulfoxide (DMSO-d₆), deuterated methanol (CD₃OD) and deuterated chloroform (CDCl₃), and the internal standard is tetramethylsilane (TMS).

The measurement of LC-MS is performed by using an Agilent 6120 mass spectrometer. The measurement of HPLC is performed by using an Agilent 1200 DAD high pressure liquid chromatograph (Sunfire C18 150×4.6 mm column) and a Waters 2695-2996 high pressure liquid chromatograph (Gimini C18 150×4.6 mm column).

The thin layer chromatography silica gel plate is Yantai Yellow Sea HSGF254 or Qingdao GF254 silica gel plate. The specification of TLC is 0.15 mm-0.20 mm, and the specification for thin layer chromatography separation and purification is 0.4 mm-0.5 mm. 200-300 mesh silica gel (Yantai Huanghai silica gel) as a carrier is generally used in column chromatography.

The starting materials in the examples of the present invention are known and commercially available or can be synthesized according to methods known in the art.

Unless otherwise stated, all reactions of the present invention are carried out under continuous magnetic stirring under a dry nitrogen or argon atmosphere, the solvent is a dry solvent, and the unit of the reaction temperature is degrees Celsius.

Preparation of Intermediates Intermediate 1: Preparation of 7-chloro-3-(2,6-dichloro-3,5-dimethoxyphenyl)-2H-pyrano [3,2-c]pyridin-2-one

Step 1: Preparation of Ethyl 6-chloro-4-methoxynicotinate

Ethyl 4,6-dichloronicotinate (10.0 g, 45.4 mmol) was added to anhydrous THF (100 mL), and cooled to 0° C. with ice water, then MeONa (2.8 g, 51.8 mmol) was added. After the addition was completed, the mixture was stirred at room temperature overnight. After the reaction as completed, the mixture was concentrated to remove THF. The crude product was dissolved in ethyl acetate (100 mL), washed twice with water and dried over anhydrous Na₂SO₄ filtrated and concentrated to obtain ethyl 6-chloro-4-methoxynicotinate (8.2 g, yield: 84%). MS (ESI): m/z 216.3 [M+1]⁺.

Step 2: Preparation of (6-chloro-4-methoxypyridin-3-yl)methano

Ethyl 6-chloro-4-methoxynicotinate (8.2 g, 38.1 mmol) was dissolved in anhydrous THF (200 mL), then LiAH₄(3.0, 81.1 mmol) was added under ice-water bath. After the addition was completed, the mixture, was stirred at room temperature for 2 h. After the reaction was completed, 2N aqueous NaOH (25 mL) was added for extraction. The solid residue was removed by filtration, and the filtrate was concentrated to obtain compound (6-chloro-4-methoxypyridin-3-yl)methanol (6.0 g, yield: 91%). MS (ESI): m/z 2174.2 [M+1]⁺.

Step 3: Preparation of 6-chloro-4-methoxynicotinaldehyde

(6-chloro-4-methoxypyridin-3-yl)methanol (6.0 g, 34.6 mmol) was dissolved in acetone (100 mL), then IBX (12.0 g, 42.9 mmol) was added. The mixture was heated to reflux for 18 h. After the reaction was completed, the mixture was filtered and concentrated to obtain compound 6-chloro-4-methoxynicotinaldehyde (4.2 g, yield: 71%). MS (ESI): m/z 172.2 [M+1]⁺.

Step 4: Preparation of 6-chloro-4-hydroxyinicotinaldehyde

6-chloro-4-methoxynicotinaldehyde (4.2 g, 24.5 mmol) was dissolved in 1,4-dioxane (30 ml), then concentrated hydrochloric acid (10 n) was added. The mixture was heated to 90° for 16 h. After the reaction was completed, the mixture was concentrated. The crude product was separated by silica gel column chromatography to obtain compound 6-chloro-4-hydroxylnicotinaldehyde (1.5 g, yield: 39%).

¹H NMR (400 MHz, CDCl₃): δ ppm 11.37 (s, 1H), 9.99 (s, 1H), 8.57 (s, 1H), 6.99 (s, 1H).

Step 5: Preparation of 7-cloro-3-(3,5-dimethoxyphenyl)-2H-pyrano[3,2-c]pyridin-2-one

6-chloro-4-hydroxylnicotinaldehyde (0.60 g, 3.82 mmol) was added to acetic anhydride (10 mL), then 2-(3,5-dimethoxyphenyl)acetic acid (0.80 g, 4.08 mmol) and triethylamine (1.5 g, 107 mmol) were added, the mixture was heated to 110° C. for 40 min. After the reaction was completed, the mixture was cooled to room temperature and concentrated. The obtained solids were washed with petroleum ether/ethyl acetate (3:1) to obtain compoundd 7-chloro-3-(3,5-dimethoxyphenyl)-2H-pyrano[3,2-c]pyridin-2-one (0.35 g, yield: 29%). MS (ESI): m/z 318.3 [M+1]⁺.

Step 6: Preparation of 7-chloro-3-(2,6-dichloro-3,5-dimethoxyphenyl)-2H-pyrano[3,2-c]pyridin-2-one

7-chloro-3-(3,5-dimethoxyphenyl)-2H-pyrano[3,2-c]pyridin-2-one (0.35 g, 1.1 mmol) was dissolved in anhydrous acetonitrile (10 mL), the mixture was cooled to −30° C., then SO₂Cl₂ (1.0 g, 7.4 mmol) was added dropwise, the mixture was stirred at this temperature for 1 h. A saturated aqueous solution of NaHCO₃ was added to quench the reaction, and then acetonitrile was removed by concentration. After filtration, the solids were washed with water and then petroleum ether/ethyl acetate (3:1) to obtain 7-chloro-3-(2,6-dichloro-3,5-dimethoxyphenyl)-2H-pyrano[3,2-c]pyridin-2-one (0.21 g, yield: 49%). MS (ESI): m/z 3863 [M+1]⁺.

Intermediate 2: Preparation of 2-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido [3,4-d]pyrimidine

Step 1 Preparation of 2-Chloro-5-Nitroisonicotinic Acid

Chromium trioxide (40.0 g, 40 mmol) was added to a solution of 2-chloro-4-methyl-5-nitropyridine (20.0 g, 11.6 mmol) in sulfuric acid (200 mL) at 0°. After the addition was completed, the mixture was stirred at 0° C. for 1 h, then slowly warmed to room temperature and stirred overnight, and then poured into ice water (1 L) and filtrated to obtain 2-chloro-5-nitroisonicotinic acid (18 g, yield: 77%). MS (ESI): m/z 201.1 [M−1]⁻.

Step 2: Preparation of Methyl 2-Chloro-5-Nitroisonicotinate

Oxalyl chloride (12.7 g, 100 mmol) was added to a suspension of 2-chloro-5-nitroisonicotinic acid (16 g, 80 mmol) in dichloromethane (150 mL) at 0°. After the addition was completed, the mixture was stirred at room temperature for 3 h. Methanol (100 mL) was added, the reaction mixture was stirred at room temperature for another 4 h and then concentrated. The crude product was dissolved in dichloromethane (200 ml), the mixture was washed with sodium bicarbonate solution (100 mL*2), dried over anhydrous sodium sulfate and concentrated to obtain methyl 2-chloro-5-nitroisonicotinate (17.2 g, yield: 98%).

Step 3: Preparation of Methyl 2-(3,5dimethoxyphenyl)-5-nitroisonicotinate

3,5-dimethoxyphenylboronic acid (8.47 g 46 mmol), tetrakis(triphenylphosphine)palladium (5 g, 4.6 mmol) and sodium carbonate (5 g 16 mmol) were added to a solution of methyl 2-chloro-5-nitroisonicotinate (10.0 g, 46.0 mmol) in the mixture of dioxane (200 mL) and water (50 mL). After the addition was completed, the mixture was stirred under N2 at 110° C. until the reaction of the starting materials was completed. The reaction solution was concentrated and separated by column chromatography (eluent: CH₂Cl₂/PE 20:1) to obtain compound methyl 2-(3,5-dimethoxyphenyl)-5-nitroisonicotinate (6 g, yield: 41%). MS (ESI): m/z 2318.9 [M+1]⁺.

Step 4: Preparation of Methyl 5-amino-2-(3,5-dimethoxyphenyl)isonicotinate

Palladium carbon (10%, 500 mg) was added to a solution of methyl 2-(3,5-dimethoxyphenyl)-5-nitroisonicotinate (6 g, 18.8 mmol) in methanol (100 mL). Then the mixture was stirred under a hydrogen atmosphere at room temperature for 4 h, filtrated and concentrated to obtain methyl 5-amino-2-(3,5-dimethoxyphenyl)nitroisonicotinate (5 g, yield: 92.3%). MS (ESI): m/z 289.3[M+1]⁺.

Step 5: Preparation of 6-(3,5-dimethoxyphenyl)pyrid[3,4-d]pyrimidine-2,4(1H,3H)-dione

A mixture of methyl 5-amino-2-(3,5-dimethoxyphenyl)isonicotinate (5 g, 17.4 mmol) and urea (12 g, 200 mmol) was heated to 160° C. and stirred for 4 h. Then the mixture was poured into ice water (100 mL) and filtered to obtain 6-(3,5-dimethoxyphenyl)pyrido [3,4-d]pyrimidine-2,4(1H,3H)-dione (6 g, yield: 99%). MS (ESI): m/z 300.3 [M+1]⁺.

Step 6: Preparation of 2,4-dichloro-6-(3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine

N,N-diethylaniline (3 mL) was added to a suspension of 6-(3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione (5.0 g, 16.7 mmol) in phosphorus oxychloride (50 m L). The mixture was then stirred at 110° C. overnight. The solvent was evaporated, ice w ater (200 mL) was added, and pH was adjusted to 7 with aqueous sodium bicarbonate solution. The aqueous solution was extracted for three times with EtOAc (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated and separated by column chromatography [eluent: (EA:PE=1:5)] to obtain compound 2,4-dichloro-6-(3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine (2.5 g, yield: 44.5%). MS (ESI): m/z 336.2 [M+1]⁺.

Step 7: Preparation of 2-chloro-6-(3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-4-amine

A concentrated aqueous ammonia (2 g) was added to a solution of 24-dichloro-6-(3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine (5 g, 7.5 mmol) in methanol (100 mL). The mixture was then stirred at 25° C. for 4 h. The pH was adjusted to 7 with hydrochloric acid (1N), then methanol is removed under vacuum, 2-chloro-6-(3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-4-amine (2 g, yield: 84%) was obtained after filtration. MS (ESI): m/z 317.1 [M+1]⁺.

Step 8: Preparation of 2-chloro-6-(3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine

Tert-butyl nitrite (720 mg, 6.2 mmol) was added to a solution of 2-chloro-6-(3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-4-amine (I g, 3.1 mmol) in tetrahydrofuran (100 mL). The mixture was then heated to reflux and stirred for 48 h. The reaction mixture was concentrated and separated by column chromatography [eluent: (EA:PE=1: 5-1:2)] to obtain compound 2-chlor-6-(3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine (400 mg, yield: 41%).

¹H NMR (400 MHz, DMSO-d₆: δ 9.7 (s, 1H) 9.53 (s, 1H), 8.74 (s, 1H), 7.4 (s, 2H), 6.64 (s, 1H), 3.88 (S, 61H);

MS (ESI): m/z 302.0 [M+1]⁺.

Step 9: Preparation of 2-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine

The compound was prepared referring to the synthesis method of step 6 of intermediate 1.

Intermediate 3 and Intermediate 4: Preparation of 2-chloro-6-(2,6-difluoro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine and 2-chloro-6-(2-fluoro-3,5-dimethoxyphenyl)pyrido [3,4-d]pyrimidine

2-chloro-6-(3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine (120 mg, 0.4 mmol) was dissolved in anhydrous acetonitrile (20 mL) then the mixture was cooled to 0° C. with ice-water bath. 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (select-fluor, 283 mg, 0.8 mmol) was added dropwise. After the addition was completed, the reaction solution was warmed to room temperature for 6 h. The reaction was completed monitored by TLC. A saturated aqueous NaHCO₃ solution was added to quench the reaction, and then majority of acetonitrile was removed. The mixture was extracted with ethyl acetate, concentrated, and separated by silica gel column chromatography (PE/EA=10/11, adjusted by adding 10% DCM) to obtain 2-chloro-6-(2,6-difluoro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine(20 mg, yield: 15%), MS m/z (ESI): 338 [M+H]+. At the same time, 2-chloro-6-(2-fluoro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine(70 mg, yield:55%) was also obtained, MS m/z (ESI): 320 [M+H]⁺.

Intermediates 5-10 were prepared referring to the the synthesis method of intermediate 2.

Intermediate MS: m/z No. Compound structure Compound name [M + 1]⁺ 5

2-chloro-6-(2-chloro-6-fluoro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidine 355 6

2-chloro-6-(2-fluoro-6-isopropyl- 3,5-dimethoxyphenyl)pyrido[3,4- d]pyrimidine 362 7

2-chloro-6-(2-cyclopropyl-6-fluoro- 3,5-dimethoxyphenyl)pyrido[3,4- d]pyrimidine 360 8

2-chloro-6-(2-chloro-6-cyclopropyl- 3,5-dimethoxyphenyl)pyrido[3,4- d]pyrimidine 377 9

2-chloro-6-(6-fluoro-7-methoxy-2,3- dihydrobenzo[b][1,4]dioxin-5- yl)pyrido[3,4-d]pyrimidine 348 10

2-chloro-6-(6-chloro-7-methoxy-2,3- dihydrobenzo[b][1,4]dioxin-5- yl)pyrido[3,4-d]pyrimidine 365

Intermediate 11: Preparation of 7-chloro-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrano [4,3-c]pyridin-1-one

Step 1: Preparation of Methyl 5-bromo-2-chloroisonicotinate

5-bromo-2-chloroisonicotinic acid (30.0 g 12.6 mmol) was dissolved in methanol (300 mL), then SOCl₂ (18.0 g, 15 mmol) was added, the mixture was heated to 75° C. for 8 h. The reaction was completed monitored by LCMS. The mixture was cooled to room temperature and concentrated by reduced pressure, and then EtOAc (300 mL) was added to the residue. The mixture was washed with a saturated aqueous solution of NaHCO₃ dried over anhydrous Na₂SO₄, filtered and concentrated to obtain methyl 5-bromo-2-chloroisonicotinate (32.0 g, yield: 99%). MS (ESI): m/z 251.9 [M+1]⁺.

Step 2: Preparation of Methyl 2-chloro-5-((3,5-dimethoxyphenyl)ethynyl)isonicotinate

Methyl 5-bromo-2-chloro isonicotinate 30 g, 120 mmol) was dissolved in 1,4-dioxane (300 mL), and 3,5-dimethoxyphenylacetylene (20.4 g, 120 mmol), CuI (2.28 g, 12 mmol), Pd(dppf)Cl₂ (4.2 g, 6 mmol) and Et₃N (12.0 g, 120 mmol) were added, and the mixture was heated to 60° C. under N2 for 6 h. The reaction was complete, and the mixture was filtered and concentrated. The crude product was separated by silica gel column chromatography (DCM:PE=20:1) to obtain compound methyl 2-chloro-5-((3,5-dimethoxyphenyl)ethynyl)isonicotinate (22 g, yield: 55%). MS (ESI): m/z 332.1 [M+1]⁺.

Step 3: Preparation of 7-choro-3-(3,5-dimethoxyphenyl)-H-pyrano[4,3-c]pyridin-1-one

Methyl 2-chloro-5-((3,5-dimethoxyphenyl)ethynyl)isonicotinate (21.0 g 63 mmol) was added to PPA (200 mL), and the mixture was heated to 80° for 8 h. The reaction was completed monitored by LCMS. The reaction mixture was poured into ice water (1000 ml.), and then filtered to obtain solid compound 7-choro-3-(3,5-dimethoxyphenyl)-1H-pyrano[4,3-c]pyridin-1-one (15.0 g, yield: 75%). MS (ESI): m/z 318.2 [M+1]⁺.

Step 4: Preparation of 7-cloro-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrano[4,3-c]pyridin-1-one

The compound was prepared referring to the synthetic method of step 6 of Intermediate 1.

Intermediate 12: Preparation of 7-choro-3-(2,6-dichloro-3,5-dimethoxyphenyl)-2-methyl-2,6-naphthyridin-1(2H)-one

Step 1: Preparation of 7-chloro-3-(3,5-dimethoxyphenyl)-2,6-naphthyridin-1(2H)-one

7-chloro-3-(3,5-dimethoxyphenyl)-1H-pyrano[4,3-c]pyridin-1-one (15 g, 47.3 mmol) was dissolved in DMF (200 mL), then concentrated aqueous ammonia (150 mL) was added. The reaction mixture was heated to 80° C. for 48 h. The reaction was completed monitored by LCMS, and then filtered to obtain solid compound 7-chloro-3-(3,5-dimethoxyphenyl)-2,6-naphthyridin-1(2H)-one (7.5 g, yield: 50.5%).

¹H NMR (400 MHz, DMSO-d6): δ ppm 11.7 (m, 1H), 8.97 (s, 1-), 8.01 (s, 1-), 7.14 (s, 1H), 6.97 (s, 21), 6.61 (s, 1H), 3.86 (s, 611).

MS (ESI): m/z 317.2 [M+1]⁺.

Step 2: Preparation of 7-chloro-3-(3,5-dimethoxyphenyl)-2-methyl-2,6-naphthyridin-1(2H)-one

7-chloro-3-(3,5-dimethoxyphenyl)-2,6-naphthyridin-(2H)-one (2 g, 6.32 mmol) was dissolved in DMF (30 mL), and Na (758 mg, 18.95 mmol) was added under ice water bath. The mixture was stirred at 0° C. for 15 minutes, then MeI (8,967 g, 63.151 mmol) was added dropwise, the mixture was stirred at room temperature for 1 h. After the reaction was completed, it was quenched with water. The mixture was extracted for three times with ethyl acetate, and the organic phases were combined and washed with water, saturated brine, dried over anhydrous sodium sulfate, filtrated, concentrated and separated by column chromatography (Eluent: PE/EtOAc=2:1) to obtain compound 7-chloro-3-(3,5-dimethoxyphenyl)-2-methyl-2,6-naphthyridin-1(2H)-one (1.35 g, yield: 65%).

MS m/z (ESI): 331.0 [M+H]⁺.

Step 3: Preparation of 7-chloro-3-(2,6-dichloro-3,5-dimethoxyphenyl)-2-methyl-2,6-naphthyridin-1(2H)-one

The compound was prepared referring to the synthetic method of step 6 of Intermediate 1 MS m/z (ESI): 399.2 [M+H]⁺.

Intermediate 13-19 were prepared referring to the synthesis method of Intermediate 12.

Intermediate MS: m/z No. Compound structure Compound name [M + 1]⁺ 13

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1(2H)-one 385 14

7-chloro-2-(cyclopropylmethyl)-3- (2,6-dichloro-3,5-dimethoxyphenyl)- 2,6-naphthyridin-1(2H)-one 440 15

N-(tert-butyl)-2-(7-chloro-3-(2,6- dichloro-3,5-dimethoxyphenyl)-1- oxo-2,6-naphthyridin-2(1H)- yl)acetamide 499 16

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(2- methoxyethyl)-2,6-naphthyridin- 1(2H)-one 444 17

2-chloro-6-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-8(7H)-one 387 18

2-chloro-6-(2,6-dichloro-3,5- dimethoxyphenyl)-7- methylpyrido[3,4-d]pyrimidin- 8(7H)-one 401 19

2-chloro-7-(cyclopropylmethyl)-6- (2,6-dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidin-8(7H)-one 441

Intermediate 20: Preparation of 6-chloro-2-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido [3,4-d]pyrimidine-4(3H)-one

Step-1: Preparation of 5-amino-2-chloroisonicotinamide

5-amino-2-chloroisonicotinic acid (4.0 g, 23 mmol) was added to SOCl₂ (50 mL), the mixture was heated to 80° C. for 4 h. After the reaction was completed, the mixture was cooled to room temperature and concentrated. The residue was dissolved in anhydrous THF (20 mL), and then the mixture was cooled under ice water bath, a concentrated aqueous ammonia (100 mL) was added. The reaction was completed, and the mixture was extracted for five times with CH₂Cl₂ (100 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtrated and concentrated to obtain compound 5-amino-2-chloroisonicotinamide (3.5 g yield: 88%).

Step 2: Preparation of 6-chloro-2-(3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-4(3H)-one

5-amino-2-chloroisonicotinamide (3.5 g, 20.4 mmol) and 3,5-dimethoxybenzaldehyde (3.7 g, 22.3 mmol) were dissolved in EtOH (50 mL) then HOAc (10 mL) was added, the mixture was heated to 80° C. for 2 days. The reaction liquid was concentrated, the residue was dissolved in the mixture of CH₂Cl₂ (100 mL) and THF (100 mL). Then MnO₂ (17.0 g, 87.0 mmol) was added, and the mixture was stirred at room temperature for 4 days. The reaction was completed, the mixture was filtered and concentrated. The residue was added to EtOAc (100 mL), stirred and filtrated to obtain compound 6-chloro-2-(3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-4(3H)-one (4.0 g, yield: 63%).

¹H NMR (400 MHz, DMSO-d6): δ ppm 12.78 (s, 1H), 8.91 (s, 1H), 7.95 (s, 1H), 7.44 (s, 1H), 7.43 (s, 1H), 3.84 (s, 611).

Step 3: Preparation of 6-chloro-2-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-4(3H)-one

6-chloro-2-(3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-4(3H)-one (1.0 g, 3.2 mmol) was dissolved in CH₃CN (50 mL), then the mixture was cooled to −20° C., SO₂Cl₂ (0.85 g, 6.3 mmol) was added, the mixture was reacted at this temperature for 3 h. After the reaction was completed, a saturated aqueous solution of NaHCO₃ was added to quench the reaction, and the mixture was filtrated to obtain compound 6-chloro-2-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-4(3H)-one (1.1 g, 92%). MS (ESI): m/z 386 [M+H]⁺.

Intermediate 21: Preparation of 6-chloro-2-(2,6-dichloro-3,5-dimethoxyphenyl)-3-methylpyrido [3,4-d]pyrimidine-4(3H)-one

6-chloro-2-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[34-d]pyrimidine-4(3H)-one (0.65 g, 1.68 mmol) was dissolved in DMF (20 mL), then the mixture was cooled to 0° under ice water bath, NaH (134 mg, 3.36 mmol) was added, the mixture was stirred at room temperature for 2 h. The reaction was completed, water (50 mL) was added to quench the reaction. The mixture was filtrated, washed with water and dried to obtain compound 6-chloro-2-(2,6-dichloro-3,5-dimethoxyphenyl)-3-methylpyrido[3,4-d]pyrimidin-4(3H)-one (0.65 g, yield:96%) MS n/z (ESI): 400 [M+H]⁺.

Intermediate 22: Preparation of 7-chloro-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(2,2,2-trifluoroethyl)-1,6-naphthyridin-2(1H)-one

Step 1: Preparation of Ethyl 6-chloro-4-((2,2,2-trifluoroethyl)amino)nicotinate

Ethyl 4,6-dichloronicotinate (4.0 g, 18.18 mmol) and trifluoroethylamine (2.7 g, 27.27 mmol) were dissolved in DMSO (50 mL) then Et₃N (5.5 g, 54.55 mmol) was added, the mixture was heated to 120° C. for 12 h. The reaction was completed, the mixture was cooled to room temperature, water (200 ml) was added, and then the mixture was extracted for three times with EtOAc (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtrated and concentrated. The crude product was separated by silica gel column chromatography (PE:EA=3:1) to obtain compound ethyl 6-chloro-4-((2,2,2-trifluoroethyl)amino)nicotinate (1.5 g, yield: 29.1%). MS (ESI): m/z 283.0 [M+1]⁺.

Step 2: Preparation of (6-chloro-4-((2,2,2-trifluoroethyl)amino)pyridin-3-yl)methanol

Ethyl 6-chloro-4-((2,2,2-trifluoroethyl)amino)nicotinate (1.5 g, 5.32 mmol) was dissolved in dried T-IF (30 mL) then the mixture was cooled under ice water bath LiAlH₄ (0.39 g, 10.64 mmol) was slowly added, and the mixture was stirred at 0° C. for 2 h. The reaction was completed, Na₂SO₄.10H₂O was added to quench the reaction. The mixture was filtrated, and the filtrate was concentrated to obtain compound (6-chloro-4-((2,2,2-trifluoroethyl)amino)pyridin-3-yl)methanol (1.1 g, yield: 86%).

Step 3: Preparation of 6-chloro-4-(22,2-trifluoroethylamino)nicotinaldehyde

(6-chloro-4-((2,2-trifluoroethyl)amino)pyridin-3-yl)methanol (1.1 g, 4.58 mmol) was dissolved in the mixture of CH₂Cl₂ and THF (30 mL/10 mL), then MnO₂ (4.78 g, 54.9 mmol) was added, and the mixture was stirred at room temperature for 12 h. The reaction was completed, filtrated, and the filtrate was concentrated to obtain crude product 6-chloro-4-((2,2,2-trifluoroethyl)amino)nicotinaldehyde (0.86, yield: 79%).

Step 4: Preparation of 7-chloro-3(3,5-dimethoxyphenyl)-1-(22,2-trifluoroethyl)1,6-naphthyridin-2(1H)-one

6-chloro-4-((2,2-trifluoroethyl)amino)nicotinaldehyde (0.86 g, 3.61 mmol) was dissolved in DMF (20 mL), then methyl 3,5-dimethoxyphenylacetate (760 mg, 3.61 mmol) and K₂CO₃ (1.5 g, 10.84 mmol) were added, the mixture was heated to 110° C. for 3 h. After the reaction was completed, the mixture was concentrated and separated by silica gel col un chromatography (PE:EA=10:1) to obtain 7-chloro-3-(3,5-dimethoxyphenyl)-1-(2,2,2-trifluoroethyl)-16-naphthyridin-2(1H)-one (960 mg, yield: 67%). MS (ESI): m/z 399.0 [M+1]⁺.

Step 5: Preparation of 7-cloro-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(2,2,2-trifluoroethyl)-1,6=naphthyridin-2(1H)-one

The compound was prepared referring to the synthetic method of step 6 of Intermediate 1.

Intermediates 23-25 were prepared according to the synthesis method of Intermediate 22.

Intermediate MS: m/z No. Compound structure Compound name [M + 1]⁺ 23

7-chloro-3-(2,6-dichloro- 3,5-dimethoxyphenyl)-1- methyl-1,6-naphthyridin- 2(1H)-one 400 24

7-chloro-3-(2,6-dichloro- 3,5-dimethoxyphenyl)-1- (tetrahydrofuran-3-yl)- 1,6-naphthyridin-2(1H)- one 456 25

7-chloro-3-(2,6-dichloro- 3,5-dimethoxyphenyl)-1- (2-morpholinoethyl)-1,6- naphthyridin-2(1H)-one 499

Intermediate 26: Preparation of 3-chloro-7-(2,6-dichloro-3,5-dimethoxyphenyl)-2,6-naphthyridine

Step 1: Preparation of 5-bromo-2-chloroisonicotinaldehyde

Diisopropylamine (8.95 g, 88 mmol) was dissolved in dried THF (100 mL) under N2, then the mixture was cooled to −78° C. N-butyllithium (50 ml, 78 mmol) was added dropwise, and then the mixture was stirred at 0° C. for 10 min. The mixture was cooled to −78° C., then 2-chloro-5-bromopyridine (10.0 g, 52 mmol) was added, the mixture was stirred at −78° C. for 1 h then dried DMF (11.4 g, 0.16 mol) was added dropwise, the mixture was stirred at this temperature for another 1 h. A ammonium chloride solution was added to quench the reaction, and the mixture was diluted with EtOAc (300 mL), washed for three times with water (50 mL), washed with saturated brine (100 ml.), dried over anhydrous sodium sulfate, filtrated, concentrated and separated by column chromatography (Eluent: PE/EtOAc 9:1) to obtain compound 5-bromo-2-chloroisonicotinaldehyde (7.0 g, yield: 61%).

¹H NMR (400 MHz, CDCl3): δ 10.3 (s, 1H), 8.69 (s, 1H), 7.73 (s, 1H).

MS m/z (ESI): 252.0, 254.0, 256.0 [M+MeOH+H]⁺.

Step 2: Preparation of 2-chloro-5-((3,5-dimethoxy phenyl)ethynyl)isonicotinaldehyde

5-bromo-2-chloroisonicotinaldehyde (2.5 g, 11.3 mmol), 1-ethynyl-3,5-dimethoxybenzene (1.93 g, 11.9 mmol), DIPEA (3.66 g, 28.4 mmol), CuI (108 mg, 0.6 mmol) and Pd(PPh₃)₂Cl₂ (398 mg, 0.6 mmol) were added to 1,4-dioxane (50 mL) under N2, the mixture was heated to 50° C. for 1 h. After the reaction was completed, the mixture was diluted with EtOAc (300 mL), washed successively with water (50 mL×3) and saturated brine (100 mL), concentrated and separated by column chromatography (Eluent: PE/EtOAc 9:1) to obtain compound 2-chloro-5-((3,5-dimethoxyphenyl)ethynyl)isonicotinaldehyde (3.0 g, yield: 75%). MS m/z (ESI): 302.2, 3042 [M+H]⁺.

Step 3: Preparation of 2-chloro-5-((3,5-dimethoxyphenyl)ethynyl)isonicotinaldehydeoxime

2-chloro-5-((3,5-dimethoxyphenyl)ethynyl)isonicotinaldehyde (0.6 g, 2 mmol), NaOAc (245 mg, 3.0 mmol) and hydroxylamine hydrochloride (207 mg, 3.0 mol) were dissolved in the mixture of ethanol and 1,2-dichloroethane (20 ml/1.2 mL) under N2, the mixture was heated to 50° C. for 50 min. After the reaction was completed, the mixture was diluted with EtOAc (200 mL) washed successively with water (50 mL×2) and saturated brine (80 mL), dried over anhydrous sodium sulfate, filtrated and concentrated to obtain compound 2-chloro-5-((3,5-dimethoxyphenyl)ethynyl)isonicotinaldehydeoxime (612 mg, yield: 100%).

Step 4: Preparation of 7-chloro-3-(3,5-dimethoxyphenyl)-2,6-naphthyridin-2-oxide

2-chloro-5-((3,5-dimethoxyphenyl)ethynyl)isonicotinaldehydeoxime (612 mg, 1.9 mmol) and AgNO₃ (66 mg 0.38 mmol) were added to chloroform (20 mL), the mixture was heated to 60° C. for 1 h. After the reaction was completed, the mixture was concentrated and separated by column chromatography (Eluent: CH₂Cl₂/MeOH 35:1) to obtain compound 7-chloro-3-(3,5-dimethoxyphenyl)-2,6-naphthyridin-2-oxide (580 mg, yield: 95%).

MS m/z (ESI): 317.2, 319.2 [M+H]⁺.

Step 5: Preparation of 3-chloro-7-(3,5-dimethoxyphenyl)-2,6-naphthyridine

7-chloro-3-(3,5-dimethoxyphenyl)-2,6-naphthyridin-2-oxide (200 ng, 0.63 mmol) was dissolved in dichloromethane (10 mL) tinder ice water bath, then phosphorus trichloride (0.7 mL, 1.4 mmol) was added, the mixture was stirred at room temperature overnight. The reaction was completed, the mixture was washed successively with a saturated aqueous solution of NaHCO₃ (20 ml), DCM (80 mL), saturated brine (50 ml), dried over anhydrous sodium sulfate, filtrated, concentrated and separated by column chromatography (Eluent: CH₂Cl₂/MeOH 50:1) to obtain compound 3-chloro-7-(3,5-dimethoxyphenyl)-2,6-naphthyridine (60 mg, yield: 32%). MS m/z (ESI): 301.1303.2 [M+H]+.

Step 6: Preparation of 3-chloro-7-(2,6-dichloro-3,5-dimethoxyphenyl)-2,6-naphthyridine

The compound was prepared referring to the synthesis method of Intermediate 1.

Intermediates 27-32 were prepared referring to the synthesis method of Intermediate 26.

Intermediate MS: m/z No. Compound structure Compound name [M + 1]⁺ 27

3-chloro-7-(2,6-difluoro-3,5- dimethoxyphenyl)-2,6-naphthyridine 337 28

3-chloro-7-(2-chloro-3,5- dimethoxyphenyl)-2,6-naphthyridine 336 29

3-chloro-7-(2-chloro-6-fluoro-3,5- dimethoxyphenyl)-2,6-naphthyridine 354 30

3-chloro-7-(2-chloro-3,5-dimethoxy- 6-methylphenyl)-2,6-naphthyridine 350 31

3-chloro-7-(2-chloro-6-isopropyl- 3,5-dimethoxyphenyl)-2,6- naphthyridine 378 32

3-chloro-7-(2-chloro-6-cyclopropyl- 3,5-dimethoxyphenyl)-2,6- naphthyridine 376

Intermediate 33: Preparation of 7-chloro-N-(cyclopropylmethyl)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-2,6-naphthyridine-1-amine

Step 1: Preparation of 7-chloro-1-((cyclopropylmethyl)amino)-3-(3,5-dimethoxyphenyl)-2,6-naphthyridine 2-oxide

7-chloro-3-(3,5-dimethoxyphenyl)-2,6-naphthyridine 2-oxide (4.0 g, 12.6 mmc) was dissolved in toluene (80 mL), cyclopropylmethylamine (7.19 g, 0.1 mol) and CuI (241 mg, 1.26 mmol) were added successively, the mixture was heated to 50 T overnight under an oxygen atmosphere. After the reaction was completed, the reaction liquid was filtrated and concentrated. The residue was separated by column chromatography (Eluent: dichloromethane/methanol 25:1) to obtain compound 7-choro-1-((cyclopropylmethyl)amino)-3-(3,5-dimethoxyphenyl)-2,6-naphthyridine 2-oxide (2.8 g, 57%).

MS m/z (ESI): 386.4 [M+H]⁺.

Step 2: Preparation of 7-chloro-N-(cyclopropylmethyl)-3-(3,5-dimethoxyphenyl)-2,6-naphthyridine-1-amine

7-chloro-1-((cyclopropylmethyl)amino)-3-(3,5-dimethoxyphenyl)-2,6-naphthridine 2-oxide (2.8 g, 5.1 mmol) was dissolved in dichloromethane (40 mL), PCl₃ (3 mL, 6.1 mmol) w as added dropwise under ice water bath, the mixture was stirred at room temperature for 1 h. A saturated solution of sodium hydrogencarbonate (50 mL) was added, then the mixture was extracted with dichloromethane (100 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and separated by column chromatography (Eluent: dichloromethane/methanol 50:1) to obtain compound 7-chloro-N-(cyclopropylmethyl)-3-(3,5-dimethoxyphenyl)-2,6-naphthyridine-1-amine (570 mg, 21%).

MS m/z (ESI): 370.4 [M+H]⁺.

Step 3: Preparation of 7-chloro-N(cyclopropylmethyl)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-2,6-naphthyridine-1-amine

7-chloro-N-(cyclopropylmethyl)-3-(3,5-dimethoxyphenyl)-2,6-naphthyridine-1-amine (550 mg, 0.27 mmol) was added to acetonitrile (20 mL), then sulfonyl chloride (73 mg, 0.54 mmol) was added dropwise at −30° C., the mixture was stirred at this temperature for 1 h. A saturated solution of sodium hydrogencarbonate (30 mL) was added, then the mixture was extracted with ethyl acetate (50 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtrated, concentrated and separated by column chromatography (Eluent: petroleum ether/ethyl acetate 10:1) to obtain compound 7-chloro-N-(cyclopropyl methyl)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-2,6-naphthyridine-1-amine (337 mg, 52%).

MS m/z (ESI+APCI): 438.2/440.2 [M+H]⁺.

Intermediates 34-131 were prepared referring to the synthesis method of Intermediate 33.

Intermediate MS: m/z No. Compound structure Compound name [M + 1]⁺ 34

7-chloro-N-(cyclopropylmethyl)-3-(2,6- dichloro-3,5-dimethoxyphenyl)-2,6- naphthyridine-1-amine 438 35

7-chloro-N-(cyclopropylmethyl)-3-(2,6- dichloro-3,5-di(methoxy-d₃)phenyl)-2,6- naphthyridine-1-amine 444 36

7-chloro-N-(cyclopropylmethyl)-3-(2,6- difluoro-3,5-di(methoxy-d₃)phenyl)-2,6- naphthyridine-1-amine 412 37

7-chloro-N-(cyclopropylmethyl)-3-(2,6- difluoro-3,5-dimethoxyphenyl)-2,6- naphthyridine-1-amine 406 38

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(2-methoxyethyl)- 2,6-naphthyridine-1-amine 442 39

2-((7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-1- yl)amino)ethan-1-ol 428 40

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(2-(isopropylthio) ethyl)-2,6-naphthyridine-1-amine 486 41

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(2-(ethylsulfonyl) ethyl)-2,6-naphthyridine-1-amine 504 42

N¹-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-1- yl)-N²,N²-dimethylethane-1,2-diamine 455 43

N¹-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-1- yl)-N³,N³-dimethylpropane-1,3-diamine 469 44

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-methyl-2,6- naphthyridine-1-amine 398 45

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-ethyl-2,6- naphthyridine-1-amine 412 46

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(2,2,2- trifluoroethyl)-2,6-naphthyridine-1- amine 466 47

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N,N-dimethyl-2,6- naphthyridine-1-amine 412 48

7-chloro-N-(cyclopropylmethyl)-3-(2,6- dichloro-3,5-dimethoxyphenyl)-N- methyl-2,6-naphthyridine-1-amine 452 49

N-(2-((7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-1- yl)amino)ethyl)methanesulfonamide 505 50

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((tetrahydrofuran2- yl)methyl)-2,6-naphthyridine-1-amine 468 51

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((tetrahydrofuran- 3-yl)methyl)-2,6-naphthyridine-1-amine 468 52

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(oxetan-3- ylmethyl)-2,6-naphthyridine-1-amine 454 53

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((tetrahydro-2H- pyran-4-yl)methyl)-2,6-naphthyridine- 1-amine 482 54

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(oxetan-3-yl)-2,6- naphthyridine-1-amine 440 55

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(tetrahydro-2H- pyran-4-yl)-2,6-naphthyridine-1-amine 468 56

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(tetrahydrofuran- 3-yl)-2,6-naphthyridine-1-amine 454 57

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((1- methylpyrrolidin-3-yl)methyl)-2,6- naphthyridine-1-amine 481 58

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((1- methylpyrrolidin-2-yl)methyl)-2,6- naphthyridine-1-amine 481 59

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(1- methylpyrrolidin-3-yl)-2,6- naphthyridine-1-amine 467 60

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((1- methylazetidin-3-yl)methyl)-2,6- naphthyridine-1-amine 467 61

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(1- methylazetidin-3-yl)-2,6- naphthyridine-1-amine 453 62

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(1- methylpiperidin-4-yl)-2,6- naphthyridine-1-amine 481 63

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((1- methylpiperidin-4-yl)methyl)- 2,6-naphthyridine-1-amine 495 64

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(3,3- difluorocyclobutyl)-2,6- naphthyridine-1-amine 474 65

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(3,3- difluorocyclopentyl)-2,6- naphthyridine-1-amine 488 66

7-chloro-N-(cyclopentylmethyl)-3- (2,6-dichloro-3,5-dimethoxyphenyl)- 2,6-naphthyridine-1-amine 466 67

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-phenethyl-2,6- naphthyridine-1-amine 488 68

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((1-methyl-1H- pyrazol-4-yl)methyl)-2,6- naphthyridine-1-amine 478 69

2-(4-(((7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-1- yl)amino)methyl)-1H-pyrazol-1- yl)ethan-1-ol 508 70

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((1-(2- methoxyethyl)-1H-pyrazol-4- yl)methyl)-2,6-naphthyridine-1-amine 522 71

N-benzyl-7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridine- 1-amine 474 72

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(2-(4- methylpiperazin-1-yl)ethyl)- 2,6-naphthyridine-1-amine 510 73

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(2- morpholinoethyl)-2,6-naphthyridine- 1-amine 497 74

2-((7-chloro-3-(2-chloro-3- methoxyphenyl)-2,6-naphthyridin- 1-yl)amino)ethan-1-ol 364 75

2-((7-chloro-3-(3,5-dimethoxyphenyl)- 2,6-naphthyridin-1-yl)amino)ethan-1-ol 360 76

2-((7-chloro-3-(2-fluoro-3- methoxyphenyl)-2,6-naphthyridin-1- yl)amino)ethan-1-ol 348 77

N¹-(7-chloro-3-(2-chloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-N²,N²-dimethylethane-1,2-diamine 421 78

N¹-(7-chloro-3-(3,5-dimethoxyphenyl)- 2,6-naphthyridin-1-yl)-N²,N²- dimethylethane-1,2-diamine 387 79

N¹-(7-chloro-3-(2-fluoro-3- methoxyphenyl)-2,6-naphthyridin-1-yl)- N²,N²-dimethylethane-1,2-diamine 375 80

7-chloro-3-(2-fluoro-3,5- dimethoxyphenyl)-N- ((tetrahydrofuran2-yl)methyl)- 2,6-naphthyridine-1-amine 418 81

7-chloro-3-(2-fluoro-3-methoxyphenyl)- N-((tetrahydrofuran2-yl)methyl)-2,6- naphthyridine-1-amine 388 82

(S)-7-chloro-N-(1-cyclopropylethyl)-3- (2,6-dichloro-3,5-dimethoxyphenyl)- 2,6-naphthyridine-1-amine 452 83

(S)-7-chloro-N-(1-cyclopropylethyl)-3- (2,6-difluoro-3,5-dimethoxyphenyl)-2,6- naphthyridine-1-amine 420 84

7-chloro-N-cyclopropyl-3-(2,6-dichloro- 3,5-dimethoxyphenyl)-2,6- naphthyridine-1-amine 424 85

7-chloro-N-cyclopropyl-3-(2,6-difluoro- 3,5-dimethoxyphenyl)-2,6- naphthyridine-1-amine 392 86

1-(azetidin-1-yl)-7-chloro-3-(2,6- dichloro-3,5-dimethoxyphenyl)-2,6- naphthyridine 424 87

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(3- methoxyazetidin-1-yl)-2,6- naphthyridine 454 88

7-chloro-3-(2,6-difluoro-3,5- dimethoxyphenyl)-1-(3- methoxyazetidin-1-yl)- 2,6-naphthyridine 422 89

1-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6- naphthyridin-1-yl)-N,N- dimethylazetidin-3-amine 467 90

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(3- (trifluoromethyl)azetidin-1-yl)- 2,6-naphthyridine 492 91

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(3,3- dimethylazetidin-1-yl)-2,6- naphthyridine 452 92

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(3,3- difluoroazetidin-1-yl)-2,6- naphthyridine 460 93

1-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-3-methylazetidin-3-ol 454 94

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(3-methoxy- 3-methylazetidin-1-yl)-2,6- naphthyridine 468 95

7-chloro-3-(2,6-difluoro-3,5- dimethoxyphenyl)-1-(3-methoxy-3- methylazetidin-1-yl)-2,6- naphthyridine 436 96

1-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-3-methylazetidin-3-carbonitrile 463 97

6-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-2-oxa-6-azaspiro[3.3]heptane 466 98

6-(7-chloro-3-(2,6-difluoro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-2-oxa-6-azaspiro[3.3]heptane 434 99

6-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-1-oxa-6-azaspiro[3.3]heptane 466 100

6-(7-chloro-3-(2,6-difluoro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-1-oxa-6-azaspiro[3.3]heptane 434 101

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(2-azaspiro[3.3] hept-2-yl)-2,6-naphthyridine 464 102

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(2-azaspiro[3.4] oct-2-yl)-2,6-naphthyridine 478 103

2-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-1- yl)-6-oxa-2-azaspiro[3.4]octane 480 104

2-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-7-oxa-2-azaspiro[3.5]nonane 494 105

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(pyrrolidin-1-yl)- 2,6-naphthyridine 438 106

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(3- methoxypyrrolidin-1-yl)-2,6- naphthyridine 468 107

7-chloro-3-(2,6-difluoro-3,5- dimethoxyphenyl)-1-(3- methoxypyrrolidin-1-yl)-2,6- naphthyridine 436 108

1-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)pyrrolidine-3-carbonitrile 463 109

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(3,3- difluoropyrrolidin-1-yl)-2,6- naphthyridine 474 110

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(3-methoxy- 3-methylpyrrolidin-1-yl)-2,6- naphthyridine 482 111

7-chloro-3-(2,6-difluoro-3,5- dimethoxyphenyl)-1-(3-methoxy- 3-methylpyrrolidin-1-yl)-2,6- naphthyridine 450 112

1-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-3-methylpyrrolidine-3-carbonitrile 477 113

1-(3-azabicyclo[3.1.0]hex-3-yl)-7- chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridine 450 114

7-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-2-oxa-7-azaspiro[34.4]nonane 494 115

4-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)morpholine 454 116

4-(7-chloro-3-(2,6-difluoro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)morpholine 422 117

4-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-2-methylmorpholine 468 118

4-(7-chloro-3-(2,6-difluoro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-2-methylmorpholine 436 119

4-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-2,6-dimethylmorpholine 482 120

4-(7-chloro-3-(2,6-difluoro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-2,6-dimethylmorpholine 450 121

1-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)piperidin-4-ol 468 122

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(4- methoxypiperidin-1-yl)-2,6- naphthyridine 482 123

7-chloro-3-(2,6-difluoro-3,5- dimethoxyphenyl)-1-(4- methoxypiperidin-1-yl)-2,6- naphthyridine 450 124

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(3- methoxypiperidin-1-yl)-2,6- naphthyridine 482 125

1-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-4-methylpiperidin-4-ol 482 126

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-(4-methoxy-4- methylpiperidin-1-yl)-2,6- naphthyridine 496 127

7-chloro-3-(2,6-difluoro-3,5- dimethoxyphenyl)-1-(4-methoxy- 4-methylpiperidin-1-yl)-2,6- naphthyridine 464 128

1-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)-4-methylpiperidine-4-carbonitrile 491 129

N-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)cyclopropyl carboxamide 452 130

N-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)tetrahydrofuran 2-carboxamide 482 131

N-(7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin- 1-yl)sulfonamide 462

Intermediate 132: Preparation of 6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-methoxy-2-(methylthio)pyrido[3,4-d]pyrimidine

Step 1: Preparation of Methyl 5-(3,5-diethoxyphenyl)ethynyl)-2-methylthio)pyrimidine-4-carboxylate

Methyl 5-bromo-2-(methylthio)pyrimidine-4-carboxylate (2631 mg, 10.0 mmol) and 1-ethynyl-3,5-dimethoxybenzene (1622 mg, 10.0 mmol) were dissolved in dried THF (50 mL). The gas was exchanged with N₂, Et₃N (2.8 mL, 20.0 mmol), Pd(PPh₃)₂Cl₂ (702 mg, 1.0 mmol), PPh₃ (525 mg, 2.0 mmol) and CuI (190 mg, 1.0 mmol) were added successively under N₂, the mixture was heated to 90° C. and stirred overnight. After the reaction was completed, the mixture was cooled to room temperature, added with a saturated aqueous solution of NaHCO₃ (100 mL), extracted tice with EtOAc (100 mL), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtrated, concentrated, and separated by silica gel column chromatography (PE:EA 4:1) to obtain compound methyl 5-((3,5-dimethoxyphenyl)ethynyl)-2-(methylthio)pyrimidine-4-carboxylate (2.5 g, yield: 73%). MS m/z (ESI): 345.2 [M+H]⁺.

Step 2: Preparation of 5-((3,5-dimethoxyphenyl)ethynyl)-2-(methylthio)pyrimidine-4-carboxylic Acid

Methyl 5-((3,5-dimethoxyphenyl)ethynyl)-2-(methylthio)pyrimidine-4-carboxylate (600 m g, 1.742 mmol) was dissolved in methanol (15 mL), and then an aqueous lithium hydroxide monohydrate (366 mg, 8.711 mmol) in water (5 mL) was added, and the mixture was stirred at room temperature overnight. The reaction was completed. The organic solvent was evaporated by reduced pressure, EtOAc (30 mL) was added to the residue, and the pH was adjusted with 1 N hydrochloric acid solution to 34. The organic phase was separated, washed with saturated brine, dried over anhydrous sodium sulfate, filtrated, and concentrated to obtain compound 5-((3,5-dimethoxyphenyl)ethynyl)-2-(methylthio)pyrimidine-4-carboxylic acid (584 mg, quantitative yield). MS m/z (ESI): 331.2 [M+H]+.

Step 3: Preparation of 6-(3,5-dimethoxyphenyl)-2-(methylthio)-8H-pyrano[3,4-d]pyrimidine-8-one

5-((3,5-dimethoxyphenyl)ethynyl)-2-(methylthio)pyrimidine-4-carboxylic acid (584 mg, 1.768 mmol) was suspended in acetone (25 mL), and AgNO₃ (180 mg, 1.059 mmol) was added to the suspension. The mixture was stirred at room temperature for 4 h, and green so lid was precipitated, filtered to obtain 6-(3,5-dimethoxyphenyl)-2-(methylthio)-8H-pyrano[3,4-d]pyrimidine-8-one (600 mg, the crude product) MS m/z (ESI): 331.2 [M+H]⁺.

Step 4: Preparation of 6-(3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine-8(7H)-one

6-(3,5-dimethoxyphenyl)-2-(methylthio)-8H-pyrano[3,4-d]pyrimidine-8-one (600 mg, the crude product) was added to glacial acetic acid (50 mL), then ammonium acetate (2.1 g, 27.243 mmol) was added, the mixture was heated to 115° C. for 16 h. The reaction was completed, the mixture was cooled to room temperature, poured slowly into a saturated aqueous sodium bicarbonate solution, and extracted with EtOAc (100 mL). The organic phase was separated, and washed with saturated brine, dried over anhydrous sodium sulfate, filtrated, concentrated and separated by column chromatography (Eluent: CH₂Cl₂/MeOH 0˜6%) to obtain compound 6-(3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine-8(7H)-one (298 mg, two-step yield: 50%). MS m/z (ESI): 330.2 [M+H]⁺.

Step 5: Preparation of 6-(3,5-dimethoxyphenyl)-8-methoxy-2-(methylthio)pyrido[3,4-d]pyrimidine

6-(3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine-8(7H)-one (100 mg, 0.304 mmol) and silver carbonate (109 mg, 0.395 mmol) were suspended in toluene (3 mL), then methyl iodide (431 mg, 3.036 mmol) was added. The mixture was heated to 100° C. in a sealed tube for 3 h. The reaction was completed, the mixture was cooled to room temperature, diluted with EtOA, and filtrated to remove salt. The filtrate was concentrated and separated by column chromatography (Eluent: PE/EtOAc 10-80%) to obtain compound 6-(3,5-dimethoxyphenyl)-8-methoxy-2-(methylthio)pyrido[3,4-d]pyrimidine (47 mg, yield: 4 5%). MS m/z (ESI):344.3 [M+H]⁺.

Step 6: Preparation of 6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-methoxy-2-(methylthio) pyrido[3,4-d]pyrimidine

The compound was prepared referring to the synthesis method of Intermediate 1.

Intermediates 133-134 were prepared by referring, to the synthesis method of example 1.2.

Intermediate MS: m/z No. Compound structure Compound name [M + 1]⁺ 133

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-ethoxy-2,6- naphthyridine 413 134

6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-ethoxy-2- (methylthio)pyrido[3,4- d]pyrimidine 426

Intermediate 135: Preparation of 6-(2,6-dichloro-3,5-dimethoxyphenyl)-N-(2-methoxyethyl)-2-(methylthio)pyrido[3,4-d]pyrimidine-8-amine

Step 1: Preparation of 8-chloro-6-(3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine

6-(3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine-8(7H)-one (20.0 mg, 0.06 1 mmol) and N,N-diisopropylethylamine (78 mg, 0.610 mmol) were added to acetonitrile (2 mL), then POCl₃ (0.8 mL) was added, the mixture was heated to 90° C. and stirred overnight. The solvent was removed by reduced pressure. The residue was diluted with EtO Ac (10 mL) and washed with a saturated sodium bicarbonate solution. The organic phase was separated, washed with saturated brine, dried over anhydrous sodium sulfate, filtrated, concentrated and separated by column chromatography (Eluent: PE/EtOAc 040%) to obtain compound 8-chloro-6-(3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine (6 mg, yield: 28%).

MS m/z (ESI): 348.2 [M+H]⁺.

Step 2: Preparation of 6-(3,5-dimethoxyphenyl)-N-(2-methoxyethyl)-2-(methylthio)pyrido[3,4-d]pyrimidine-8-amine

8-chloro-6-(3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine (6 mg, 0.017 mmol) and N,N-diisopropylethylamine (6.5 mg, 0.052 mmol) were dissolved in acetonitrile (1.5 mL), then 2-methoxyethyl-1-amine (4 mg, 0.052 mmol) was added, the mixture was heated to 90° C. and stirred overnight. The reaction was completed, the mixture was cooled to room temperature, diluted with EtOAc (5 mL), washed with saturated brine, dried over anhydrous sodium sulfate, filtrated, concentrated and separated by column chromatography (Eluent: PE/EtOAc 0-50%) to obtain compound 6-(3,5-dimethoxyphenyl)-N-(2-methoxyethyl)-2-(methylthio)pyrido[3,4-d]pyrimidine-8-amine (4 mg, yield: 61%).

MS m/z (ESI): 387.4 [M+H]⁺.

Step 3: Preparation of 6-(2,6-dichloro-3,5-dimethoxyphenyl)-N-(2-methoxyethyl)-2-(methylthio)pyrido[3,4-d]pyrimidine-8-amine

The compound was prepared referring to the synthesis method of Intermediate 1.

Intermediate 139: Preparation of 4-(6-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidin-8-yl)morpholine

Step 1: Preparation of 2,4-difluoro-3-iodo-1,5-dimethoxybenzene

2,6-difluoro-3,5-dimethoxyaniline (27.0 g, 143 mmol) was added to 6.0 M hydrochloric acid solution (240 mL), and NaNO₂ aqueous solution (10.35 g, 150 mmol, 30 mL water) was slowly added dropwise under ice water for cooling within 25 min. After the addition was completed, the mixture was reacted for another 15 min to obtain an orange-re d suspension, and then added to an aqueous KI solution (94.9 g, 570 mmol, 150 mL water), the mixture was heated to room temperature and stirred for 30 min to precipitate a solid. The mixture was filtrated and washed with water to obtain a crude product. MeOH (60 mL) was added to the crude product, then the mixture was stirred at room temperature for 30 min, filtrated, and dried to obtain 2,4-difluoro-3-iodo-1,5-dimethoxybenzene (29.3 g, yield: 68%).

Step 2: Preparation of (2,6-difluoro-3,5-dimethoxyphenylacetylene)trimethylsilane

2,4-difluoro-3-iodo-1,5-dimethoxybenzene (25.8 g, 86.0 mmol), trimethylsilylacetylene (36.5 mL, 258 mmol), CuI (817 mg, 4.3 mmol) and triethylamine (35.8 mL, 258 mmol) were added to DMF (250 mL) under N2, then Pd(PPh₃)₂Cl₂ (3.15 g, 4.3 mmol) was added, and the mixture was heated to 50° C. for 2 h. The reaction was completed, a saturated aqueous NH₄Cl solution was added to quench the reaction, the mixture was extracted for three times with dichloromethane, and the organic phases were combined, dried over Na₂SO₄, filtrated and concentrated to obtain a crude product (27.0 g) which was used directly in the next step.

Step 3: Preparation of 3-ethynyl-2,4-difluoro-1,5-dimethoxybenzene

(2,6-difluoro-3,5-dimethoxyphenylacetylene)trimethylsilane (27.0 g, a crude product) was added to the mixture of THF and MeOH (200/200 mL), then aqueous NaOH solution (8.6 mL, 8.6 mmol, 1.0 N) was added, and the mixture was stirred at room temperature for 15 mm. The reaction was completed, a saturated aqueous NH₄Cl solution was added to quench the reaction, and the mixture was extracted for three times with dichloromethane, and the organic phases were combined, dried over anhydrous sodium sulfate, filtrated and concentrated. MeOH (50 mL) was added to the crude product, and then the mixture was stirred at room temperature for 30 min, filtered to obtain the target product (15.0 g, two-step yield: 88%).

Step 4: Preparation of Methyl 5-((2,6-difluoro-3,5-dimethoxyphenyl)ethynyl)-2-(methylthio)pyrimidine-4-carboxylate

3-ethynyl-2,4-difluoro-1,5-dimethoxybenzene (10.0 g, 50.5 mmol) and methyl 5-bromo-2-methylthio-pyrimidine-4-carboxylate (13.0 g, 49.5 mmol) were dissolved in DMF (100 mL), then CuI (479 mg, 2.52 mmol), Pd(PPh₃)₄ (2.91 g, 2.52 mmol) and Et₃N (35.0 mL, 252.5 mmol) were added, the mixture was heated to 100° C. for 1.5 h under N2. The reaction was completed, the mixture was cooled to room temperature, a saturated aqueous NH₄Cl solution was added to quench the reaction, then the mixture was extracted for three times with dichloromethane, and the organic phases were combined, dried over anhydrous sodium sulfate, filtrated and concentrated to obtain a crude product, then the crude product was separated by silica gel column chromatography (PE:EA:DCM=10:2:1) to obtain the target product (15.4 g, yield: 82%). ¹H NMR (400 MHz, CDCl₃) δ 8.82 (s, 1H), 6.69 (t, J=8.0 Hz, 1H), 4.03 (s, 3H), 3.90 (s, 6H), 2.63 (s, 3H).

Step 5: Preparation of 5-((2,6-difluoro-3,5-dimethoxyphenyl)ethynyl)-2-(methylthio)pyrimidine-4-carboxylic Acid

Methyl 5-((2,6-difluoro-3,5-dimethoxyphenyl)ethynyl)-2-(methylthio)pyrimidine-4-carboxylate (30.0 g, 78.9 mmol) was dissolved in THF (300 mL), then LiOH/H₂O (236.8 mL, 236.8 mmol, 1 M) was added, the mixture was stirred at room temperature for 2 h. The reaction was completed, the mixture was concentrated to remove THF, then acidified to pH 3 with diluted hydrochloric acid to precipitate a solid. The mixture was filtrated, washed with water, and dried to obtain the target product (28.5 g, yield: 99%).

Step 6: Preparation of 6-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylthio)-8H-pyrano[3,4-d]pyrimidine-8-one

5-((2,6-difluoro-3,5-dimethoxyphenyl)ethynyl)-2-(methylthio)pyrimidine-4-carboxylic acid (2.5 g, 6.83 mmol) was dissolved in DCE (50 mL), then TFA (0.5 mL) was added, the mixture was heated to reflux overnight. The reaction was completed, the mixture was concentrated, MeOH (50 mL) was added, then the mixture was stirred at room temperature for 30 min. The mixture was filtrated, and the solid was washed with MeOH (10 mL) to obtain the target product (2.0 g, yield: 80%). ¹H NMR (400 MHz, DMSO-d₆) δ 9.23 (s, 1H), 7.22 (t, J=8.4 Hz, 1H), 7.17 (s, 1H), 3.93 (s, 6H), 2.63 (s, 3H).

Step 7: Preparation of 6-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine-8(7H)-one

The compound was prepared referring to the synthesis method of step 4 of Intermediate 132.

Step 8: Preparation of 8-chloro-6-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine

6-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine-8(7H)-one (1 g, 2.74 mmol) was dissolved in DCE (80 mL), the mixture was heated to 90° C., then phenylphosphonic dichloride (3.0 mL, 21.92 mmol) was added, the mixture was heated and stirred for 16 h, and then cooled. pH was adjusted to neutral under ice bath. The mixture was extracted with DCM, and then separated by silica gel column chromatography (MeOH/DCM 1/20) to obtain compound 8-chloro-6-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine (930 mg, yield:88%). MS m/z (ESI): 384 [M+H]⁺.

Step 9: Preparation of N-(cyclopropylmethyl)-6-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine-8-amine

The compound was prepared referring to the synthesis method of step 2 of Intermediate 135.

Intermediates 136-330 were prepared referring to the synthesis method of Intermediate 135 or 139.

Intermediate MS: m/z No. Compound structure Compound name [M + 1]⁺ 136

N-(cyclopropylmethyl)-6-(2,6-dichloro- 3,5-dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidine-8-amine 451 137

N-(cyclopropylmethyl)-6-(2,6-dichloro- 3,5-di(methoxy-d₃)phenyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 457 138

N-(cyclopropylmethyl)-6-(2,6-difluoro- 3,5-di(methoxy-d₃)phenyl)-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 425 140

2-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)amino) ethan-1-ol 441 141

6-(2,6-dichloro-3,5-dimethoxyphenyl)- N-(2-(isopropylthio)ethyl)-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 499 142

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(2-(ethylsulfonyl) ethyl)-2-(methylthio)pyrido[3,4- d]pyrimidine-8-amine 518 143

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-methyl-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 411 144

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-ethyl-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 425 145

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N,N-dimethyl-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 425 146

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)-N- (2,2,2-trifluoroethyl)pyrido[3,4- d]pyrimidine-8-amine 479 147

N-(cyclopropylmethyl)-6-(2,6-dichloro- 3,5-dimethoxyphenyl)-N-methyl-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 465 148

N¹-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-N²,N²- dimethylethane-1,2-diamine 468 149

N¹-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-N³,N³- dimethylpropane-1,3-diamine 482 150

N-(2-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8- yl)amino)ethyl)sulfonamide 518 151

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)- N-((tetrahydrofuran2-yl)methyl) pyrido[3,4-d]pyrimidine-8-amine 481 152

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)-N- ((tetrahydrofuran-3-yl)methyl) pyrido[3,4-d]pyrimidine-8-amine 481 153

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)-N- (oxetan-3-ylmethyl)pyrido[3,4- d]pyrimidine-8-amine 467 154

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)-N- ((tetrahydro-2H-pyran-4-yl)methyl) pyrido[3,4-d]pyrimidine-8-amine 495 155

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)-N- (oxetan-3-yl)pyrido[3,4-d]pyrimidine- 8-amine 453 156

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)-N- (tetrahydro-2H-pyran-4-yl)pyrido[3,4- d]pyrimidine-8-amine 481 157

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)-N- (tetrahydrofuran-3-yl)pyrido[3,4- d]pyrimidine-8-amine 467 158

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((1- methylpyrrolidin-3-yl)methyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 494 159

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((1- methylpyrrolidin-2-yl)methyl)- 2-(methylthio)pyrido[3,4- d]pyrimidine-8-amine 494 160

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(1- methylpyrrolidin-3-yl)-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 480 161

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((1- methylazetidin-3-yl)methyl)- 2-(methylthio)pyrido[3,4- d]pyrimidine-8-amine 480 162

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(1- methylazetidin-3-yl)-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 466 163

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(1- methylpiperidin-4-yl)-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 494 164

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((1- methylpiperidin-4- yl)methyl)-2-(methylthio) pyrido[3,4-d]pyrimidine-8- amine 508 165

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(3,3- difluorocyclobutyl)-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 487 166

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(3,3- difluorocyclopentyl)-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 501 167

N-(cyclopentylmethyl)-6-(2,6- dichloro-3,5-dimethoxyphenyl)- 2-(methylthio)pyrido[3,4- d]pyrimidine-8-amine 479 168

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)- N-phenethylpyrido[3,4- d]pyrimidine-8-amine 501 169

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)- N-phenylpyrido[3,4- d]pyrimidine-8-amine 473 170

N-benzyl-6-(2,6-dichloro-3,5- dimethoxyphenyl)-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 487 171

N-(3-aminobenzyl)-6-(2,6-dichloro- 3,5-dimethoxyphenyl)-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 502 172

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((1-methyl- 1H-pyrazol-4-yl)methyl)-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 491 173

2-(4-(((6-(2,6-dichloro-3,5- dimethoxyphenyl)-2- (methylthio)pyrido[3,4- d]pyrimidin-8-yl)amino)methyl)- 1H-pyrazol-1-yl)ethan-1-ol 521 174

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((1-(2- methoxyethyl)-1H-pyrazol-4- yl)methyl)-2-(methylthio) pyrido[3,4-d]pyrimidine-8-amine 535 175

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)-N- neopentylpyrido[3,4-d]pyrimidine-8- amine 467 176

N¹-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-N³- isopropylpropane-1,3-diamine 496 177

N¹-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-N⁴- isopropylbutane-1,4-diamine 510 178

N¹-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-N⁴,N⁴- dimethylbutane-1,4-diamine 496 179

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)-N- (4-(pyrrolidin-1-yl)butyl)pyrido[3,4- d]pyrimidine-8-amine 522 180

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(2-(4- methylpiperazin-1-yl)ethyl)-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 523 181

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)-N- (2-morpholinoethyl)pyrido[3,4- d]pyrimidine-8-amine 510 182

N-(2-(3-aminopyrrolidin-1-yl)ethyl)- 6-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-(methylthio)pyrido[3,4-d]pyrimidine- 8-amine 509 183

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(2-(3- (dimethylamino)pyrrolidin-1-yl) ethyl)-2-(methylthio)pyrido[3,4- d]pyrimidine-8-amine 537 184

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(2-(2- (dimethylamino)ethoxy)ethyl)-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 512 185

(1-(4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)amino) butyl)pyrrolidin-2-yl)methanol 552 186

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(4-(3,3- difluoropyrrolidin-1-yl)butyl)-2- (methylthio)pyrido[3,4- d]pyrimidine-8-amine 558 187

6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(4-(3- methoxypyrrolidin-1-yl)butyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 552 188

N-(cyclopropylmethyl)-6-(2-fluoro- 3,5-dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidine-8-amine 401 189

N-(cyclopropylmethyl)-6-(2-fluoro-3- methoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidine-8-amine 371 190

6-(2-chloro-3-(methoxy-d₃)phenyl)-N- (cyclopropylmethyl)-2-(methylthio) pyrido[3,4-d]pyrimidine-8-amine 390 191

N-(cyclopropylmethyl)-6-(2-fluoro-3- (methoxy-d₃)phenyl)-2-(methylthio) pyrido[3,4-d]pyrimidine-8-amine 374 192

6-(2-chloro-3,5-di(methoxy-d₃) phenyl)-N-(cyclopropylmethyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 423 193

N-(cyclopropylmethyl)-6-(2-fluoro- 3,5-di(methoxy-d₃)phenyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 407 194

6-(2-chloro-3-methoxyphenyl)-2- (methylthio)-N-((tetrahydrofuran2- yl)methyl)pyrido[3,4-d]pyrimidine- 8-amine 417 195

6-(2-chloro-3-methoxyphenyl)-N-((1- methylpyrrolidin-2-yl)methyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 430 196

6-(2-chloro-3,5-dimethoxyphenyl)- N-((1-methylpyrrolidin-2-yl)methyl)- 2-(methylthio)pyrido[3,4-d]pyrimidine- 8-amine 460 197

6-(2-fluoro-3-methoxyphenyl)-N-((1- methylpyrrolidin-2-yl)methyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 414 198

6-(2-chloro-3-methoxyphenyl)-N-(2- (4-methylpiperazin-1-yl)ethyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 459 199

6-(2-chloro-3,5-dimethoxyphenyl)-N- (2-(4-methylpiperazin-1-yl)ethyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 489 200

6-(2-chloro-3,5-dimethoxyphenyl)-2- (methylthio)-N-(tetrahydro-2H-pyran- 4-yl)pyrido[3,4-d]pyrimidine-8-amine 447 201

6-(3,5-dimethoxyphenyl)-N-(2-(4- methylpiperazin-1-yl)ethyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 455 202

6-(2,6-difluoro-3,5-dimethoxyphenyl)- N-(2-methoxyethyl)-2-(methylthio) pyrido[3,4-d]pyrimidine-8-amine 423 203

6-(2,6-difluoro-3,5-dimethoxyphenyl)- 2-(methylthio)-N-(tetrahydro-2H- pyran-4-yl)pyrido[3,4-d]pyrimidine-8- amine 449 204

6-(2,6-difluoro-3,5-dimethoxyphenyl)- N-(1-methylpiperidin-4-yl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 462 205

6-(2,6-difluoro-3,5-dimethoxyphenyl)- N-(2-(4-methylpiperazin-1-yl)ethyl)- 2-(methylthio)pyrido[3,4-d]pyrimidine- 8-amine 491 206

6-(2,6-difluoro-3,5-dimethoxyphenyl)- N-((1-methylpyrrolidin-2-yl)methyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 462 207

6-(2,6-difluoro-3,5-dimethoxyphenyl)- N-(1-methylpyrrolidin-3-yl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 448 208

6-(2,6-difluoro-3,5-dimethoxyphenyl)- N-((1-methylpyrrolidin-3-yl)methyl)- 2-(methylthio)pyrido[3,4-d]pyrimidine- 8-amine 462 209

6-(2,6-difluoro-3,5-dimethoxyphenyl)- N-((1-methyl-1H-pyrazol-4-yl)methyl)- 2-(methylthio)pyrido[3,4- d]pyrimidine-8-amine 459 210

6-(2,6-difluoro-3,5-dimethoxyphenyl)- 2-(methylthio)-N-((tetrahydrofuran2- yl)methyl)pyrido[3,4-d]pyrimidine-8- amine 449 211

6-(2,6-difluoro-3,5-dimethoxyphenyl)- 2-(methylthio)-N-(tetrahydrofuran-3- yl)pyrido[3,4-d]pyrimidine-8-amine 435 212

7-chloro-3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-isopropyoxy-2,6- naphthyridine 427 213

7-chloro-1-(cyclopropylmethoxy)-3- (2,6-dichloro-3,5-dimethoxyphenyl)- 2,6-naphthyridine 439 214

6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-isopropyoxy-2-(methylthio) pyrido[3,4-d]pyrimidine 440 215

8-(cyclopropylmethoxy)-6-(2,6- dichloro-3,5-dimethoxyphenyl)-2- (methylthio)pyrido[3,4-d]pyrimidine 452 216

(R)-N-(1-cyclopropylethyl)-6-(2,6- dichloro-3,5-dimethoxyphenyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 465 217

(S)-N-(1-cyclopropylethyl)-6-(2,6- dichloro-3,5-dimethoxyphenyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 465 218

(S)-6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(3,3-dimethylbut- 2-yl)-2-(methylthio)pyrido[3,4- d]pyrimidine-8-amine 481 219

(R)-6-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(3,3-dimethylbut- 2-yl)-2-(methylthio)pyrido[3,4- d]pyrimidine-8-amine 481 220

(R)-N-(1-cyclopropylethyl)-6-(2,6- difluoro-3,5-dimethoxyphenyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 433 221

(S)-N-(1-cyclopropylethyl)-6-(2,6- difluoro-3,5-dimethoxyphenyl)-2- (methylthio)pyrido[3,4-d]pyrimidine- 8-amine 433 222

(S)-6-(2,6-difluoro-3,5- dimethoxyphenyl)-N-(3,3-dimethylbut- 2-yl)-2-(methylthio)pyrido[3,4- d]pyrimidine-8-amine 449 223

(R)-6-(2,6-difluoro-3,5- dimethoxyphenyl)-N-(3,3-dimethylbut- 2-yl)-2-(methylthio)pyrido[3,4- d]pyrimidine-8-amine 449 224

N-cyclopropyl-6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidine-8-amine 437 225

N-cyclopropyl-6-(2,6-difluoro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidine-8-amine 405 226

8-(azetidin-1-yl)-6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidine 437 227

6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-(3-methoxyazetidin-1-yl)-2- (methylthio)pyrido[3,4-d]pyrimidine 467 228

6-(2,6-difluoro-3,5-dimethoxyphenyl)- 8-(3-methoxyazetidin-1-yl)-2- (methylsulfanyl)pyrido[3,4- d]pyrimidine 435 229

1-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-N,N- dimethylazetidin-3-amine 480 230

6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio)-8- (3-(trifluoromethyl)azetidin-1- yl)pyrido[3,4-d]pyrimidine 505 231

6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-(3,3-dimethylazetidin-1-yl)-2- (methylthio)pyrido[3,4-d]pyrimidine 465 232

6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-(3,3-difluoroazetidin-1-yl)-2- (methylthio)pyrido[3,4-d]pyrimidine 473 233

1-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-3- methylazetidin-3-ol 467 234

6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-(3-methoxy-3-methylazetidin-1-yl)- 2-(methylthio)pyrido[3,4-d]pyrimidine 481 235

6-(2,6-difluoro-3,5-dimethoxyphenyl)- 8-(3-methoxy-3-methylazetidin-1-yl)- 2-(methylthio)pyrido[3,4-d]pyrimidine 449 236

1-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-3- methylazetidin-3-carbonitrile 476 237

6-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-2-oxa- 6-azaspiro[3.3]heptane 479 238

6-(6-(2,6-difluoro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-2-oxa- 6-azaspiro[3.3]heptane 447 239

6-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-1-oxa- 6-azaspiro[3.3]heptane 479 240

6-(6-(2,6-difluoro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-1-oxa- 6-azaspiro[3.3]heptane 447 241

6-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-(methylthio)-8-(2-azaspiro[3.3]hept- 2-yl)pyrido[3,4-d]pyrimidine 477 242

6-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-(methylthio)-8-(2-azaspiro[3.4]oct- 2-yl)pyrido[3,4-d]pyrimidine 491 243

2-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-6-oxa- 2-azaspiro[3.4]octane 493 244

2-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-7-oxa- 2-azaspiro[3.5]nonane 507 245

6-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-(methylthio)-8-(pyrrolidin-1- yl)pyrido[3,4-d]pyrimidine 451 246

6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-(3-methoxypyrrolidin-1-yl)-2- (methylthio)pyrido[3,4-d]pyrimidine 481 247

6-(2,6-difluoro-3,5-dimethoxyphenyl)- 8-(3-methoxypyrrolidin-1-yl)-2- (methylthio)pyrido[3,4-d]pyrimidine 449 248

1-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl) pyrrolidine-3-carbonitrile 476 249

6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-(3,3-difluoropyrrolidin-1-yl)-2- (methylthio)pyrido[3,4-d]pyrimidine 487 250

6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-(3-methoxy-3-methylpyrrolidin-1- yl)-2-(methylthio)pyrido[3,4- d]pyrimidine 495 251

6-(2,6-difluoro-3,5-dimethoxyphenyl)- 8-(3-methoxy-3-methylpyrrolidin-1- yl)-2-(methylthio)pyrido[3,4- d]pyrimidine 463 252

1-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-3- methylpyrrolidine-3-carbonitrile 490 253

8-(3-azabicyclo[3.1.0]hex-3-yl)-6- (2,6-dichloro-3,5-dimethoxyphenyl)- 2-(methylthio)pyrido[3,4-d]pyrimidine 463 254

7-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-2-oxa- 7-azaspiro[34.4]nonane 507 255

4-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl) morpholine 467 256

4-(6-(2,6-difluoro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl) morpholine 435 257

4-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylsulfanyl) pyrido[3,4-d]pyrimidin-8-yl)-2- methylmorpholine 481 258

4-(6-(2,6-difluoro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-2- methylmorpholine 449 259

4-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-2,6- dimethylmorpholine 495 260

4-(6-(2,6-difluoro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-2,6- dimethylmorpholine 463 261

1-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8- yl)piperidin-4-ol 481 262

6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(4- methoxypiperidin-1-yl)- 2-(methylthio)pyrido[3,4- d]pyrimidine 495 263

6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(4- methoxypiperidin-1-yl)- 2-(methylthio)pyrido[3,4- d]pyrimidine 463 264

6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3- methoxypiperidin-1-yl)- 2-(methylthio)pyrido[3,4- d]pyrimidine 495 265

1-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8-yl)-4- methylpiperidin-4-ol 495 266

6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(4- methoxy-4-methylpiperidin- 1-yl)-2-(methylthio)pyrido[3,4- d]pyrimidine 509 267

6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(4- methoxy-4-methylpiperidin- 1-yl)-2-(methylthio)pyrido[3,4- d]pyrimidine 477 268

1-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2- (methylthio)pyrido[3,4- d]pyrimidin-8-yl)-4- methylpiperidine-4- carbonitrile 504 269

N-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2- (methylthio)pyrido[3,4- d]pyrimidin-8-yl)cyclopropyl carboxamide 465 270

N-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2- (methylthio)pyrido[3,4- d]pyrimidin-8-yl)tetrahydrofuran2- carboxamide 495 271

N-(6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidin-8- yl)sulfonamide 475 272

6-chloro-N-(cyclopropylmethyl)-2- (2,6-dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidine-4-amine 439 273

6-chloro-N-(cyclopropylmethyl)-2- (2,6-difluoro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidine-4-amine 407 274

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(2-methoxyethyl) pyrido[3,4-d]pyrimidine-4-amine 443 275

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(tetrahydrofuran- 3-yl)pyrido[3,4-d]pyrimidine-4-amine 455 276

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((tetrahydrofuran- 2-yl)methyl)pyrido[3,4-d]pyrimidine- 4-amine 469 277

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(tetrahydro-2H- pyran-4-yl)pyrido[3,4-d]pyrimidine- 4-amine 469 278

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-N-(3,3- difluorocyclopentyl)pyrido[3,4- d]pyrimidine-4-amine 489 279

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-N- neopentylpyrido[3,4-d]pyrimidine- 4-amine 455 280

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-N-((1-methyl-1H- pyrazol-4-yl)methyl)pyrido[3,4- d]pyrimidine-4-amine 479 281

(S)-6-chloro-N-(1-cyclopropylethyl)- 2-(2,6-dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidine-4-amine 453 282

(S)-6-chloro-N-(1-cyclopropylethyl)- 2-(2,6-difluoro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidine-4-amine 421 283

6-chloro-N-cyclopropyl-2-(2,6- dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidine-4-amine 425 284

6-chloro-N-cyclopropyl-2-(2,6- difluoro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidine-4-amine 393 285

4-(azetidin-1-yl)-6-chloro-2-(2,6- dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidine 425 286

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3- methoxyazetidin-1-yl)pyrido[3,4- d]pyrimidine 455 287

6-chloro-2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(3- methoxyazetidin-1-yl)pyrido[3,4- d]pyrimidine 423 288

1-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-N,N- dimethylazetidin-3-amine 468 289

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3- (trifluoromethyl)azetidin-1- yl)pyrido[3,4-d]pyrimidine 493 290

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3,3- dimethylazetidin-1-yl)pyrido[3,4- d]pyrimidine 453 291

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3,3- difluoroazetidin-1-yl)pyrido[3,4- d]pyrimidine 461 292

1-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-3-methylazetidin- 3-ol 455 293

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3-methoxy- 3-methylazetidin-1-yl)pyrido[3,4- d]pyrimidine 469 294

6-chloro-2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(3-methoxy- 3-methylazetidin-1-yl)pyrido[3,4- d]pyrimidine 437 295

1-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-3-methylazetidin- 3-carbonitrile 464 296

6-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-2-oxa-6- azaspiro[3.3]heptane 467 297

6-(6-chloro-2-(2,6-difluoro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-2-oxa-6- azaspiro[3.3]heptane 435 298

6-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-1-oxa-6- azaspiro[3.3]heptane 467 299

6-(6-chloro-2-(2,6-difluoro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-1-oxa-6- azaspiro[3.3]heptane 435 300

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(2-azaspiro[3.3] hept-2-yl)pyrido[3,4-d]pyrimidine 465 301

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(2- azaspiro[3.4]oct-2-yl)pyrido[3,4- d]pyrimidine 479 302

2-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-6-oxa-2- azaspiro[3.4]octane 481 303

2-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-7-oxa-2- azaspiro[3.5]nonane 495 304

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(pyrrolidin- 1-yl)pyrido[3,4-d]pyrimidine 439 305

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3- methoxypyrrolidin-1- yl)pyrido[3,4-d]pyrimidine 469 306

6-chloro-2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(3- methoxypyrrolidin-1-yl)pyrido[3,4- d]pyrimidine 437 307

1-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)pyrrolidine-3- carbonitrile 464 308

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3,3- difluoropyrrolidin-1-yl)pyrido[3,4- d]pyrimidine 475 309

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3-methoxy- 3-methylpyrrolidin-1-yl) pyrido[3,4-d]pyrimidine 483 310

6-chloro-2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(3-methoxy-3- methylpyrrolidin-1-yl)pyrido[3,4- d]pyrimidine 451 311

1-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-3-methylpyrrolidine- 3-carbonitrile 478 312

4-(3-azabicyclo[3.1.0]hex-3-yl)- 6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidine 451 313

7-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-2-oxa-7- azaspiro[4.4]nonane 495 314

4-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)morpholine 455 315

4-(6-chloro-2-(2,6-difluoro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)morpholine 423 316

4-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-2-methylmorpholine 469 317

4-(6-chloro-2-(2,6-difluoro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-2-methylmorpholine 437 318

4-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-2,6- dimethylmorpholine 483 319

4-(6-chloro-2-(2,6-difluoro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-2,6- dimethylmorpholine 451 320

1-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)piperidin-4-ol 469 321

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(4- methoxypiperidin-1-yl)pyrido[3,4- d]pyrimidine 483 322

6-chloro-2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(4- methoxypiperidin-1-yl)pyrido[3,4- d]pyrimidine 451 323

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3- methoxypiperidin-1-yl)pyrido[3,4- d]pyrimidine 483 324

1-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-4-methylpiperidin- 4-ol 483 325

6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(4-methoxy- 4-methylpiperidin-1-yl)pyrido[3,4- d]pyrimidine 497 326

6-chloro-2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(4-methoxy- 4-methylpiperidin-1-yl)pyrido[3,4- d]pyrimidine 465 327

1-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)-4-methylpiperidine- 4-carbonitrile 492 328

N-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)cyclopropyl carboxamide 453 329

N-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)tetrahydrofuran2- carboxamide 483 330

N-(6-chloro-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-yl)sulfonamide 463

Intermediate 331: Preparation of 8-cyclopropyl-6-(2,6-dichloro-3-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine

Step 1: Preparation of 8-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidine

8-chloro-6-(3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine (500 mg, 1.43 mmol) was added to dichloromethane (30 mL), then the mixture was cooled to −30° C. SO₂Cl₂ (0.35 mL, 4.31 mmol) was dissolved in dichloromethane (30 mL), and slowly added dropwise to the above reaction liquid with stirring. After the addition, the mixture was stirred for another 0.5 h. The reaction was completed, then quenched with a saturated aqueous sodium bicarbonate solution (50 mL). The mixture was extracted, washed with water and then saturated brine, dried over anhydrous sodium sulfate, filtrated, concentrated and separated by column chromatography to obtain 8-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine (620 mg, 88%). MS m/z (ESI): 416.2 [M+H]⁺.

Step 2: Preparation of 8-cyclopropyl-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methyl thio)pyrido[3,4-d]pyrimidine

8-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine (83 mg, 0.20 mmol), cyclopropyl boronic acid (26 mg, 0.30 mmol), Pd(OAc)₂ (5 mg, 0.02 m mol), PCy₃ (11 mg, 0.04 mmol) and K₃PO₄ (127 mg, 0.60 mmol) were added to the mixture of toluene and water (6:1, 5 mL), the mixture was heated to 100° C. and stirred over night. The reaction was completed, then the mixture was cooled to room temperature, diluted with EtOAc, washed with saturated brine, dried over anhydrous sodium sulfate, filtrate d, concentrated and separated by column chromatography to obtain 8-cyclopropyl-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine (60 mg, 71%). MS m/z (ESI): 422.2 [M+H]⁺.

Intermediates 332-364 were prepared referring to the synthesis method of 331.

Intermediate MS: m/z No. Compound structure Compound name [M + 1]⁺ 332

6-(2,6-dichloro-3,5-dimethoxyphenyl)-8- methyl-2-(methylthio)pyrido[3,4-d] pyrimidine 396 333

6-(2,6-dichloro-3,5-dimethoxyphenyl)-8- ethyl-2-(methylthio)pyrido[3,4-d] pyrimidine 410 334

6-(2,6-dichloro-3,5-dimethoxyphenyl)-8- isopropyl-2-(methylthio)pyrido[3,4-d] pyrimidine 424 335

6-(2,6-dichloro-3,5-dimethoxyphenyl)-2- (methylthio)-8-neopentylpyrido[3,4-d] pyrimidine 452 336

8-(cyclopropylmethyl)-6-(2,6-dichloro-3,5- dimethoxyphenyl)-2-(methylthio) pyrido[3,4-d]pyrimidine 436 337

6-(2,6-dichloro-3,5-dimethoxyphenyl)-2- (methylthio)-8-((tetrahydrofuran-3-yl) methyl)pyrido[3,4-d]pyrimidine 466 338

6-(2,6-dichloro-3,5-dimethoxyphenyl)-2- (methylthio)-8-((tetrahydrofuran2-yl) methyl)pyrido[3,4-d]pyrimidine 466 339

6-(2,6-dichloro-3,5-dimethoxyphenyl)-2- (methylthio)-8-(tetrahydro-2H-pyran-4-yl) pyrido[3,4-d]pyrimidine 466 340

6-(2,6-dichloro-3,5-dimethoxyphenyl)-8- ((1-methylpyrrolidin-3-yl)methyl)-2- (methylthio)pyrido[3,4-d]pyrimidine 479 341

6-(2,6-dichloro-3,5-dimethoxyphenyl)-8- ((1-methylpyrrolidin-2-yl)methyl)-2- (methylthio)pyrido[3,4-d]pyrimidine 479 342

6-(2,6-dichloro-3,5-dimethoxyphenyl)-8- (1-methylpiperidin-4-yl)-2-(methylthio) pyrido[3,4-d]pyrimidine 479 343

6-(2,6-dichloro-3,5-dimethoxyphenyl)-8- (2-methoxyethyl)-2-(methylthio)pyrido [3,4-d]pyrimidine 440 344

6-(2,6-dichloro-3,5-dimethoxyphenyl)-8- (methoxymethyl)-2-(methylthio)pyrido [3,4-d]pyrimidine 426 345

N-((6-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-(methylthio)pyrido[3,4-d]pyrimidin-8- yl)methyl)cyclopropylamine 451 346

N-((6-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-(methylthio)pyrido[3,4-d]pyrimidin-8- yl)methyl)sulfonamide 489 347

N-((6-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-(methylthio)pyrido[3,4-d]pyrimidin-8- yl)methyl)propane-2-sulfonamide 517 348

N-(2-(6-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-(methylthio)pyrido[3,4-d]pyrimidin- 8-yl)ethyl)propane-2-amine 467 349

6-(2,6-dichloro-3,5-dimethoxyphenyl)-2- (methylthio)-8-(2,2,2-trifluoroethyl)pyrido [3,4-d]pyrimidine 464 350

8-benzyl-6-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-(methylthio)pyrido[3,4-d]pyrimidine 472 351

6-(2,6-dichloro-3,5-dimethoxyphenyl)-2- (methylthio)-8-phenylpyrido[3,4-d]pyrimidine 458 352

6-(2,6-dichloro-3,5-dimethoxyphenyl)-2- (methylthio)-8-(pyridin-4-yl)pyrido[3,4-d] pyrimidine 459 353

6-(2,6-dichloro-3,5-dimethoxyphenyl)-2- (methylthio)-8-(pyridin-3-yl)pyrido[3,4-d] pyrimidine 459 354

6-(2,6-dichloro-3,5-dimethoxyphenyl)-8- (1-methyl-1H-pyrazol-4-yl)-2-(methylthio) pyrido[3,4-d]pyrimidine 462 355

6-(2,6-dichloro-3,5-dimethoxyphenyl)-8- ((1-methyl-1H-pyrazol-4-yl)methyl)-2- (methylthio)pyrido[3,4-d]pyrimidine 476 356

8-(1-cyclopropyl-1H-pyrazol-4-yl)-6-(2,6- dichloro-3,5-dimethoxyphenyl)-2- (methylthio)pyrido[3,4-d]pyrimidine 488 357

8-(1-(cyclopropylmethyl)-1H-pyrazol-4-yl)- 6-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-(methylthio)pyrido[3,4-d]pyrimidine 502 358

6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-(1- (2-methoxyethyl)-1H-pyrazol-4-yl)-2- (methylthio)pyrido[3,4-d]pyrimidine 506 359

2-(4-(6-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-(methylthio)pyrido[3,4-d]pyrimidin- 8-yl)-1H-pyrazol-1-yl)ethan-1-ol 492 360

6-(2,6-dichloro-3,5-dimethoxyphenyl)-2- (methylthio)-8-(1-(tetrahydrofuran-3-yl)-1H- pyrazol-4-yl)pyrido[3,4-d]pyrimidine 518 361

6-(2,6-dichloro-3,5-dimethoxyphenyl)-2- (methylthio)-8-phenethylpyrido[3,4-d] pyrimidine 486 362

6-(2,6-difluoro-3,5-dimethoxyphenyl)-8- (1-methyl-1H-pyrazol-4-yl)-2-(methylthio) pyrido[3,4-d]pyrimidine 430 363

6-(2,6-difluoro-3,5-dimethoxyphenyl)-8- (1-(2-methoxyethyl)-1H-pyrazol-4-yl)-2- (methylthio)pyrido[3,4-d]pyrimidine 474 364

2-(4-(6-(2,6-difluoro-3,5-dimethoxyphenyl)- 2-(methylthio)pyrido[3,4-d]pyrimidin- 8-yl)-1H-pyrazol-1-yl)ethan-1-ol 460

Intermediate 365: Preparation of (3S,4S)-4-azidotetrahydro-2H-pyran-3-amine Hydrochloride

Step 1: Preparation of Tert-Butyl ((3S,4S)-4-hydroxyltetrahydro-2H-pyran-3-yl)carbamate

(3R,4R)-3-aminotetrahydro-2H-pyran-4-ol (5.00 g, 42.7 mmol) was dissolved in MeOH (100 mL), and then Et₃N (4.75 g, 47.0 mmol) and Boc₂O (10.25 g, 47.0 mmol) were successively added, the mixture was stirred at room temperature overnight. The reaction was completed monitored by LCMS. The mixture was concentrated to remove methanol, and the crude product was washed with petroleum ether (100 mL), and then filtrated to obtain tert-butyl ((3S,4S)-4-hydroxyltetrahydro-2H-pyran-3-yl)carbamate (8.50 g, yield: 92%).

¹H NMR (400 MHz, CDCl₃): δ ppm 4.68 (m, 1H), 4.03 (m, 1H), 3.93 (m, 1H), 3.63 (m, 1H), 3.45 (m, 2H), 3.19 (m, 1H), 2.81 (m, 1H), 2.04 (m, 1H), 1.68 (m, 1H), 1.61 (s, 9H).

Step 2: Preparation of (3R,4R)-3-((tert-butoxycarbonyl)amino)tetrahydro-2H-pyran-4-yl methanesulfonate

Tert-butyl ((3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl)carbamate (8.5 g, 39.2 mmol) was dissolved in CH₂Cl₂ (100 ML), the mixture was cooled under ice water bath, and then Et₃N (4.30 g, 43.0 mmol) and MsCl (4.98 g, 43.0 mmol) were successively added, the mixture was stirred at 0° C. for 6 h. The reaction was completed, the mixture was washed with water (20 mL), then the organic phase was dried over anhydrous sodium sulfate, filtrated, and concentrated to obtain (3R,4R)-3-((tert-butoxycarbonyl)amino)tetrahydro-2H-pyran-4-yl methanesulfonate (10.2 g, yield: 88%).

¹H NMR (400 MHz, CDCl₃): δ ppm 4.90 (m, 1H), 4.76 (m, 1H), 4.03 (m, 1H), 3.98 (m, 1H), 3.67 (m, 2H), 3.47 (m, 1H), 3.14 (s, 3H), 2.18 (m, 1H), 1.92 (m, 1H), 1.44 (s, 9H).

Step 3: Preparation of Tert-butyl ((3S,4S)-4-azidotetrahydro-2H-pyran-3-yl)carbamate

(3R,4R)-3-((tert-butoxycarbonyl)amino)tetrahydro-2H-pyran-4-yl methanesulfonate (10.2 g, 34.6 mmol) was dissolved in dried DMF (100 mL), NaOAc (9.38 g, 69.0 mmol) and NaN₃ (4.49 g, 69.0 mmol) were successively added, the mixture was heated at 90° C. overnight. The reaction was completed, then the reaction solution was poured into water (200 mL) and extracted twice with EtOAc (50 mL), the organic phases were combined, washed twice with aqueous LiCl solution (50 mL), dried over anhydrous sodium sulfate, filtrated and concentrated to obtain compound tert-butyl ((3S,4S)-4-azidotetrahydro-2H-pyran-3-yl)carbamate (6.8 g, yield: 81%).

¹H NMR (400 MHz, CDCl₃): δ ppm 4.85 (m, 1H), 3.89 (m, 2H), 3.77 (m, 1H), 3.63 (m, 2H), 3.51 (m, 1H), 1.93 (m, 2H), 1.45 (s, 9H).

Step 4: Preparation of (3S,4S)-4-azidotetrahydro-2H-pyran-3-amine Hydrochloride

Tert-butyl ((3S,4S)-4-azidotetrahydro-2H-pyran-3-yl)carbamate (6.8 g, 28.0 mmol) was added to the mixture of HCl and EtOAc (100 mL), the mixture was stirred at room temperature for 8 h. The reaction was completed monitored by LCMS. The mixture was concentrated to obtain compound (3S,4S)-4-azidotetrahydro-2H-pyran-3-amine hydrochloride (4.0 g, yield: 80%).

¹H NMR (400 MHz, DMSO-d6): δ ppm 8.47 (m, 3H), 4.36 (m, 1H), 3.80 (m, 2H), 3.63 (m, 3H), 2.0 (m, 2H).

Intermediate 366: Preparation of (3S,4R)-4-azidotetrahydro furan-3-amine Hydrochloride

Intermediate 366 was prepared referring to the synthesis method of Intermediate 365 from (3S,4R)-4-aminotetrahydro furan-3-ol.

Intermediate 367: Preparation of Tert-Butyl ((3R,4S)-4-aminotetrahydrofuran-3-yl)carbamate

Step 1: Preparation of Tert-Butyl ((3S,4R)-4-hydroxyltetrahydrofuran-3-yl)carbamate

(3R,4S)-4-aminotetrahydrofuran-3-ol (5.00 g, 48.487 mmol) was dissolved in methanol (100 mL), then triethylamine (12.24 g, 121.2 mmol) was added, the mixture was cooled under ice water bath, then Boc₂O (11.64 g, 53.34 mmol) was added. After the addition, the mixture was stirred at room temperature for 24 h. The reaction was completed, the organic phase was concentrated to remove the majority solvent. Water (100 mL) was added, and the mixture was stirred to precipitate a large amount of white solids. The mixture was filtrated and washed with water to obtain compound tert-butyl ((3S,4R)-4-hydroxyltetrahydrofuran-3-yl)carbamate (8.00 g, yield: 81%).

¹H NMR (400 MHz, Chloroform-d) δ 4.72 (s, 1H), 4.29 (m, 1H), 4.09 (m, 1H), 4.08-4.02 (m, 1H), 3.95 (s, 1H), 3.69 (m, 1H), 3.61 (m, 1H), 1.45 (s, 9H).

Step 2: Preparation of Tert-Butyl ((3R,4S)-4-(1,3-dicarbonylisoindolin-2-yl)tetrahydrofuran-3-yl)carbamate

Tert-butyl ((3S,4R)-4-hydroxyltetrahydrofuran-3-yl)carbamate (200 mg, 0.984 mmol), triphenylphosphine (620 mg, 2.364 mmol) and isoindoline-1,3-dione (173 mg, 1.181 mmol) were dissolved in tetrahydrofuran (10 mL), the mixture was cooled under ice water bath, then diisopropyl azodicarboxylate (717 mg, 3.546 mmol) was slowly added dropwise. After addition, the mixture was stirred under ice water bath for 1 h. The reaction liquid was directly concentrated and separated by column chromatography (Eluent: PE/EA 15-30%) to obtain a crude product compound tert-butyl ((3R,4S)-4-(1,3-dicarbonylisoindolin-2-yl)tetrahydrofuran-3-yl)carbamate (950 mg).

¹H NMR (400 MHz, Chloroform-d) δ 7.87 (m, 2H), 7.75 (m, 2H), 4.84 (d, J=9.5 Hz, 1H), 4.51 (t, J=8.0 Hz, 1H), 4.37 (t, J=8.3 Hz, 1H), 4.21-4.15 (m, 1H), 4.09 (t, J=8.8 Hz, 1H), 3.85 (m, J=9.2, 6.4 Hz, 1H), 1.11 (s, 9H).

MS m/z (ESI): 559.5 [M+H]⁺.

Step 3: Preparation of Tert-Butyl ((3R,4S)-4-aminotetrahydrofuran-3-yl)carbamate

Tert-buty ((3R,4S)-4-(1,3-dicarbonylisoindolin-2-yl)tetrahydrofuran-3-yl)carbamate (950 mg, 21%, 0.600 mmol) was dissolved in ethanol (6 mL), then hydrazine hydrate (45 mg, 0.900 mmol) was added, the mixture was heated to 75° C. and stirred for 2 h. The react ion was completed, then the mixture was concentrated and separated by column chromatography (Eluent: DCM/MeOH 0-5%) to obtain compound tert-butyl ((3R,4S)-4-aminotetrahydrofuran-3-yl)carbamate (120 mg, two-step yield: 60/).

¹H NMR (400 MHz, Chloroform-d) δ 5.24 (s, 1H), 4.11 (s, 1H), 4.05 (m, 1H), 4.00 (m, 1H), 3.63-3.52 (m, 2H), 3.49 (m, 1H), 1.46 (s, 9H).

Intermediates 368-375 were prepared referring to the synthesis method of Intermediate 367.

Intermediate Compound MS: m/z No. structure Compound name [M + 1]⁺ 368

tert-butyl (3R,4S)-3-amino-4-(((2,2,2-trichloroeth- oxy)carbonyl)amino)pyrrolidine-1-carbox- ylate 377 369

2,2,2-trichloroethyl ((3S,4R)-4-amino-1-methylpyrrolidin-3-yl) carbamate 291 370

2,2,2-trichloroethyl ((3S,4R)-1-acetyl-4-aminopyrrolidin-3-yl) carbamate 319 371

2,2,2-trichloroethyl ((3S,4R)-4-amino-1-(2-(dimethylamino) ethyl)pyrrolidin-3-yl)carbamate 348 372

2,2,2-trichloroethyl ((3S,4R)-4-amino-1-(methylaminoformyl) pyrrolidin-3-yl)carbamate 334 373

2,2,2-trichloroethyl ((3S,4R)-4-amino-1-(oxetan-3-yl)pyrolidin- 3-yl)carbamate 333 374

2,2,2-trichloroethyl ((3S,4R)-4-amino-1-(1H-pyrazol-4-yl)pyr- rolidin-3-yl)carbamate 343 375

2,2,2-trichloroethyl ((3S,4R)-4-amino-1-(1-methyl-1H-pyrazol- 4-yl)pyrrolidin-3-yl)carbamate 357

Preparation of Specific Examples Example 1 Preparation of N-(2-((7-(2,6-dichloro-3,5-dimethoxyphenyl)-6-methyl-5-oxo-5,6-dihydro-2,6-naphthyridin-3-yl)amino)-3-methylphenyl)acrylamide

Step 1: Preparation of 3-(2,6-dichloro-3,5-dimethoxyphenyl)-2-methyl-7-((2-methyl-6-nitrophenyl)amino)-2,6-naphthyridin-1(2H)-one

7-chloro-3-(2,6-dichloro-3,5-dimethoxyphenyl)-2-methyl-2,6-naphthyridin-1(2H)-one (150 mg, 0.375 mmol) was dissolved in 14-dioxane (20 mL), then 2-methyl-6-nitroaniline (114 mg, 0.751 mmol), cesium carbonate (367 mg, 1.126 mmol), brett-phos (161 mg, 0.3 m mol) and Pd₂(dba)₃ (172 mg, 0.188 mmol) were added. The gas was exchanged with N2, and the mixture was heated to 120° C. for 2 h. The reaction was completed, and the mixture was concentrated and separated by silica gel column chromatography (Eluent: PE/EtO Ac=2:1) to obtain compound 3-(2,6-dichloro-3,5-dimethoxyphenyl)-2-methy-7-((2-methyl-6-nitrophenyl)amino)-2,6-naphthyridin-1(2H)-one (40 mg, yield: 21%). MS m/z (ESI): 516 [M+H]⁺.

Step 2: Preparation of 7-((2-amino-6-methylphenyl)amino)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-2-methyl-2,6-naphthyridin-1(2H)-one

3-(2,6-dichloro-3,5-dimethoxyphenyl)-2-methyl-7-((2-methyl-6-nitrophenyl)amino)-2,6-naphthyridin-1(2H)-one (40 mg, 0.078 mmol) was dissolved in 10 mL of methanol, then 10 mg of Pd—C was added. The mixture was stirred at room temperature under H₂ for 30 min. The reaction was completed, and the mixture was concentrated and separated by silica gel column chromatography (Eluent: CH₂Cl₂/MeOH=10:1) to obtain compound 7-((2-amino-6-methylphenyl)amino)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-2-methyl-2,6-naphthyridin-1(2H)-one (9.5 mg, yield:25%).

MS m/z (ESI): 486.4 [M+H]⁺.

Step 3: Preparation of N-(2-((7-(2,6-dichloro-3,5-dimethoxyphenyl)-6-methyl-5-oxo-5,6-dihydro-2,6-naphthyridin-3-yl)amino)-3-methylphenyl)acrylamide

7-((2-amino-6-methylphenyl)amino)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-2-methyl-2,6-naphthyridin-1(2H)-one (9.5 mg, 0.02 mmol) was dissolved in the mixture of THF and H₂O (4 mL/1 mL), then sodium bicarbonate (9 mg, 0.104 mmol) was added, the mixture was cooled with ice water bath, and the solution of acryloyl chloride in THF (2 mg/2 mL, 0.02 mmol) was added dropwise. The mixture was stirred at 0° C. for 10 min. After the re action was completed, the mixture was extracted for three times with dichloromethane. The organic phases were combined, washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, filtrated and concentrated. The crude product was separated by silica gel column chromatography, to obtain compound N-(2-((7-(2,6-dichloro-3,5-dimethoxyphenyl)-6-methyl-5-oxo-5,6-dihydro-2,6-naphthyridin-3-yl)amino)-3-methylphenyl)acrylamide (1 mg, yield: 9%).

¹H NMR (400 MHz, CDCl₃) δ 8.60 (s, 1H), 8.30 (d, J=8.1 Hz, 1H), 7.31 (s, 1H), 7.10-7.05 (m, 2H), 6.68 (s, 1H), 6.52-6.48 (m, 1H), 6.44 (s, 1H), 6.39 (s, 1H), 6.33 (d, J=1.4 Hz, 1H), 6.19 (d, J=10.2 Hz, 1H), 5.68 (dd. J=10.2, 1.4 Hz, 1H), 3.99 (s, 6H), 3.25 (s, 3H), 2.21 (s, 3H).

MS m/z (ESI): 541.4 [M+H]⁺.

Examples 2-75 were prepared referring to the synthesis method of Example 1.

Example MS: m/z No. Compound structure Compound name [M + 1]⁺ 2

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-oxo-5, 6-dihydro-2,6-naphthyridin- 3-yl)amino)-3-methylphe- nyl)acrylamide 525 3

N-(2-((6-(cyclopropylmeth- yl)-7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-oxo-5,6- dihydro-2,6-naphthyridin-3- yl)amino)-3-methylphenyl) acrylamide 579 4

N-(2-((6-(2-(tert-butylamino)- 2-oxoethyl)-7-(2,6-dichloro- 3,5-dimethoxyphenyl)- 5-oxo-5,6-dihydro-2,6- naphthyridin-3-yl)amino)-3- methylphenyl)acrylamide 638 5

N-(2-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-oxo-3, 4-dihydropyrido[3,4-d] pyrimidin-6-yl)amino)-3-methyl- phenyl)acrylamide 526 6

N-(2-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-3-methyl- 4-oxo-3,4-dihydropyrido [3,4-d]pyrimidin-6-yl)amino)- 3-methylphenyl)acrylamide 540 7

N-(2-((3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-oxo-1 H-pyrano[4,3-c]pyridin-7-yl) amino)-3-methylphenyl) acrylamide 526 8

N-(2-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-7-methyl- 8-oxo-7,8-dihydropyrido [3,4-d]pyrimidin-2-yl)amino)- 3-methylphenyl)acrylamide 540 9

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-dimethoxy- 2,6-naphthyridin-3-yl) amino)-3-methylphenyl)acryl- amide 539 10

N-(2-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-methoxy- pyrido[3,4-d]pyrimidin- 6-yl)amino)-3-methylphenyl) acrylamide 540 11

N-(2-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-3-(2- methoxyethyl)-4-oxo-3,4- dihydropyrido[3,4-d]pyrimidin- 6-yl)amino)-3-methylphenyl) acrylamide 584 13

N-(-2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6- naphthyridin-3-yl)amino)-3- methylphenyl)acrylamide 509 14

N-(2-((6-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3, 4-d]pyrimidin-2-yl)amino)- 3-methylphenyl)acrylamide 510 15

N-(2-((6-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3, 4-d]pyrimidin-2-yl)amino)- 5-(4-ethylpiperazin-1-yl) phenyl)acrylamide 608 16

N-(2-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-2,6- naphthyridin-3-yl)amino)-5-(4- ethylpiperazin-1-yl)-3- methylphenyl)acrylamide 589 17

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6- naphthyridin-3-yl)amino)-5-(4- ethylpiperazin-1-yl)-3- methylphenyl)acrylamide 621 18

N-(2-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-2,6- naphthyridin-3-yl)amino)-5-(4- ethylpiperazin-1-yl)phenyl) acrylamide 575 19

N-(2-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-2,6- naphthyridin-3-yl)amino)-5-((4- methylpiperazin-1-yl)meth- yl)phenyl)acrylamide 575 20

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naph- thyridin-3-yl)amino)-5-(4- ethylpiperazin-1-yl)phenyl) acrylamide 607 21

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naph- thyridin-3-yl)amino)-5-(2- dimethylamino)dimethoxy) phenyl)acrylamide 582 22

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naph- thyridin-3-yl)amino)-5- morpholinophenyl)acrylamide 580 23

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naph- thyridin-3-yl))amino)-5-((4- methylpiperazin-1-yl)meth- yl)phenyl)acrylamide 607 24

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naph- thyridin-3-yl)amino)-5-(1- ethylpiperidin-4-yl)phenyl) acrylamide 606 25

N-(2-((5-((cyclopropylmeth- yl)amino)-7-(2,6-dichloro- 3,5-dimethoxyphenyl)-2,6- naphthyridin-3-yl)amino)- 3-methylphenyl)acrylamide 578 26

N-(2-((5-((cyclopropylmeth- yl)amino)-7-(2,6-dichloro- 3,5-bis(dimethoxy-d₃)phenyl)- 2,6-naphthyridin-3-yl) amino)-3-methylphenyl) acrylamide 584 27

N-(2-((5-((cyclopropylmeth- yl)amino)-7-(2,6-difluoro- 3,5-bis(dimethoxy-d₃)phenyl)- 2,6-naphthyridin-3-yl) amino)-3-methylphenyl) acrylamide 552 28

N-(2-((5-((cyclopropylmeth- yl)amino)-7-(2,6-difluoro- 3,5-dimethoxyphenyl)-2,6- naphthyridin-3-yl)amino-3- methylphenyl)acrylamide 546 29

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2- hydroxyethyl)amino)-2,6- naphthyridin-3-yl)amino)-3- methylphenyl)acrylamide 568 30

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2- isopropylthio)ethyl)amino)-2,6- naphthyridin-3-yl)amino)-3- methylphenyl)acrylamide 626 31

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2- (ethylsulfonyl)ethyl)amino)-2,6- naphthyridin-3-yl)amino)-3- methylphenyl)acrylamide 644 32

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2- (dimethylamino)ethyl)amino)-2, 6-naphthyridin-3-yl)amino)- 3-methylphenyl)acrylamide 595 33

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((3- (dimethylamino)propyl)amino)- 2,6-naphthyridin-3-yl) amino)-3-methylphenyl) acrylamide 609 34

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(meth- ylamino)-2,6-naphthyridin- 3-yl)amino)-3-methylphe- nyl)acrylamide 538 35

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(ethyl- amino)-2,6-naphthyridin-3- yl)amino)-3-methylphenyl) acrylamide 552 36

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2,2, 2-trifluoroethyl)amino)-2,6- naphthyridin-3-yl)amino)- 3-methylphenyl)acrylamide 606 37

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(dimeth- ylamino)-2,6-naphthyridin- 3-yl)amino)-3-methylphe- nyl)acrylamide 552 38

N-(2-((5-((cyclopropylmeth- yl)(methyl)amino)-7-(2,6- dichloro-3,5-dimethoxyphe- nyl)-2,6-naphthyridin-3-yl) amino)-3-methylphenyl) acrylamide 592 39

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2- (methylsulfonamido)ethyl) amino)-2,6-naphthyridin-3-yl) amino)-3-methylphenyl) acrylamide 645 40

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5- (((tetrahydrofuran-2-yl)methyl) amino)-2,6-naphthyridin-3-yl) amino)-3-methylphenyl) acrylamide 608 41

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((tetra- hydrofuran-3-yl)methyl) amino)-2,6-naphthyridin-3-yl) amino)-3-methylphenyl) acrylamide 608 42

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((oxetan- 3-ylmethyl)amino)-2,6- naphthyridin-3-yl)amino)-3- methylphenyl)acrylamide 594 43

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((tetra- hydro-2H-pyran-4-yl)meth- ylamino)-2,6-naphthyridin- 3-yl)amino)-3-methylphe- nyl)acrylamide 622 44

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(oxetan- 3-ylamino)-2,6-naphthyridin- 3-yl))amino)-3-methyl- phenyl)acrylamide 580 45

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((tetra- hydro-2H-pyran-4-yl)amino)- 2,6-naphthyridin-3-yl) amino)-3-methylphenyl)acryl- amide 608 46

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((tetra- hydrofuran-3-yl)amino)-2,6- naphthyridin-3-yl)amino)-3 methylphenyl)acrylamide 594 47

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1- methylpyrrolidin-3-yl)methyl) amino)-2,6-naphthyridin-3- yl)amino)-3-methylphenyl) acrylamide 621 48

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1- methyl)pyrrolidin-2-yl)methyl) amino)-2,6-naphthyridin-3- yl)amino)-3-methylphenyl) acrylamide 621 49

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((1- methylpyrrolidin-3-yl)amino)- 2,6-naphthyridin-3-yl) amino)-3-methylphenyl)acryl- amide 607 50

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1- methylazetidin-3-yl)methyl) amino)-2,6-naphthyridin-3-yl) amino)-3-methylphenyl) acrylamide 607 51

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((1- methylazetidin-3-yl)amino)-2,6- naphthyridin-3-yl)amino)-3- methylphenyl)acrylamide 593 52

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((1- methylpiperidin-4-yl)amino)-2, 6-naphthyridin-3-yl)amino)- 3-methylphenyl)acrylamide 621 53

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1- methylpiperidin-4-yl)methyl) amino)-2,6-naphthyridin-3- yl)amino)-3-methylphenyl) acrylamide 635 54

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((3,3- difluorocyclobutyl)amino)-2,6- naphthyridin-3-yl)amino)-3- methylphenyl)acrylamide 614 55

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((3,3- difluorocyclopentyl)amino)- 2,6-naphthyridin-3-yl)ami- no)-3-methylphenyl)acryl- amide 628 56

N-(2-((5-((cyclopentylmeth- yl)amino)-7-(2,6-dichloro- 3,5-dimethoxyphenyl)-2,6- naphthyridin-3-yl)amino)-3- methylphenyl)acrylamide 606 57

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(phen- ethylamino)-2,6-naphthyridin- 3-yl)amino)-3-methyl- phenyl)acrylamide 628 58

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1- methyl-1H-pyrazol-4-yl)meth- yl)amino)-2,6-naphthyridin- 3-yl)amino)-3-methylphe- nyl)acrylamide 618 59

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1- (2-hydroxyethyl)-1H-pyrazol- 4-yl)methyl)amino)-2,6- naphthyridin-3-yl)amino)-3- methylphenyl)acrylamide 648 60

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1- (2-dimethoxyethyl)-1H-pyrazol- 4-yl)methyl)amino)-2,6- naphthyridin-3-yl)amino)-3- methylphenyl)acrylamide 662 61

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-ethoxy- 2,6-naphthyridin-3-yl) amino)-3-methylphenyl) acrylamide 553 62

N-(2-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-isopro- poxy-2,6-naphthyridin-3-yl)- amino)-3-methylphenyl) acrylamide 567 63

N-(2-((5-(cyclopropyl- methoxy)-7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naph- thyridin-3-yl)amino)-3- methylphenyl)acrylamide 579 64

N-(3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-2-yl)amino)- 1-methyl-1H-pyrazol-4-yl) acrylamide 500 65

N-(3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4- d]pyrimidin-2-yl)amino- 1-(2-dimethoxyethyl)-1H-pyr- azol-4-yl)acrylamide 544 66

N-(3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-methoxy- pyrido[3,4-d]pyrimidin- 2-yl)amino)-1-methyl-1H- pyrazol-4-yl)acrylamide 530 67

N-(3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naph- thyridin-3-yl)amino)-1- methyl-1H-pyrazol-4-yl)acryl- amide 499 68

N-(3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2- methoxyethyl)amino)-2,6- naphthpyridin-3-yl)amino)-1- methyl-1H-pyrazol-4-yl) acrylamide 572 69

N-(2-((6-(2,6-dichloro-3,5- dimethoxyphenyl)thieno[2, 3-d]pyrimidin-2-yl)amino)- 3-methylphenyl)acrylamide 515 70

N-(2-((2-(2,6-dichloro-3,5- dimethoxyphenyl)thieno[3, 2-c]pyridin-6-yl)amino)-3- methylphenyl)acrylamide 515 71

N-(2-((2-(2,6-dichloro-3,5- dimethoxyphenyl)thiazolo [5,4-d]pyrimidin-5-yl)amino)- 3-methylphenyl)acrylamide 516 72

N-(2-((2-(2,6-dichloro-3,5- dimethoxyphenyl)thiazolo [4,5-c]pyridin-6-yl)amino)- 3-methylphenyl)acrylamide 515 73

N-(2-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-oxo-4H- 1-pyrano[2,3-c]pyridin-6- yl)amino)-3-methylphenyl) acrylamide 526 74

N-(2-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-oxo-8H- pyrano[3,2-d]pyrimidin- 2-yl)amino)-3-methylphenyl) acrylamide 527 75

N-(2-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-3-methyl- 4-oxo-3,4-dihydropyrido [3,4-d]pyrimidin-6-yl)amino)- 3-methyl-5-(4-methyl- piperazin-1-yl)phenyl) acrylamide 638

Example 76 Preparation of N-(3-((8-((cyclopropylmethyl)amino)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-1-methyl-1H-pyrazol-4-yl)acrylamide

Step 1: Preparation of N-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine-8-amine

N-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine-8-amine (210 mg, 0.465 mmol) was dissolved in dichloromethane (6 mL), then m-chloroperoxybenzoic acid (200 mg, 1.163 mmol) was added, and the mixture was stirred at room temperature for 18 h. After the reaction was completed, a saturated sodium sulfite solution (5 mL) was added, and the mixture was stirred for 5 min and extracted with dichloromethane, the organic phase was washed successively with a saturated sodium bicarbonate solution and then saturated brine, dried over anhydrous sodium sulfate, filtrated, concentrated and separated by column chromatography (Eluent: PE/EA=2/1) to obtain compound N-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylsulfonyl)pyrido [3,4-d]pyrimidine-8-amine (186 mg, yield: 82.7%).

MS m/z (ESI): 483.4 [M+H]⁺.

Step 2: Preparation of N-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-N²-(1-methy-4-nitro-1H-pyrazol-3-yl)pyrido[3,4-d]pyrimidine-2,8-diamine

N-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine-8-amine (90 mg, 0.186 mmol) was dissolved in dried DMF (5 mL), and NaH (15 mg, 0.372 mmol) was added at 0° C., and the mixture was stirred at room temperature for 10 min. Then 1-methyl-4-nitro-1H-pyrazol-3-amine (32 mg, 0.223 mmol) was added, and the mixture was stirred at room temperature for 3 h. The mixture was quenched with a saturated aqueous ammonium chloride, extracted with ethyl acetate and separated by silica gel column chromatography (PE/EA=1/1) to obtain compound Ne-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-N²-(1-methyl-4-nitro-1H-pyrazol-3-yl)pyrido[3,4-d]p yrimidine-2,8-diamine (100 mg, yield:98%). MS m/z (ESI): 545 [M+H].

Step 3: preparation of N-(4-amino-1-methyl-H-pyrazol-3-yl)-N-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]imidine-2,8-diamine

N⁸-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-N²-(1-methyl-4-nitro-1H-pyrazol-3-yl)pyrido[3,4-d]pyrimidine-2,8-diamine (40 mg, 0.074 mmol) was dissolved in methanol (10 mL), and then triethylamine (3 drops) and Pd/C (20 mg, 10% content) were successively added, and the mixture was stirred at room temperature under H₂ for 45 min. The reaction was completed and the mixture was filtrated and separated by silica gel column chromatography (DCM/MeOH) to obtain compound N²-(4-amino-1-methyl-H-pyrazol-3-yl)-N⁸-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-2,8-diamine (30 mg, yield:80%). MS m/z (ESI): 515 [M+H]⁺.

Step 4: Preparation of N-(3-((-((cyclopropylmethyl)amino)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-1-methyl-1H-pyrazol-4-yl)acrylamide

N²-(4-amino-1-methyl-1H-pyrazol-3-yl)-N^(B)-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimeth oxyphenyl)pyrido[3,4-d]pyrimidine-2,8-diamine (30 mg, 0.058 mmol) was dissolved in the mixture of THF and H₂O (8 mL/2 mL), then NaHCO₃ (33 mg, 0.39 mmol) was added, and acetyl chloride (7 mg, 0.078 mmol, dissolved in 1 mL of THF) was added dropwise under ice bath, and the mixture was stirred for 10 minutes, a saturated aqueous sodium bi carbonate solution (20 mL) was added, and the mixture was extracted with ethyl acetate and separated by silica gel column chromatography (PE/EA=1/1) to obtain compound N-(3-((8-((cyclopropylmethyl)amino)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)-1-methyl-H-pyrazol-4-yl)acrylamide (10 mg, yield:22%). MS m/z (ESI): 569 [M+H]⁺.

¹H NMR (400 MHz, CDCl₃) δ 9.03 (s, 1H), 8.17 (s, 1H), 6.77 (s, 1H), 6.63 (s, 1H), 6.38 (d, J=16.6 Hz, 2H), 6.33-6.24 (m, 1H), 5.70 (d, J=10.1 Hz, 1H), 3.95 (s, 6H), 3.87 (s, 3H), 3.53-3.36 (m, 2H), 1.19-1.10 (m, 1H), 0.55-0.41 (m, 2H), 0.42-0.29 (m, 2H).

Examples 77-117 were prepared referring to the synthesis method of Example 76.

Example MS: m/z No. Compound structure Compound name [M + 1]⁺ 77

N-(2-((8-((cyclopropylmethyl)ami- no)-6-(2,6-dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-2- yl)amino)-3-methylphenyl)acryl- amide 579 78

N-(2-((8-((cyclopropylmethyl)ami- no)-6-(2,6-dichloro-3,5-bis(dimethoxy- d₃)phenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)-3-methylphenyl) acrylamide 585 79

N-(2-((8-((cyclopropylmethyl)ami- no)-6-(2,6-difluoro-3,5-bis(me- thoxy-d₃)phenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)-3-methylphenyl) acrylamide 553 80

N-(2-((8-((cyclopropylmethyl)ami- no)-6-(2,6-difluoro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-2- yl)amino)-3-methylphenyl)acryl- amide 547 81

N-(2-((6-(2,6-dichloro-3,5-dimethoxy- phenyl)-8-((2-hydroxyethyl) amino)pyrido[3,4-d]pyrimidin-2-yl- amino)-3-methylphenyl)acrylamide 569 82

N-(2-((6-(2,6-dichloro-3,5-dimethoxy- phenyl))-8-((2-dimethoxyethyl)) amino)pyrido[3,4-d]pyrimidin-2-yl)- amino)-3-methylphenyl)acrylamide 583 83

N-(2-((6-(2,6-dichloro-3,5-dimethoxy- phenyl)-8-((2-(ethylsulfonyl) ethyl)amino)pyrido[3,4-dilpyrimidin- 2-yl)amino)-3-methylphenyl) acrylamide 645 84

N-(2-((6-(2,6-dichloro-3,5-dimethoxy- phenyl)-8-((2-(dimethylamino) ethyl)amino)pyrido[3,4-d]pyrim- idin-2-yl)amino)-3-methylphenyl) acrylamide 596 85

N-(2-((6-(2,6-dichloro-3,5-dimethoxy- phenyl)-8-((3-(dimethylamino) propyl)amino)pyrido[3,4-d] pyrimidin-2-yl)amino)-3-methylphenyl) acrylamide 610 86

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(methylamino)pyrido [3,4-d]pyrimidin-2-yl)amino)-3- methylphenyl)acrylamide 539 87

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(ethylamino)pyrido [3,4-d]pyrimidin-2-yl)amino)-3- methylphenyl)acrylamide 553 88

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(ethylamino)pyrido [3,4-d]pyrimidin-2-yl)amino)-3- methylphenyl)acrylamide 607 89

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(dimethylamino) pyrido[3,4-d]pyrimidin-2-yl)amino)- 3-methylphenyl)acrylamide 553 90

N-(2-((8-((cyclopropylmethyl) (methyl)amino)-6-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4-d] pyrimidin-2-yl)amino-3-methylphenyl) acrylamide 593 91

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-((2-(methylsulfon- amido)ethyl)amino)pyrido[3,4-d] pyrimidin-2-yl)amino)-3-methyl- phenyl)acrylamide 646 92

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(((tetrahydrofuran-2- yl)methyl)amino)pyrido[3,4-d] pyrimidin-2-yl)amino)-3-methyl- phenyl)acrylamide 609 93

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(((tetrahydrofuran-3- yl)methyl)amino)pyrido[3,4-d] pyrimidin-2-yl)amino)-3-methylphe- nyl)acrylamide 609 94

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-((oxetan-3-ylmethyl) amino)pyrido[3,4-d]pyrimidin-2- yl)amino)-3-methylphenyl)acryl- amide 595 95

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(((tetrahydro-2H- pyran-4-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)-3-methyl- phenyl)acrylamide 623 96

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(oxetan-3-ylamino) pyrido[3,4-d]pyrimidin-2-yl)amino)- 3-methylphenyl)acrylamide 581 97

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-((tetrahydro-2H- pyran-4-yl)amino)pyrido[3,4-d] pyrimidin-2-yl)amino)-3-methyl- phenyl)acrylamide 609 98

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-((tetrahydrofuran-3- yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)-3-methylphenyl)acryl- amide 595 99

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(((1-methylpyrrolidin- 3-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)-3-methyl- phenyl)acrylamide 622 100

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(((1-methylpyrrolidin- 2-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)-3-methyl- phenyl)acrylamide 622 101

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-((1-methylpyrrolidin- 3-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)-3-methylphenyl) acrylamide 608 102

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(((1-methylazetidin- 3-yl)methyl)amino)pyrido[3,4-d] pyrimidin-2-yl)amino)-3-methyl- phenyl)acrylamide 608 103

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(((1-methylazetidin- 3-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)-3-methylphenyl) acrylamide 594 104

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-((1-methylpiperidin- 4-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)-3-methylphenyl) acrylamide 622 105

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(((1-methylpiperidin- 4-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)-3-methyl- phenyl)acrylamide 636 106

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-((3,3-difluorocyclobutyl) amino)pyrido[3,4-d]pyrimidin- 2-yl)amino-3-methylphenyl) acrylamide 615 107

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-((3,3-difluorocyclopentyl) amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)-3-methylphenyl) acrylamide 629 108

N-(2-((8-((cyclopentylmethyl)ami- no)-6-(2,6-dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-2- yl)amino)-3-methylphenyl)acrylamide 607 109

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(phenethylamino) pyrido[3,4-d]pyrimidin-2-yl)amino)- 3-methylphenyl)acrylamide 629 110

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(((1-methyl-1H-pyr- azol-4-yl)methyl)amino)pyrido[3, 4-]pyrimidin-2-yl)amino)-3- methylphenyl)acrylamide 619 111

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(((1-(2-hydroxyethyl)- 1H-pyrazol-4-yl)methyl)amino) pyrido[3,4-d]pyrimidin-2-yl)amino)- 3-methylphenyl)acrylamide 649 112

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-(((1-(2-dimethoxyethyl)- 1H-pyrazol-4-yl)methyl)amino) pyrido[3,4-d]pyrimidin-2-yl)amino)- 3-methylphenyl)acrylamide 663 113

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-methoxypyrido[3,4- d]pyrimidin-2-yl)amino)-3-methyl- phenyl)acrylamide 540 114

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-ethoxypyrido[3,4- d]pyrimidin-2-yl)amino)-3-methyl- phenyl)acrylamide 554 115

N-(2-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-isopropoxypyrido [3,4-d]pyrimidin-2-yl)amino)-3- methylphenyl)acrylamide 568 116

N-(2-((8-(cyclopropylmethoxy)-6- (2,6-dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidin-2-yl) amino)-3-methylphenyl)acrylamide 117

N-(3-((6-(2,6-dichloro-3,5-dime- thoxyphenyl)-8-((2-dimethoxyethyl) amino)pyrido[3,4-d]pyrimidin-2-yl) amino)-1-methyl-1H-pyrazol-4- yl)acrylamide 573

Example 118 Preparation of (1-N-((3R,4S)-4-((6-(2,6-dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide

Step 1: Preparation of (±)-(3S,4R)—N³-(6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)tetrahydrofuran-3,4-diamine

2-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine (40.0 mg, 0.108 m mol) and trans-tetrahydrofuran-3,4-diamine dihydrochloride (28.3 mg, 0.162 mmol) were dissolved in acetonitrile (2 mL), then N,N-diisopropylethylamine (70 mg, 0.543 mmol) was added, the mixture was heated to reflux for 16 h. After being cooled, the reaction liquid was diluted with EtOAc (10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, filtrated, concentrated and separated by PTLC (Eluent. CH₂Cl₂/MeOH=10:1) to obtain compound (3S,4R)—N-(6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)tetrahydrofuran-3,4-diamine (30 mg, yield: 64%). MS m/z (ESI): 436.1 [M+H]⁺.

Step 2: Preparation of (±)—N-((3R,4S)-4-((6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido [3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide

(±)-(3S,4R)—N³-(6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)tetrahydrofuran-3,4-diamine (30.0 mg, 0.069 mmol) was dissolved in the mixture THF and H₂O (1.2/0.3 mL), NaHCO₃ (23.0 mg, 0.276 mmol) was added, and the mixture was cooled under ice water bath, and then acryloyl chloride (6.8 mg, 0.076 mmol) was added. After addition, the mixture was stirred at 0° C. for 10 min. The reaction liquid was diluted with EtOAc (5 mL), washed with saturated brine, dried over anhydrous sodium sulfate, filtrated and concentrated. The crude product was separated by PTLC (Eluent: CH₂Cl₂/MeOH=10:1) to obtain compound N-((3R,4S)-4-((6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide (17.4 mg, yield: 52%).

¹H NMR (400 MHz, CDCl₃) δ 9.21 (s, 1H), 9.16 (s, 1H), 7.55 (s, 1H), 6.68 (s, 1H), 6.45 (d, J=7.3 Hz, 111), 6.27 (dd, J=17.0, 1.4 Hz, 1H), 6.07 (dd, J=16.9, 10.3 Hz, 1H), 5.63 (dd, J=10.2, 1.4 Hz, 11), 4.94 (dd, J=11.6, 4.9 Hz, 11), 4.90-4.79 (m, 111), 4.34-4.19 (m, 2H), 3.98 (s, 6H), 3.90-3.79 (m, 2H). MS m/z (ESI): 490.1 [M+H]⁺.

Example 119 Preparation of N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide

Step 1: Preparation of N-((3S,4S)-4-azidotetrahydro-2H-pyran-3-yl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-2-amine

2-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine (100 mg, 0.27 m mol) was dissolved in NMP (3 mL), and Na₂CO₃ (143 mg, 1.349 mmol) and (3S,4S)-4-azidotetrahydro-2H-pyran-3-amine hydrochloride (72 mg, 0.405 mmol) were added, the mixture was heated to 120° C. for 2 h. The reaction was completed, and the mixture was cooled to room temperature, added with water, and extracted for three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtrated, concentrated and separated by column chromatography (Eluent: petroleum ether/ethyl acetate 2:1) to obtain compound N-((3S,4S)-4-azidotetrahydro-2H-pyran-3-yl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-2-amine (38 mg, yield: 29%). MS m/z (ESI): 478.4 [M+H]⁺.

Step 2: Preparation of (3S,4S)—N³-(6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)tetrahydro-2H-pyran-3,4-diamine

N-((3S,4S)-4-azidotetrahydro-2H-pyran-3-yl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-2-amine (38 mg, 0.08 mmol) was dissolved in MeOH (8 mL), then Pd/C (10 mg) was added, and the mixture was stirred under H₂ at room temperature for 30 min. The reaction was completed, and the mixture was concentrated and separated by column chromatography (Eluent: dichloromethane/methanol 10:1) to obtain compound (3S,4S)—N³-(6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)tetrahydro-2H-pyran-3,4-diamine (12 mg, yield: 33%). MS m/z (ESI): 451.2 [M+H]⁺.

Step 3: Preparation of N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide

(3S,4S)—N³-(6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)tetrahydro-2H-pyran-3,4-diamine (12 mg, 0.027 mmol) was dissolved in the mixture of THF and H₂O (4 mL/I mL), then NaHCO₃ (12 mg, 0.141 mmol) was added, the mixture was cooled under ice water bath, and a solution of acryloyl chloride (3 mg, 0.027 mmol) in THF (2 mL) was added dropwise, and the mixture was stirred at low temperature for 10 min. After the reaction was completed, the mixture was extracted three times with dichloromethane. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography (Eluent: dichloromethane/petroleum ether (10:1)) to obtain compound N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide (6.3 mg, yield: 47%).

¹H NMR (400 MHz, CDCl₃) δ 9.17 (s, 2H), 7.56 (s, 1H), 6.68 (s, 1H), 6.25 (dd, J=16.9, 1.4 Hz, 1H), 6.01 (dd, J=17.0, 10.3 Hz, 1H), 5.60 (dd, J=10.3, 1.4 Hz, 1H), 4.55 (s, 1H), 4.35 (s, 1H), 4.11-4.00 (m, 2H), 3.98 (s, 6H), 3.78 (d, J=12.1 Hz, 1H), 3.64 (dd. J=13.4, 10.9 Hz, 1H), 2.24-2.20 (m, 2H), 2.02-1.99 (m, 2H). MS m/z (ESI): 505.4 [M+H]⁺.

Examples 120-420 and 752 were prepared referring to the synthesis method of Example 118 or 119.

Example MS: m/z No. Compound structure Compound name [M + 1]⁺ 120

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-dime- thoxyphenyl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acrylamide 458 121

N-((3R,4S)-4-((6-(2-chloro-3,5-dime- thoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl) amino)tetrahydrofuran-3-yl)acrylamide 456 122

N-((3R,4S)-4-((6-(2-chloro-3,5-dime- thoxy-6-methyl)phenyl))pyrido[3,4-d] pyrimidin-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 470 123

N-((3R,4S)-4-((6-(2-chloro-6-fluoro-3, 5-dimethoxyphenyl)pyrido[3,4-d]pyrim- idin-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 474 124

N-((3R,4S)-4-((7-(2,6-dichloro-3,5-dime- thoxyphenyl)-2,6-naphthyridin-3-yl) amino)tetrahydrofuran-3-yl)acrylamide 489 125

N-((3R,4S)-4-((7-(2,6-dichloro-3,5-dime- thoxyphenyl)-5-((2-dimethoxyethyl)ami- no)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 562 126

N-((3R,4S)-4-((5-((cyclopropylmethyl) amino)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 558 127

N-((3R,4S)-4-((7-(2,6-dichloro-3,5-dime- thoxyphenyl)-5-oxo-5,6-dihydro-2,6- naphthyridin-3-yl)amino)tetrahydrofuran- 3-yl)acrylamide 505 128

N-((3R,4S)-4-((7-(2,6-dichloro-3,5-dime- thoxyphenyl)-6-methyl-5-oxo-5,6- dihydro-2,6-napthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 519 129

N-((3R,4S)-4-((7-(2,6-dichloro-3,5-dime- thoxyphenyl)-5-methoxy-2,6- naphthyridin-3-yl)amino)tetrahydrofuran-3-yl) acrylamide 519 130

N-((3R,4S)-4-((6-(2-chloro-6-cyclopropyl- 3,5-dimethoxyphenyl)pyrido[3,4-d] pyrimidin-2-yl)amino)tetrahydrofuran- 3-yl)acrylamide 496 131

N-((3R,4S)-4-((6-(2-chloro-6-isopropyl- 3,5-dimethoxyphenyl)pyrido[3,4-d] pyrimidin-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 498 132

N-((3R,4S)-4-((7-(2-chloro-6-isopropyl- 3,5-dimethoxyphenyl)-2,6-naphthyridin- 3-yl)amino)tetrahydrofuran-3-yl)acryl- amide 497 133

N-((3R,4S)-4-((5-((cyclopropylmethyl) amino)-7-(2,6-difluoro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 526 134

N-((3R,4S)-4-((5-(cyclopropylmethyl) amino)-7-(2,6-dichloro-3,5-bis(methoxy- d₃)phenyl)-2,6-naphthyridin-3-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 564 135

N-((3R,4S)-4-((5-((cyclopropylmethyl) amino)-7-(2,6-difluoro-3,5-bis(methoxy- d₃)phenyl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 532 136

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2-hydroxyethyl)ami- no)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 548 137

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2-(ethylsulfonyl) ethyl)amino)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 624 138

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2-(dimethylamino) ethyl)amino)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 575 139

N-((R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(ethylamino)-2,6- naphthyridin-3-yl)amino)tetrahydrofuran-3- yl)acrylamide 532 140

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2,2,2-trifluoroethyl) amino)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 586 141

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(dimethylamino)-2,6- naphthyridin-3-yl)amino)tetrahydrofuran- 3-yl)acrylamide 532 142

N-((3R,4S)-4-((5-((cyclopropylmethyl) methyl)amino)-7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-3-yl) amino)tetrahydrofuran-3-yl)acrylamide 572 143

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2-(methylsulfonamido) ethyl)amino)-2,6-naphthyridin-3-yl) amino)tetrahydrofuran-3-yl)acrylamide 625 144

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((tetrahydrofuran-2-yl) methyl)amino)-2,6-naphthyridin-3-yl) amino)tetrahydrofuran-3-yl)acrylamide 588 145

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((tetrahydrofuran-3-yl) methyl)amino)-2,6-naphthyridin-3-yl) amino)tetrahydrofuran-3-yl)acrylamide 588 146

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((oxetan-3-ylmethyl) amino)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 574 147

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((tetrahydro-2H-pyran- 4-yl)methyl)amino)-2,6-naphthyridin- 3-yl)amino)tetrahydrofuran-3-yl)acrylamide 602 148

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(oxetan-3-ylamino)-2, 6-naphthyridin-3-yl)amino)tetrahydrofu- ran-3-yl)acrylamide 560 149

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((tetrahydrofuran-3-yl) amino)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 574 150

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((tetrahydro-2H-pyran- 4-yl)amino)-2,6-naphthryridin-3-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 588 151

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1-methylpiperidin-4-yl) methyl)amino)-2,6-naphthyridin-3-yl) amino)tetrahydrofuran-3-yl)acrylamide 615 152

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((3,3-difluorocyclopentyl) amino)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 608 153

N-((3R,4S)-4-((5-((cyclopentylmethyl) amino)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 586 154

N-((3R,4S)-4-((5-(benzylamino)-7-(2,6- dichloro-3,5-dimethoxyphenyl)-2,6- naphthyridin-3-yl)amino)tetrahydrofuran- 3-yl)acrylamide 594 155

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1-methyl-1H-pyrazol- 4-yl)methyl)amino)-2,6-naphthyridin- 3-yl)amino)tetrahydrofuran-3-yl)acrylamide 598 156

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1-(2-hydroxyethyl)- pyrazol-4-yl)methyl)amino)-2,6- naphthyridin-3-yl)amino)tetrahydrafuran- 3-yl)acrylamide 628 157

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1-(2-methoxyethyl-) 1H-pyrazol-4-yl)methyl)amino)-2,6- naphthyridin-3-yl)amino)tetrahydrofuran- 3-yl)acrylamide 642 158

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2-(4-methylpiperazin- 1-yl)ethyl)amino)-2,6-naphthyridin-3-yl amino)tetrahydrofuran-3-yl)acrylamide 630 159

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2-morpholinoethyl) amino)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 617 160

N-((3R,4S)-4-((7-(2-chloro-3-methoxy- phenyl)-5-((2-hydroxyethyl)amino)-2,6- naphthyridin-3-yl)amino)tetrahydro- furan-3-yl)acrylamide 484 161

N-((3R,4S)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-5-((2-hydroxyethyl)ami- no)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 516 162

N-((3R,4S)-4-((7-(2-fluoro-3-methoxy- phenyl)-5-((2-hydroxyethyl)amino)-2,6- naphthyridin-3-yl)amino)tetrahydrofuran- 3-yl)acrylamide 468 163

N-((3R,4S)-4-((7-(2-chloro-3,5-dimethoxy- phenyl)-5-((2-(dimethylamino)ethyl) amino)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 541 164

N-((3R,4S)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-5-((2-(dimethylamino) ehyl)amino)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 543 165

N-((3R,4S)-4-((5-((2-(dimethylamino) ethyl)amino)-7-(2-fluoro-3-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 495 167

N-((3R,4S)-4-((7-(2-fluoro-3,5-dimethoxy- phenyl)-5-(((tetrahydrofuran-2-yl) methyl)amino)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 538 168

N-((3R,4S)-4-((7-(2-fluoro-3-methoxy- phenyl)-5-(((tetrahydrofuran-2-yl)methyl amino)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 508 169

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-ethoxy-2,6-naphthyridin- 3-yl)amino)tetrahydrofuran-3-yl)acrylamide 533 170

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-isopropoxy-2,6- naphthyridin-3-yl)amino)tetrahydrofuran-3- yl)acrylamide 547 171

N-((3R,4S)-4-((5-(cyclopropylmethoxy)- 7-(2,6-dichloro-3,5-dimethoxyphenyl) 2,6-naphthyridin-3-yl)amino)tetrahydro- furan-3-yl)acrylamide 559 172

N-((3S,4S)-3-((6-(2-chloro-6-fluoro-3,5- dimethoxyphenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 488 173

N-((3S,4S)-3-((6-(6-chloro-7-dimethoxy- 2,3-dihydrobenzo[b][1,4]dioxin-5-yl) pyrido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 498 174

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-oxo-7,8-dihydropyrido [3,4-d]pyrimidin-2-yl)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 520 175

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-7-methyl-8-oxo-7,8- dihydropyrido[3,4-d]pyrimidin-2-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 534 176

N-((3S,4S)-3-((7-(cyclopropylmethyl)- 6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-oxo-7,8-dihydropyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran-4-yl) acrylamide 574 177

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-3-yl) amino)tetrahydro-2H-pyran-4-yl)acrylamide 503 178

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2-dimethoxyethyl)ami- no)-2,6-naphthyridin-3-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 576 179

N-((3S,4S)-3-((5-((cyclopropylmethyl) amino)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 572 180

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-dimethoxy-2,6-naphthyridin- 3-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 533 181

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-oxo-5,6-dihydro-2,6- naphthyridin-3-yl)amino)teahydro-2H- pyran-4-yl)acrylamide 519 182

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-6-methyl-5-oxo-5,6- dihydro-2,6-naphthyridin-3-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 533 183

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)thieno[2,3-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran-4-yl) acrylamide 509 184

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)thiazolo[5,4-d]pyrimidin- 5-yl)amino)tetrahydro-2H-pyran-4-yl) acrylamide 510 185

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)thiazolo[4,5-c]pyridin-6- yl)amino)tetrahydro-2H-pyran-4-yl) acrylamide 509 186

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-oxo-4H-pyrano[2,3-c] pyridin-6-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 520 187

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-oxo-8H-pyrano[3,2-d] pyrimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 521 188

N-((3S,4S)-3-((6-(2-chloro-6-cyclopropyl- 3,5-dimethoxyphenyl)pyrido[3,4-d] pyrimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 510 189

N-((3S,4S)-3-((6-(2-fluoro-6-isopropyl- 3,5-dimethoxyphenyl)pyrido[3,4-d] pyrimidin-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 496 190

N-((3S,4S)-3-((6-(2-cyclopropyl-6- fluoro-3,5-dimethoxyphenyl)pyrido[3,4-d] pyrimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 493 191

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran-4-yl) acrylamide 472 192

N-((3S,4S)-3-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-2,6-naphthyridin-3-yl) amino)tetrahydro-2H-pyran-4-yl)acrylamide 471 193

N-((3S,4S)-3-((7-(2-chloro-6-cyclopropyl- 3,5-dimethoxyphenyl)-2,6-naphthyridin- 3-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 509 194

N-((3S,4S)-3-((7-(2-cyclopropyl-6-fluoro- 3,5-dimethoxyphenyl)-2,6-naphthyridin- 3-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 493 195

N-((3S,4S)-3-((7-(2-fluoro-6-isopropyl- 3,5-dimethoxyphenyl)-2,6-naphthyridin- 3-yl)amino)tetrahydro-2H-pyran-4-yl) acrylamide 495 196

N-((3S,4S)-3-((7-(6-chloro-7-methoxy- 2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-2, 6-naphthyridin-3-yl)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 496 197

N-((3S,4S)-3-((7-(6-fluoro-7-methoxy- 2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-2, 6-naphthyridin-3-yl)amino)tetrahydro- 2H-pyrah-4-yl)acrylamide 481 198

N-((3S,4S)-3-((5-((cyclopropylmethyl) amino)-7-(2,6-difluoro-3,5-dimethoxy- phenyl)-2,6-haphthyridin-3-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 540 199

N-((3S,4S)-3-((5-((cyclopropylmethyl) amino)-7-(2,6-dichloro-3,5-bis(methoxy- d₃)phenyl)-2,6-naphthyridin-3-yl)ami- no)tetrahydro-2H-pyran-4-yl)acrylamide 578 200

N-((3S,4S)-3-((5-((cyclopropylmethyl) amino)-7-(2,6-difluoro-3,5-bis(methoxy- d₃)phenyl)-2,6-naphthyridin-3-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 546 201

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2-hydroxymethyl)ami- no)-2,6-naphthyridin-3-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 562 202

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2-(dimethylamino) ethyl)amino)-2,6-naphthyridin-3-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 589 203

N-(3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(methylamino)-2,6- naphthyridin-3-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 532 204

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(ethylamino)-2,6- naphthyridin-3-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 546 205

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2,2,2-trifluoroethyl) amino)-2,6-naphthyridin-3-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 600 206

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(dimethylamino)-2,6- naphthyridin-3-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 546 207

N-((3S,4S)-3-((5-((cyclopropylmethyl) (methyl)amino)-7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-3-yl) amino)tetrahydro-2H-pyran-4-yl)acrylamide 586 208

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2-(methylsulfonamido) ethyl)amino)-2,6-naphthyridin-3-yl) amino)tetrahydro-2H-pyran-4-yl)acrylamide 639 209

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((tetrahydrofuran-2- yl)amino)-2,6-naphthyridin-3-yl) amino)tetrahydro-2H-pyran-4-yl) acrylamide 602 210

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((tetrahydrofuran-3-yl) methyl)amino)-2,6-naphthyridin-3-yl) amino)tetrahydro-2H-pyran-4-yl) acrylamide 602 211

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((oxetan-3-ylmethyl) amino)-2,6-naphthyridin-3-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 588 212

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((tetrahydro-2H-pyran- 4-yl)methyl)amino)-2,6-naphthyridin- 3-yl)amino)tetrahydro-2H-pyran-4-yl) acrylamide 616 213

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(oxetan-3-yl)amino)-2, 6-naphthyridin-3-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 574 214

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((tetrahydrofuran-3-yl) amino)-2,6-naphthyridin-3-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 588 215

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((tetrahydro-2H-pyran- 4-yl)amino)-2,6-naphthyridin-3-yl))ami- no)tetrahydro-2H-pyran-4-yl)acrylamide 607 216

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1-methylpiperidin-4- yl)methyl)amino)-2,6-naphthyridin-3- yl)amino)tetrahydro-2H-pyran-4-yl) acrylamide 629 217

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((3,3-diftuorocyclopentyl) amino)-2,6-naphthyridin-3-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 622 218

N-((3S,4S)-3-((5-((cyclopentylmethyl) amino)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 600 219

N-((3S,4S)-3-((5-(benzylamino)-7-(2,6- dichloro-3,5-dimethoxyphenyl)-2,6- naphthyridin-3-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 608 220

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1-methyl-1H-pyrazol- 4-yl)methyl)amino)-2,6-naphthyridin- 3-yl)amino)tetrahydro-2H-pyran-4-yl) acrylamide 612 221

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1-(2-hydroxyethyl)- 1H-pyrazol-4-yl)methyl)amino)-2,6- naphthyridin-3-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 642 222

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((1-(2-dimethoxyethyl)- 1H-pyrazol-4-yl)methyl)amino)-2,6- naphthyridin-3-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 656 223

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2-(4-methylpiperazin- 1-yl)ethyl)amino)-2,6-naphthyridin-3- yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide 644 224

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((2-morpholinoethyl) amino)-2,6-naphthyridin-3-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 631 225

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-dimethoxy-2,6-naphthyridin- 3-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 547 226

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-isopropoxy-2,6- naphthyridin-3-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 561 227

N-((3S,4S)-3-((5-(cyclopropylmethoxy)- 7-(2,6-dichloro-3,5-dimethoxyphenyl)- 2,6-naphthyridin-3-yl)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 573 228

N-((3S,4R)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2- yl)amino)pyrrolidin-3-yl)acrylamide 489 229

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-3-yl) amino)pyrrolidin-3-yl)acrylamide 488 230

N-((3S,4R)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-2,6-naphthyridin-3-yl) amino)pyrrolidin-3-yl)acrylamide 455 231

N-((3S,4R)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-oxo-7,8-dihydropyrido [3,4-d]pyrimidin-2-yl)amino)pyrrolidin- 3-yl)acrylamide 505 232

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-oxo-5,6-dihydro-2,6- naphthyridin-3-yl)amino)pyrrolidin-3-yl) acrylamide 504 233

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-6-methyl-5-oxo-5,6- dihydro-2,6-naphthyridin-3-yl)amino)pyrrolidin- 3-yl)acrylamide 518 234

N-((3S,4R)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-oxo-8H-pyrano[3,4-d] pyrimidin-2-yl)amino)pyrrolidin-3-yl) acrylamide 506 235

N-((3S,4R)-4-((3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-oxo-1H-pyrano[4,3-c] pyridin-7-yl)amino)pyrrolidin-3-yl)acrylamide 505 236

N-((3S,4R)-4-((3-(2,6-difluoro-3,5- dimethoxyphenyl)-1-oxo-1H-pyrano[4,3-c] pyridin-7-yl)amino)pyrrolidin-3-yl)acrylamide 472 237

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-3-yl)amino)- 1-methylpyrrolidin-3-yl)acrylamide 502 238

N-((3S,4R)-1-acetyl-4-((7-(2,6-dichloro- 3,5-dimethoxyphenyl)-2,6-naphthyridin- 3-yl)amino)pyrrolidin-3-yl)acrylamide 530 239

N-((3S,4R)-1-acetyl-4-((7-(2,6-dichloro- 3,5-dimethoxyphenyl)-5-(methylamino)- 2,6-naphthyridin-3-yl)amino)pyrrolidin- 3-yl)acrylamide 559 240

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-3-yl) amino)-1-(2-(dimethylamino)ethyl) pyrrolidin-3-yl)acrylamide 559 241

(3S,4R)-3-acrylamido-4-((7-(2,6-dichloro- 3,5-dimethoxyphenyl)-2,6-naphthyridin- 3-yl)amino)-N-methylpyrrolidine-1- carboxamide 545 242

(3S,4R)-3-acrylamido-4-((5-((cyclopropyl- methyl)amino)-7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-3-yl) amino)-N-methylpyrrolidine-1-carboxamide 614 243

N-((3S,4R)-1-acetyl-4-((5-((cyclopropyl- methyl)amino)-7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-3-yl) amino)pyrrolidin-3-yl)acrylamide 599 244

N-((3S,4R)-4-((5-((cyclopropylmethyl) amino)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino)-1- (oxetan-3-yl)pyrrolidin-3-yl)acrylamide 613 245

N-((3S,4R)-4-((5-((cyclopropylmethyl) amino)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino-1- (2-(dimethylamino)ethyl)pyrrolidin-3- yl)acrylamide 628 246

N-((3S,4R)-4-((5-((cyclopropylmethyl) amino)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino)-1- (1H-pyrazol-4-yl)pyrrolidin-3-acrylamide 623 247

N-((3S,4R)-4-((5-((cyclopropylmethyl) amino)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino)-1- (1-methyl-1H-pyrazol-4-yl)pyrrolidin-3- yl)acrylamide 637 248

N-((3S,4R)-4-((5-((cyclopropylmethyl) amino)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino)-1- methylpyrrolidin-3-yl)acrylamide 571 249

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((tetrahydrofuran-2-yl) methyl)amino)-2,6-naphthyridin-3-yl) amino)-1-methylpyrrolidin-3-yl)acrylamide 601 250

(3S,4R)-3-acrylamido-4-((7-(2,6-dichloro- 3,5-dimethoxyphenyl)-5-(((tetrahydrofuran- 2-yl)methyl)amino)-2,6-naphthyridin- 3-yl)amino)-N-methylpyrrolidine- 1-carboxamide 644 251

N-((3S,4R)-1-acetyl-4-((7-(2,6-dichloro- 3,5-dimethoxyphenyl)-5-(((tetrahydrofuran- 2-yl)methyl)amino)-2,6-naphthyridin- 3-yl)amino)pyrrolidin-3-yl)acrylamide 629 252

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl))-5-(((tetrahydrofuran-2-yl) methyl)amino)-2,6-naphthyridin-3-yl) amino)-1-(oxetan-3-yl)pyrrolidin-3-yl) acrylamide 643 253

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((tetrahydrofuran-2-yl) methyl)amino)-2,6-naphthyridin-3-yl) amino)-1-(2-(dimethylamino)ethyl) pyrrolidin-3-yl)acrylamide 658 254

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((tetrahydrofuran-2-yl) methyl)amino)-2,6-naphthyridin-3-yl) amino)-1H-pyrazol-4-yl)pyrrolidin-3- yl)acrylamide 653 255

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(((tetrahydrofuran-2-yl) methyl)amino)-2,6-naphthyridin-3-yl) amino)-1-(1-methyl-1H-pyrazol-4-yl) pyrrolidin-3-yl)acrylamide 667 256

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(oxetan-3-ylamino)-2, 6-naphthyridin-3-yl)amino)-1-methyl- pyrrolidin-3-yl)acrylamide 573 257

(3S,4R)-3-acrylamido-4-((7-(2,6-dichloro- 3,5-dimethoxyphenyl)-5-(oxetan-3-yl- amino)-2,6-naphthyridin-3-yl)amino)- N-methylpyrrolidine-1-carboxamide 616 258

N-((3S,4R)-1-acetyl-4-((7-(2,6-dichloro- 3,5-dimethoxyphenyl)-5-(oxetan-3-yl- amino)-2,6-naphthyridin-3-yl)amino) pyrrolidin-3-yl)acrylamide 601 259

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(oxetan-3-ylamino)-2, 6-naphthyridin-3-yl)amino)-1-(oxetan-3- yl)pyrrolidin-3-yl)acrylamide 615 260

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(oxetan-3-ylamino)-2,6- naphthyridin-3-yl)amino)-1-(2-(dimethyl- amino)ethyl)pyrrolidin-3-yl)acrylamide 630 261

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(oxetan-3-ylamino)-2, 6-naphthyridin-3-yl)amino)-1-(1H-pyrazol- 4-yl)pyrrolidin-3-yl)acrylamide 625 262

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(oxetan-3-ylamino)-2, 6-naphthyridin-3-yl)amino)-1-(1-methyl- 1H-pyrazol-4-yl)pyrrolidin-3-yl)acrylamide 639 263

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((tetrahydrofuran-3-yl) amino)-2,6-naphthyridin-3-yl)amino)- 1-methylpyrrolidin-3-yl)acrylamide 587 264

(3S,4R)-3-acrylamido-4-((7-(2,6-dichloro- 3,5-dimethoxyphenyl)-5-(tetrahydrofuran- 3-yl)amino)-2,6-naphthyridin-3-yl) amino)-N-methylpyrrolidine-1-carboxamide 630 265

N-((3S,4R)-1-acetyl-4-((7-(2,6-dichloro- 3,5-dimethoxyphenyl)-5-((tetrahydrofuran- 3-yl)amino)-2,6-naphthyridin-3-yl) amino)pyrrolidin-3-yl)acrylamide 615 266

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(tetrahydrofuran-3-yl) amino)-2,6-naphthyridin-3-yl)amino)-1- (oxetan-3-yl)pyrrolidin-3-yl)acrylamide 629 267

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((tetrahydrofuran-3-yl) amino)-2,6-naphthyridin-3-yl)amino)- 1-(2-(dimethylamino)ethyl)pyrrolidin-3- yl)acrylamide 644 268

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((tetrahydrofuran-3-yl amino)-2,6-naphthyridin-3-yl)amino)- 1-(1H-pyrazol-4-yl)pyrrolidin-3-yl) acrylamide 639 269

N-((3S,4R)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-((tetrahydrofuran-3-yl amino)-2,6-naphthyridin-3-yl)amino)- 1-(1-methyl-1H-pyrazol-4-yl)pyrrolidin- 3-yl)acrylamide 653 270

N-((3R,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2 yl)amino)piperidin-4-yl)acrylamide 503 271

N-((3R,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2- yl)amino)piperidin-4-yl)acrylamide 470 272

N-((3R,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-3-yl) amino)piperidin-4-yl)acrylamide 502 273

N-((3R,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-oxo-7,8-dihydropyrido [3,4-d]pyrimidin-2-yl)amino)piperidin- 4-yl)acrylamide 519 274

N-((3R,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-oxo-5,6-dihydro-2,6- naphthyridin-3-yl)amino)piperidin-4-yl) acrylamide 518 275

N-((3R,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-7-methyl-8-oxo-7,8- hydropyrido[3,4-d]pyrimidin-2-yl)amino) piperidin-4-yl)acrylamide 533 276

N-((3R,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-oxo-8H-pyrano[3,4-d] pyrimidin-2-yl)amino)piperidin-4-yl) acrylamide 520 277

N-(3R,4S)-3-((3-(2,6-dichloro-3,5- dimethoxyphenyl)-1-oxo-1H-pyrano[4,3-c] pyridin-7-yl)amino)piperidin-4-yl) acrylamide 519 278

N-((3R,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-oxo-8H-pyrano[3,4-d] pyrimidin-2-yl)amino)piperidin-4-yl)acrylamide 487 279

N-((3R,4S)-4-((5-(((S)-1-cyclopropyl- ethyl)amino)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 572 280

N-((3R,4S)-4-((5-(((S)-1-cyclopropyl- ethyl)amino)-7-(2,6-difluoro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 540 281

N-((3R,4S)-4-((5-(cyclopropylamino)-7- (2,6-dichloro-3,5-dimethoxyphenyl)-2, 6-naphthyridin-3-yl)amino)tetrahydrofuran- 3-yl)acrylamide 544 282

N-((3R,4S)-4-((5-(cyclopropylamino)-7- (2,6-difluoro-3,5-dimethoxyphenyl)-2, 6-naphthyridin-3-ylamino)tetrahydrofuran- 3-yl)acrylamide 512 283

N-((3R,4S)-4-((5-(azetidin-1-yl)-7-(2,6- dichloro-3,5-dimethoxyphenyl)-2,6- naphthyridin-3-yl)amino)tetrahydrofuran-3- yl)acrylamide 544 284

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3-dimethoxyazetidin-1- yl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 574 285

N-((3R,4S)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-5-(3-methoxyazetidin-1- yl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 542 286

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3-(dimethylamino) azetidin-1-yl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 587 287

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3-(trifluoromethyl) azetidin-1-yl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 612 288

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3,3-dimethylazetidin- 1-yl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 572 289

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3,3-difluoroazetidin- 1-yl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 580 290

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3-hydroxy-3-methyl- azetidin-1-yl)-2,6-naphthyridin-3-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 574 291

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3-dimethoxy-3-methyl- azetidin-1-yl)-2,6-naphthyridin-3-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 588 292

N-((3R,4S)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-5-(3-dimethoxy-3-methyl- azetidin-1-yl)-2,6-naphthyridin-3-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 556 293

N-((3R,4S)-4-((5-(3-cyano-3-methyl- azetidin-1-yl)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 583 294

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(2-oxa-6-azaspiro[3.3] heptan-6-yl)-2,6-naphthyridin-3-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 586 295

N-(3R,4S)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-5-(2-(2-6-azaspiro[3.3] heptan-6-yl)-2,6-naphthyridin-3-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 554 296

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(1-oxa-6-azaspiro[3.3] heptan-6-yl)-2,6-naphthyridin-3-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 586 297

N-((3R,4S)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-5-(1-oxa-6-azaspiro[3.3] heptan-6-yl)-2,6-naphthyridin-3-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 554 298

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(2-azaspiro[3.3]heptan- 2-yl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 584 299

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(2-azaspiro[3.4]octan- 2-yl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 598 300

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(6-oxa-2-azaspiro[3,4] octan-2-yl)-2,6-naphthyridin-3-yl))amino) tetrahydrofuran-3-yl)acrylamide 600 301

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(7-oxa-2-azaspiro[3.5] nonan-2-yl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 614 302

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(pyrrolidin-1-yl)-2,6- naphthyridin-3-yl)amino)tetrahydrofuran- 3-yl)acrylamide 558 303

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3-methoxypyrrolidin- 1-yl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 588 304

N-((3R,4S)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-5-(3-methoxypyrrolidin- 1-yl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 556 305

N-((3R,4S)-4-((5-(3-cyanopyrrolidin-1- yl)-7-(2,6-dichloro-3,5-dimethoxyphenyl)- 2,6-naphthyridin-3-yl)amino)tetrahy- drofuran-3-yl)acrylamide 583 306

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3,3-difluoropyrrolidin- 1-yl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 594 307

N-(3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3-dimethoxy-3-methyl- pyrrolidin-1-yl)-2,6-naphthyridin-3-yl) amino)tetrahydrofuran-3-yl)acrylamide 602 308

N-((3R,4S)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-5-(3-methoxy-3-methyl- pyrrolidin-1-yl)-2,6-naphthyridin-3-yl) amino)tetrahydrofuran-3-yl)acrylamide 570 309

N-((3R,4S)-4-((5-(3-cyano-3-methyl- pyrrolidin-1-yl)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 597 310

N-((3R,4S)-4-((5-(3-azabicyclo[3.1.0] hexan-3-yl)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 570 311

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(2-oxa-7-azaspiro[4.4] nonan-7-yl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 614 312

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-morpholino-2,6-naphthyridin- 3-yl)amino)tetrahydrofuran-3- yl)acrylamide 574 313

N-((3R,4S)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-5-morpholino-2,6- naphthyridin-3-yl)amino)tetrahydrofuran-3- yl)acrylamide 542 314

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(2-methylmorpholino)- 2,6-naphthyridin-3-yl)amino)tetrahydro- furan-3-yl)acrylamide 588 315

N-((3R,4S)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-5-(2-methylmorpholino)- 2,6-naphthyridin-3-yl)amino)tetrahydro- furan-3-yl)acrylamide 556 316

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(2,6-dimethylmorpholino)- 2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 602 317

N-((3R,4S)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-5-(2,6-dimethylmorpholino)- 2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 570 318

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(4-hydroxypiperidin-1- yl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 588 319

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(4-dimethoxypiperidin-1- yl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 602 320

N-((3R,4S)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-5-(4-dimethoxypiperidin-1- yl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 570 321

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3-methoxypiperidin-1- yl)-2,6-naphthyridin-3-yl)amino)tetra- hydrofuran-3-yl)acrylamide 602 322

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(4-hydroxy-4-methyl- piperidin-1-yl)-2,6-naphthyridin-3-yl) amino)tetrahydrofuran-3-yl)acrylamide 602 323

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(4-methoxy-4-methyl- piperidin-1-yl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 616 324

N-((3R,4S)-4-((7-(2,6-difluoro-3,5- dimethoxyphenyl)-5-(4-methoxy-4-methyl- piperidin-1-yl)-2,6-naphthyridin-3-yl) amino)tetrahydrofuran-3-yl)acrylamide 584 325

N-((3R,4S)-4-((5-(4-cyano-4-methyl- piperidin-1-yl)-7-(2,6-dichloro-3,5-dimethoxy- phenyl)-2,6-naphthyridin-3-yl)amino) tetrahydrofuran-3-yl)acrylamide 611 326

N-(7-(((3S,4R)-4-acrylamidotetrahydro- furan-3-yl)amino)-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-1-yl) cyclopropanecarboxamide 572 327

N-(7-(((3S,4R)-4-acrylamidotetrahydro- furan-3-yl)-3-(2,6-dichloro-3,5- dimethoxyphenyl)-2,6-naphthyridin-1-yl) tetrahydrofuran-2-carboxamide 602 328

N-((3R,4S)-4-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(methylsulfonamido)- 2,6-naphthyridin-3-yl)amino)tetrahydro- furan-3-yl)acrylamide 582 329

N-((3S,4S)-3-((5-(cyclopropylamino)-7- (2,6-dichloro-3,5-dimethoxyphenyl)-2, 6-naphthyridin-3-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 558 330

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3-methoxyazetidin-1- yl)-2,6-naphthyridin-3-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 588 331

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3,3-difluoroazetidin- 1-yl)-2,6-naphthyridin-3-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 594 332

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3-dimethoxy-3-methyl- azetidin-1-yl)-2,6-naphthyridin-3-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 602 333

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(2-oxa-6-azaspiro[3.3] heptan-6-yl)-2,6-naphthyridin-3-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 600 334

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(6-oxa-2-azaspiro[3.4] octan-2-yl)-2,6-naphthyridin-3-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 614 335

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(7-oxa-2-azaspiro[3.5] nonan-2-yl)-2,6-naphthyridin-3-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 628 336

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3-dimethoxypyrrolidin- 1-yl)-2,6-naphthyridin-3-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 602 337

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(3-dimethoxy-3-methyl- pyrrolidin-1-yl)-2,6-naphthyridin-3-yl) amino)tetrahydro-2H-pyran-4-yl)acrylamide 616 338

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(2,6-dimethylmorpholino)- 2,6-naphthyridin-3-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 616 339

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(4-hydroxy-4-methylpiperidin- 1-yl)-2,6-naphthyridin-3-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 616 340

N-((3S,4S)-3-((7-(2,6-dichloro-3,5- dimethoxyphenyl)-5-(4-dimethoxy-4-methyl- piperidin-1-yl)-2,6-naphthyridin-3-yl)ami- no)tetrahydro-2H-pyran-4-yl)acrylamide 630 341

N-((3R,4S)-4-((4-((cyclopropylmethyl) amino)-2-(2,6-dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-6-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 559 342

N-((3R,4S)-4-((4-((cyclopropylmethyl) amino)-2-(2,6-difluoro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-6-yl)ami- no) tetrahydrofuran-3-yl)acrylamide 527 343

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-((2-dimethoxyethyl)ami- no)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 563 344

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-((tetrahydrofuran-3-yl) amino)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 575 345

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-((tetrahydroturan-2-yl) methyl)amino)pyrido[3,4-d]pyrimidin- 6-yl)amino)tetrahydrofuran-3-yl)acrylamide 589 346

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-((tetrahydro-2H-pyran-4- yl)amino)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 589 347

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3,3-difluorocyclopentyl) amino)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 609 348

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(neopentylamino) pyrido[3,4-d]pyrimidin-6-yl)amino)tetra- hydrofuran-3-yl)acrylamide 575 349

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(((1-methyl-1H-pyrazol- 4-yl)methyl)amino)pyrido[3,4-d] pyrimidin-6-yl)amino)tetrahydrofuran-3-yl) acrylamide 599 350

N-((3R,4S)-4-((4-(((S)-1-cyclopropyl- ethyl)amino)-2-(2,6-dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 573 351

N-((3R,4S)-4-((4-(((S)-1-cyclopropyl- ethyl)amino)-2-(2,6-difluoro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 541 352

N-((3R,4S)-4-((4-(cyclopropylamino)-2- (2,6-dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidin-6-yl)amino)tetra- hydrofuran-3-yl)acrylamide 545 353

N-((3R,4S)-4-((4-(cyclopropylamino)-2- (2,6-difluoro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidin-6-yl)amino)tetra- hydrofuran-3-yl)acrylamide 513 354

N-((3R,4S)-4-((4-(azetidin-1-yl)-2-(2,6- dichloro-3,5-dimethoxyphenyl)pyrido[3,4- d]pyrimidin-6-yl)amino)tetrahydrofuran- 3-yl)acrylamide 545 355

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3-dimethoxyazetidin-1- yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 575 356

N-((3R,4S)-4-((2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(3-dimethoxyazetidin-1- yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 543 357

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3-(dimethylamino)azetidin- 1-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 588 358

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3-(trifluoromethyl) azetidin-1-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 613 359

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3,3-dimethylazetidin- 1-yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 573 360

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3,3-difluoroazetidin- 1-yl)pyrido[3,4-d]pyritnidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 581 361

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3-hydroxy-3-methyl- azetidin-1-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 575 362

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3-methoxy-3-methyl- azetidin-1-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 589 363

N-((3R,4S)-4-((2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(3-dimethoxy-3-methyl- azetidin-1-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 557 364

N-((3R,4S)-(4-((4-(3-cyano-3-methyl- azetidin-1-yl)-2-(2,6-dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 584 365

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(2-oxa-6-azaspiro[3.3] heptan-6-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 587 366

N-((3R,4S)-4-((2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(2-oxa-6-azaspiro[3.3] heptan-6-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 555 367

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(1-oxa-6-azaspiro[3.3] heptan-6-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 587 368

N-((3R,4S)-4-((2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(1-oxa-6-azaspiro[3.3] heptan-6-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 555 369

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(2-azaspiro[3.3]heptan- 2-yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 585 370

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(2-azaspiro[3.4]octan- 2-yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 599 371

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(6-oxa-2-azaspiro[3.4] octan-2-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 601 372

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(7-oxa-2-azaspiro[3.5] nonan-2-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 615 373

N-(3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(pyrrolidin-1-yl)pyrido [3,4-d]pyrimidin-6-yl)amino)tetrahydro- furan-3-yl)acrylamide 559 374

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3-methoxypyrrolidin- 1-yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 589 375

N-((3R,4S)-4-((2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(3-methoxypyrrolidin- 1-yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 557 376

N-((3R,4S)-4-((4-(3-cyanopyrrolidin-1- yl)-2-(2,6-dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 584 377

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3,3-difluoropyrrolidin- 1-yl)pyrido[3,4-d]pyrimidin-6-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 595 378

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3-dimethoxy-3-methyl- pyrrolidin-1-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 603 379

N-((3R,4S)-4-((2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(3-methoxy-3-methyl- pyrrolidin-1-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 571 380

N-((3R,4S)-4-((4-(3-cyano-3-methyl- pyrrolidin-1-yl)-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 598 381

N-((3R,4S)-4-((4-(3-azabicyclo[3.1.0] hexan-3-yl)-2-(2,6-dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-6-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 571 382

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(2-oxa-7-azaspiro[4.4] nonan-7-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 615 383

N-(3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-morpholinopyrido[3,4- d]pyrimidin-6-yl)amino)tetrahydrofuran- 3-yl)acrylamide 573 384

N-((3R,4S)-4-((2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-morpholinopyrido[3,4- d]pyrimidin-6-yl)amino)tetrahydrofuran- 3-yl)acrylamide 543 385

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(2-methylmorpholino) pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 589 386

N-((3R,4S)-4-((2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(2-methylmorpholino) pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 557 387

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(2,6-dimethylmorpholino) pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 603 388

N-((3R,4S)-4-((2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(2,6-dimethylmorpholino) pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 571 389

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(4-hydroxypiperidin- yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 589 390

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(4-methoxypiperidin-1- yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 603 391

N-((3R,4S)-4-((2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(4-methoxypiperidin-1- yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 571 392

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3-dimethoxypiperidin-1- yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydrofuran-3-yl)acrylamide 603 393

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(4-hydroxy-4-methyl- piperidin-1-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 603 394

N-(3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(4-dimethoxy-4-methyl- piperidin-1-yl)pyrido[3,4-d]pyrimidin-6-yl amino)tetrahydrofuran-3-yl)acrylamide 617 395

N-((3R,4S)-4-((2-(2,6-difluoro-3,5- dimethoxyphenyl)-4-(4-dimethoxy-4-methyl- piperidin-1-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 585 396

N-((3R,4S)-4-((4-(4-cyano-4-methyl- piperidin-1-yl)-2-(2,6-dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydrofuran-3-yl)acrylamide 612 397

N-(6-(((3S,4R)-4-acrylamidotetrahydro- furan-3-yl)amino)-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4-d]pyrimidin- 4-yl)cyclopropanecarboxamide 573 398

N-(6-(((3S,4R)-4-acrylamidotetrahydro- furan-3-yl)amino)-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4-d]pyrimidin- 4-yl)tetrahydrofuran-2-carboxamide 603 399

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(methylsulfonamido) pyrido[3,4-d]pyrimidin-6-yl)amino)tetra- hydrofuran-3-yl)acrylamide 583 400

N-((3S,4S)-3-((4-((cyclopropylmethyl) amino)-2-(2,6-dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 573 401

N-((3S,4S)-3-((4-((cyclopropylmethyl) amino)-2-(2,6-difluoro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 541 402

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-((2-methoxyethyl)amino) pyrido[3,4-d]pyrimidin-6-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 577 403

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-((tetrahydrofuran-3-yl) amino)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 589 404

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl))-4-(((tetrahydrofuran-2-yl) methyl)amino)pyrido[3,4-d]pyrimidin- 6-yl)amino)tetrahydro-2H-pyran-4-yl) acrylamide 603 405

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-((tetrahydro-2H-pyran- 4-yl)amino)pyrido[3,4-d]pyrimidin-6- yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide 603 406

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-((3,3-difluorocyclopentyl) amino)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydro-2H-pyran-4-yl)acrylamide 623 407

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(neopentylamino) pyrido[3,4-d]pyrimidin-6-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 589 408

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(((1-methyl-1H-pyrazol- 4-yl)methyl)amino)pyrido[3,4-d]pyrimidin- 6-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 613 409

N-((3S,4S)-3-((4-(cyclopropylamino)-2- (2,6-dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidin-6-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 559 410

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3,3-difluoroazetidin- 1-yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 589 411

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3,3-difluoroazetidin- 1-yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 595 412

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3-dimethoxy-3-methyl- azetidin-1-yl)pyrido[3,4-d]pyrimidin-6-yl- amino)tetrahydro-2H-pyran-4-yl)acrylamide 603 413

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(2-oxa-6-azaspiro[3.3] heptan-6-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydro-2H-pyran-4-yl)acrylamide 601 414

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(6-oxa-2-azaspiro[3.4] octan-2-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)tetrahydro-2H-pyran-4-yl)acrylamide 615 415

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(7-oxa-2-azaspiro[3.5] nonan-2-yl)pyrido[3,4-d]pyrimidin-6-yl) amino)letrahydro-2H-pyran-4-yl)acrylamide 629 416

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3-dimethoxypyrrolidin- 1-yl)pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 603 417

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(3-methoxy-3-methyl- pyrrolidin-1-yl)pyrido[3,4-d]pyrimidin-6- yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide 617 418

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(2,6-dimethylmorpholino) pyrido[3,4-d]pyrimidin-6-yl)amino) tetrahydro-2H-pyran-4-yl)acrylamide 617 419

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(4-hydroxy-4-methyl- piperidin-1-yl)pyrido[3,4-d]pyrimidin-6- yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide 617 420

N-((3S,4S)-3-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(4-dimethoxy-4-methyl piperidin-1-yl)pyrido[3,4-d]pyrimidin-6- yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide 631 752

N-((3R,4S)-4-((2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-(methylamino)pyrido [3,4-d]pyrimidin-6-yl)amino)tetrahydro- furan-3-yl)acrylamide 519

Example 421 Preparation of N-4(8-4-((8-((cyclopropylmethyl)amino)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide

Step 1: preparation of N-(cyclopropylmethyl)-62,6-dichloro-35-dimethoxyphenyl)-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine-8-amine

N-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]p yrimidine-8-amine (210 mg, 0.465 mmol) was dissolved in dichloromethane (6 mL), then m-chloroperoxybenzoic acid (200 mg, 1.163 mmol) was added, and the mixture was stirred at room temperature for 18 h. After the reaction was completed, a saturated sodium sulfite solution was added, and then the mixture was stirred for 5 min and extracted with dichloromethane, the organic phase was washed with a saturated sodium bicarbonate and then saturated brine, dried over anhydrous sodium sulfate, filtrated, concentrated, and separated by column chromatography (Eluent: PE/EA=2/1) to obtain compound N-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine-8-amine (186 mg, yield: 82.7%).

MS m/z (ESI): 483.4 [M+H]⁺.

Step 2: Preparation of (±)—N²-((3S,4R)-4-aminotetrahydrofuran-3-yl)-N⁸-(cyclopropyl methyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-2,8-diamine

N-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine-8-amine (190 mg, 0.393 mmol) and (3R,4S)-tetrahydrofuran-3,4-diamine dihydrochloride (206 mg, 1.179 mmol) were dissolved in acetonitrile (6 mL), then N,N-diisopropylethylamine (507 mg, 3.93 mmol) was added, and the mixture was heated to reflux, an d stirred for 20 h. The reaction was completed, and the mixture was cooled to room temperature. The reaction liquid was diluted with EtOAc (20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, filtrated, concentrated, and separated by TLC (dev eloping agent: CH₂Cl₂/MeOH 10/1) to obtain compound (±)—N²-((3S,4R)-4-aminotetrahydrofuran-3-yl)-N⁸-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-2,8-diamine (120 mg, yield: 60%).

MS m/z (ESI): 505.4 [M+H]⁺.

Step 3: Preparation of (±)—N-((3R,4S)-4-((8-((cyclopropylmethyl)amino)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide

At 0° C., acryloyl chloride (22.6 mg, 0.249 mmol) was added to the solution of (±)—N²-((3S,4R)-4-aminotetrahydrofuran-3-yl)-N^(R)-(cyclopropylmethyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-2,8-diamine (120 mg, 0.237 mmol) and sodium bicarbonate (79.6 mg, 0.948 mmol) in the mixture of tetrahydrofuran (6.4 mL) and water (1.6 mL). After addition, the mixture was stirred at 0° C. for 5 min. The reaction liquid was diluted with EtOAc (10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, filtrated, concentrated and separated by TLC (Eluent: CH₂Cl₂/MeOH=20/1) to obtain compound (+)—N-((3R,4S)-4-((8-((cyclopropylmethyl)amino)-6-(2,6-dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide (93 mg, yield: 70%).

¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 6.80 (brs, 1H), 6.68 (s, 1H), 6.62 (s, 1H), 6.38 (brs, 1H), 6.21 (dd, J=17.0, 1.5 Hz, 1H), 6.02 (dd, J=17.0, 10.2 Hz, 1H), 5.56 (dd, J=10.1, 1.5 Hz, 1H), 4.93-4.83 (m, 2H), 4.30-4.18 (m, 2H), 3.96 (s, 6H), 3.90 (dd, J=9.7, 3.2 Hz, 1H), 3.79 (dd, J=9.2, 5.2 Hz, 1H), 3.52-3.37 (m, 2H), 0.88 (t, J=6.0 Hz, 1H), 0.57-0.48 (m, 2H), 0.36-0.26 (m, 2H). MS m/z (ESI): 559.5 [M+H]⁺.

Step 4: Preparation of N-((3R,4S)-4-((8-((cyclopropylmethyl)amino)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide

(±)—N-((3R,4S)-4-((8-((cyclopropylmethyl)amino)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide (93 mg, 0.166 mmol) was separated by chiral HPLC to obtain N-((3R,4S)-4-((8-((cyclopropylmethyl)amino)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide(43.5 mg, ee value>98%, yield: 46.8%) and N-((3S,4R)-4-((8-((cyclopropylmethyl)amino)-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide (39 mg, ee value>98%, yield: 41.9%).

Example 433 Preparation of N-((3R,4S)-4-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-(methylamino)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide

Step 1: Preparation of 8-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine

The compound was prepared referring to the synthesis method of step 1 of Example 421.

Step 2: Preparation of Tert-Butyl ((3R,4S)-4-((S-chloro-6-(2,6-dichloro-3,5-dimethoxy phenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)carbamate

8-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine (409 mg, 0.912 mmol) and tert-butyl ((3R,4S)-4-aminotetrahydrofuran-3-yl)carbamate (553 mg, 2.736 mmol) were dissolved in acetonitrile (50 mL), then trifluoroacetic acid (31 mg, 0.274 mmol) was added. The reaction liquid was stirred at 95° C. for 4 h. After being cooled, the mixture was diluted with ethyl acetate (50 mL), washed with a saturated sodium bicarbonate solution and saturated brine, dried over anhydrous sodium sulfate, concentrated and separated by column chromatography (CH₂Cl₂/MeOH 0-4%) to obtain compound tert-butyl ((3R,4S)-4-((8-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)carbamate (414 mg, yield: 79.6%). MS m/z (ESI): 570.4, 57 2.4 [M+H]+.

Step 3: Preparation of Tert-Butyl ((3R,4S)-4-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-(methylamino)pyrido[3,4-d]pyrimidin-2-yl)amino) tetrahydrofuran-3-yl)carbamate

A solution of tert-butyl((3R,4S)-4-((8-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)carbamate (60 mg, 0.105 mmol) and meth ylamine (1.5 mL, 33% ethanol solution) in N-methylpyrrolidone (1 mL) was heated to 11 0° C. and stirred for 18 h. The reaction liquid was diluted with ethyl acetate (5 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and separated by using a preparative TLC (PE/EA=1:1) to obtain compound tert-butyl ((3R,4S)-4-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-(methylamino)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)carbamate (32 mg, yield: 54%). MS m/z (ESI): 565.4, 567.4 [M+H]+.

Step 4: Preparation of N²-((3S,4R)-4-aminotetrahydrofuran-3-yl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-N⁸-methylpyrido[3,4-d]pyrimidine-2,8-diamine Trifluoroacetate

A solution of tert-buty ((3R,4S)-4-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-(methylamino)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)carbamate (32 mg, 0.057 mmol) in the solution of trifluoroacetic acid in dichloromethane (2 mL, 20%) was stirred at room temperature for 1 h, and then concentrated to obtain an oil product which was directly use d in the next step. MS m/z (ESI): 465.4, 467.4 [M+H]⁺.

Step 5: Preparation of N-((3R,4S)-4-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-(methylamino)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide

At 0° C., acryloyl chloride (5.7 mg, 0.063 mmol) was added to a solution of N²-((3S,4R)-4-aminotetrahydrofuran-3-yl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-N-methylpyrido[3,4-d]pyrimidine-2,8-diamine trifluoroacetate (the crude product) and NaHCO₃ (57 mg, 0.684 mmol) in the mixture of tetrahydrofuran (3.2 mL) and water (0.8 mL). After addition, the mixture was stirred at 0° C. for 5 min. The reaction liquid was diluted with EtOAc (mL), washed with a saturated sodium bicarbonate and saturated brine, dried over anhydrous sodium sulfate, concentrated and separated by using a preparative TLC (CH₂Cl₂/MeOH 20:1) to obtain compound N-((3R,4S)-4-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-(methylamino)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide (17.6 mg, yield: 59.5%).

¹H NMR (400 MHz, CDCl₃) δ 8.88 (s, 1H), 6.67 (s, 1H), 6.62 (s, 1H), 6.30 (brs, 1H), 6.19 (d, J=16.9 Hz, 1H), 5.97 (dd, J=17.0, 10.3 Hz, 1H), 5.88 (brs, 1H), 5.54 (d, J=10.4 Hz, 1H), 4.95-4.83 (m, 2H), 4.29-4.18 (m, 2H), 3.95 (s, 6H), 3.89 (dd, J=9.7, 3.0 Hz, 1H), 3.77 (dd, J=9.3, 5.5 Hz, 1H), 3.14 (d, J=4.4 Hz, 3H). MS m/z (ESI): 519.4, 521.4 [M+H]⁺.

Example 775 N-((3S,4S)-3-((6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxyazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide

Step 1: Preparation of 8-chloro-6-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine

8-chloro-6-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylthio)pyrido[3,4-d]pyrimidine (930 mg, 2.42 mmol) was dissolved in DCM (50 mL), and m-CPBA (1.23 g, 6.05 mmol) was added, and the mixture was stirred at room temperature for 2 h. The reaction was completed, and sodium thiosulfate was added to quench the reaction. The mixture was extracted with DCM and separated by silica gel column chromatography to obtain compound 8-chloro-6-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine (800 mg, yield:79%). MS m/z (ESI): 416 [M+H]+.

Step 2: Preparation of N-((3S,4S)-4-azidotetrahydro-2H-pyran-3-yl)-8-chloro-6-(2,6-difluoro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-2-amine

8-chloro-6-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine (1 g, 2.41 mmol) was dissolved in the mixture of tert-butyl alcohol (80 mL) and DCE (20 mL), then DIPEA (1.55 g, 12.05 mmol) was added, the mixture was heated to 90° C. and stirred overnight. The mixture was extracted with DCM and separated by silica gel column chromatography to obtain compound N-((3S,4S)-4-azidotetrahydro-2H-pyran-3-yl)-8-chloro-6-(2,6-difluoro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine-2-amine (650 mg, yield:56%). MS m/z (ESI): 478 [M+H]+.

Step 3: Preparation of N-((3S,4S)-4-azidotetrahydro-2H-pyran-3-yl)-6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxyazetidin-1-yl)pyrido[3,4-d]pyrimidine-2-amine

N-((3S,4S)-4-azidotetrahydro-2H-pyran-3-yl)-8-chloro-6-(2,6-difluoro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidine-2-amine (325 mg, 0.68 mmol), 3-methoxyazetidine hydrochloride (25 2 mg, 2.04 mmol) and DIPEA (439 mg, 3.4 mmol) were dissolved in n-butanol (15 mL), the mixture was heated to 100° C. for 4 h, and then the mixture was concentrated, extracted with ethyl acetate and separated by silica gel column chromatography to obtain compound N-((3S,4S)-4-azidotetrahydro-2H-pyran-3-yl)-6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxyazetidin-1-yl)pyrido[3,4-d]pyrimidine-2-amine (350 mg, yield: 97%). MS m/z (ESI): 529 [M+H]+.

Step 4: Preparation of (3S,4S)—N³-(6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxyazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)tetrahydro-2H-pyran-3,4-diamine

N-((3S,4S)-4-azidotetrahydro-2H-pyran-3-yl)-6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxyazetidin-1-yl)pyrido[3,4-d]pyrimidine-2-amine (350 mg, 0.662 mmol) was dissolved in the mixture of THF (10 mL) and water (1 mL), and then triphenylphosphine (521 mg, 1.99 mmol) was added, the mixture was heated to 80° C. and stirred for 16 h. The mixture was cooled, directly dried over anhydrous sodium sulfate, concentrated, and separated by silica gel column chromatography to obtain compound (3S,4S)—N³-(6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxyazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)tetrahydro-2H-pyran-3,4-di amine (290 mg, yield:87%). MS m/z (ESI), 503 [M+H]+.

Step 5: Preparation of N-((3S,4S)-3-((6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxyazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide

(3S,4S)—N³-(6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxyazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)tetrahydro-2H-pyran-3,4-diamine (290 mg, 0.58 mmol) was dissolved in the mixture of THF (20 mL) and water (5 mL), then NaHCO₃ (243 mg, 2.89 mmol) was added, and acryloyl chloride solution (63 mg, 0.69 mmol, dissolved in 1 mL THF) was added dropwise at room temperature, the mixture was stirred at room temperature for 10 min. The reaction was completed determined by TLC, a saturated aqueous solution of NaHCO₃ was added to quench the reaction, the mixture was extracted with ethyl acetate, concentrated and separated by silica gel column chromatography to obtain compound N-((3S,4S)-3-((6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxyazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide (204 mg, yield:63%). MS m/z (ESI): 557 [M+H]+.

1H NMR (400 MHz, CDCl₃) δ 8.92 (s, 1H), 6.96 (s, 1H), 6.69 (t, J=8.0 Hz, H), 6.65 (s, 1H), 6.25 (dd. J=17.0, 1.4 Hz, 1H), 6.08 (s, 1H), 6.02 (dd. J=16.9, 10.3 Hz, 1H), 5.60 (dd, J=10.3, 1.4 Hz, 1H), 4.73 (brs, 1H), 4.56 (brs, 1H), 4.42 (d, J=8.5 Hz, 1H), 4.39-4.22 (m, 4H), 4.05 (dd. J=12.0, 4.5 Hz, 1H), 3.99 (d, J=11.7 Hz, 1H), 3.92 (s, 6H), 3.75 (dd, J=11.9, 1.6 Hz, 1H), 3.65-3.57 (m, 1H), 3.33 (s, 3H), 2.09-2.02 (m, 1H), 1.91-1.81 (m, 1H).

Examples 422-714 and 753-806 were prepared referring to the synthesis method of Example 33, 421 or 775.

Example MS: m/z No. Compound structure Compound name [M + 1]⁺ 422

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-methoxyethyl) amino)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acrylamide 563 423

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-methoxypyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 520 424

N-((3R,4S)-4-((8-((cyclopropylmeth- yl)amino)-6-(2,6-difluoro-3,5-dimeth- oxyphenyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl)acryl- amide 527 425

N-((3R,4S)-4-((8-((cyclopropylmeth- yl)amino)-6-(2,6-dichloro-3,5-bis(meth- oxy-d₃)phenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 565 426

N-((3R,4S)-4-((8-((cyclopropylmeth- yl)amino)-6-(2,6-difluoro-3,5-bis(meth- oxy-d₃)phenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 533 427

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-hydroxyethyl)a- mino)pyrido[3,4-d]pyrimidin-2-yl) amino)tetrahydrofuran-3-yl)acryl- amide 549 428

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-(isopropylthio)eth- yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl) acrylamide 607 429

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-(ethylsulfonyl) ethyl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl)acryl- amide 625 430

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((2-(methyl- sulfonamido)ethyl)a- mino)pyrido[3,4-d]pyri- midin-2-yl)amino)tetrahydrofuran- 3-yl)acrylamide 626 431

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-(dimethylami- no)ethyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 576 432

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((3-(dimethylami- no)propyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 590 434

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(ethylamino)pyri- do[3,4-d]pyrimidin-2-yl0amino)tetra- hydrofuran-3-yl)acrylamide 533 435

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2,2,2-trifluoroeth- yl)amino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 587 436

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(dimethylamino) pyrido[3,4-d]pyrimidin-2-yl)amino) tetrahydrofuran-3-yl)acrylamide 533 437

N-((3R,4S)-4-((8-((cyclopropylmeth- yl)(methyl)amino)-6-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4-d]pyrim- idin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 573 438A

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((((R)-tetrahydro- furan-2-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 589 438B

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((((S)-tetrahydro- furan-2-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 589 439

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((tetrahydrofuran- 3-yl)methyl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran- 3-yl)acrylamide 589 440

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((oxetan-3-ylmeth- yl)amino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 575 441

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((tetrahydro-2H- pyran-4-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 603 442

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(oxetan-3-yl- amino)pyrido[3,4-d]pyrimidin-2-yl) amino)tetrahydrofuran-3-yl)acrylamide 561 443

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((tetrahydrofuran- 3-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl) acrylamide 575 444

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((tetrahydro-2H- pyran-4-yl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 589 445

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-methyl- pyrrolidin-3-yl)meth- yl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 602 446

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-methyl- pyrrolidin-2-yl)methyl)a- mino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro- furan-3-yl)acrylamide 602 447

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((1-methyl- pyrrolidin-3-yl)a- mino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 588 448

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-methylazeti- din-3-yl)methyl)amino)pyrido[3,4-d] pyrimidin-2-yl)amino)tetrahydrofuran- 3-yl)acrylamide 588 449

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((1-methylazetidin- 3-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3- yl)acrylamide 574 450

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((1-methylpiperi- din-4-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 602 451

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-methylpiper- idin-4-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydrofuran- 3-yl)acrylamide 616 452

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((3,3-difluorocyclo- butyl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl) acrylamide 595 453

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((3,3-difluorocyclo- pentyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 609 454

N-((3R,4S)-4-((8-((cyclopentylmeth- yl)amino)-6-(2,6-dichloro-3,5-dimeth- oxyphenyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl)acryl- amide 587 455

N-((3R,4S)-4-((8-(benzylamino)-6- (2,6-dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidn-2-yl)amino) tetrahydrofuran-3-yl)acrylamide 595 456

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(phenethylamino) pyrido[3,4-d]pyrimidin-2-yl)amino) tetrahydrofuran-3-yl)acrylamide 609 457

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(phenylamino)pyri- do[3,4-d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 581 458

N-((3R,4S)-4-((8-((3-aminobenzyl)a- mino)-6-(2,6-dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acrylamide 610 459

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-methyl-1H- pyrazol-4-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 599 460

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-(2-hydroxy- ethyl)-1H-pyrazol-4-yl)methyl)amino) pyrido[3,4-d]pyrimidin-2-yl)amino) tetrahydrofuran-3-yl)acrylamide 629 461

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-(2-methoxy- ethyl)-1H-pyrazol-4-yl)methyl)amino) pyrido[3,4-d]pyrimidin-2-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 643 462

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(neopentylamino) pyrido[3,4-d]pyrimidin-2-yl)amino) tetrahydrofuran-3-yl)acrylamide 575 463

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((3-(isopropyl- amino)propyl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 604 464

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((4-(isopropyl- amino)butyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 618 465

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((4-(dimethylamino) butyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 604 466

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((4-(pyrrolidin-1- yl)butyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 630 467

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-(4-methyl- piperazin-1-yl)ethyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 631 468

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-morpholinoeth- yl)amino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 618 469

N-((3R,4S)-4-((8-((2-(3-amino- pyrrolidin-1-yl)ethyl)amino)-6-(2,6- dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran- 3-yl)acrylamide 617 470

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-(3-(dimethyl- amino)pyrrolidin-1-yl)ethyl)amino) pyrido[3,4-d]pyrimidin-2-yl)amino) tetrahydrofuran-3-yl)acrylamide 645 471

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-(2-(dimethyl- amino)ethoxy)ethyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 620 472

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((4-(2-(hydroxy- methyl)pyrrolidin-1-yl)butyl)amino) pyrido[3,4-d]pyrimidni-2-yl)amino) tetrahydrofuran-3-yl)acrylamide 660 473

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((4-(3,3-difluoro- pyrrolidin-1-yl)butyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 666 474

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((4-(3-methoxy- pyrrolidin-1-yl)butyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 660 475

N-((3R,4S)-4-((6-(2-chloro-3,5-dimeth- oxyphenyl)-8-((cyclopropylmethyl)a- mino)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acrylamide 525 476

N-((3R,4S)-4-((8-((cyclopropylmeth- yl)amino)-6-(2-fluoro-3-methoxyphen- yl)pyrido[3,4-d]pyrimidin-2-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 479 477

N-((3R,4S)-4-((6-(2-chloro-3-(meth- oxy-d₃)phenyl)-8-((cyclopropylmeth- yl)amino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 498 478

N-((3R,4S)-4-((8-((cyclopropylmeth- yl)amino)-6-(2-fluoro-3-(methoxy-d3) phenyl)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acrylamide 482 479

N-((3R,4S)-4-((6-(2-chloro-3,5-bis (methoxy-d₃)phenyl)-8-((cylcopropyl- methyl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl) acrylamide 531 480

N-((3R,4S)-4-((8-((cyclopropylmeth- yl)amino)-6-(2-fluoro-3,5-bis(meth- oxy-d₃)phenyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl)acryl- amide 515 481

N-((3R,4S)-4-((6-(2-chloro-3-meth- oxyphenyl)-8-(((tetrahydrofuran-2-yl) methyl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl)acryl- amide 525 482

N-((3R,4S)-4-((6-(2-chloro-3-meth- oxyphenyl)-8-(((1-methylpyrrolidin-2- yl)methyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 538 483

N-((3R,4S)-4-((6-(2-fluoro-3-meth- oxyphenyl)-8-(((1-methylpyrrolidin-2- yl)methyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 522 484

N-((3R,4S)-4-((6-(2-chloro-3,5-dimeth- oxyphenyl)-8-(((1-methylpyrrolidin- 2-yl)methyl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran- 3-yl)acrylamide 568 485

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-(((1-methylpyrrol- idin-2-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 570 486

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-((tetrahydro-2H- pyran-4-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 557 487

N-((3R,4S)-4-((6-(2-chloro-3,5-dimeth- oxyphenyl)-8-((tetrahydro-2H-py- ran-4-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl)acryl- amide 555 488

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-((2-(4-methylpiper- azin-1-yl)ethyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 599 489

N-((3R,4S)-4-((6-(2-chloro-3-meth- oxyphenyl)-8-((2-(4-methylpiperazin- 1-yl)ethyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 567 490

N-((3R,4S)-4-((6-(2-chloro-3,5-dimeth- oxyphenyl)-8-((2-(4-methylpiperazin- 1-yl)ethyl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran- 3-yl)acrylamide 597 491

N-((3R,4S)-4-((6-(3,5-dimethoxyphen- yl)-8-((2-(4-methylpiperazin-1-yl)eth- yl)amino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 563 492

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-((2-methoxyethyl) amino)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acrylamide 531 493

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-((1-methylpiperi- din-4-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 570 494

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-(((1-methyl-1H- pyrazol-4-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 567 495

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-(((tetrahydrofuran- 2-yl)methyl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran- 3-yl)acrylamide 557 496

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-ethoxypyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 534 497

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-isopropoxy- pyrido[3,4-d]pyrimidin-2- yl)amino)tetra-hydrofuran-3-yl)acryl- amide 548 498

N-((3R,4S)-4-((8-(cyclopropylmethoxy)- 6-(2,6-dichloro-3,5-dimethoxyphen- nyl)pyrido[3,4-d]pyrimidin-2-yl)amino) tetrahydrofuran-3-yl)acrylamide 560 499

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-methoxyeth- yl)amino)pyrido[3,4-d]pyrimidin-2-yl) amino)tetrahydro-2H-pyran-4-yl) acrylamide 577 500

N-((3S,4S)-3-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-((2-methoxyeth- yl)amino)pyrido[3,4-d]pyrimidin-2-yl) amino)tetrahydro-2H-pyran-4-yl)acryl- amide 545 501

N-((3S,4S)-3-((8-((cyclopropylmeth- yl)amino)-6-(2,6-dichloro-3,5-dimeth- oxyphenyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 573 502

N-((3S,4S)-3-((8-((cyclopropylmeth- yl)amino)-6-(2,6-difluoro-3,5-dimeth- oxyphenyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 541 503

N-((3S,4S)-3-((8-((cyclopropylmeth- yl)amino)-6-(2,6-dichloro-3,5-bis(meth- oxy-d₃)phenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 579 504

N-((3S,4S)-3-((8-((cyclopropylmeth- yl)amino)-6-(2,6-difluoro-3,5-bis(meth- oxy-d₃)phenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 547 505

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-hydroxyethyl) amino)pyrido[3,4-d]pyrimidin-2-yl) amino)tetrahydro-2H-pyran-4-yl)acryl- amide 563 506

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-(isopropylthi- o)ethyl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 621 507

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-(ethylsulfonyl)eth- yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 639 508

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-(dimethylami- no)ethyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 590 509

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((3-(dimethylami- no)propyl)amino)pyrido[3,4-d]pyrim- idin-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 604 510

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(methylamino)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 549 511

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(ethylamino)pyri- do[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 547 512

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2,2,2-trifluoroeth- yl)amino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 601 513

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(dimethylamino) pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 547 514

N-((3S,4S)-3-((8-((cyclopropylmeth- yl)(methyl)amino)-6-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-py- ran-4-yl)acrylamide 587 515

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-(methyl- sulfonamido)ethyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 640 516

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((tetrahydrofuran- 2-yl)methyl)amino)pyrido[3,4-d]py- rimidn-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 603 517

N-((3S,4S)-3-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-(((tetrahydrofuran- 2-yl)methyl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 571 518

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((tetrahydrofuran- 3-yl)methyl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 603 519

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((oxetan-3-ylmeth- yl)amino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 589 520

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((tetrahydro-2H- pyran-4-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 617 521

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(oxetan-3-ylami- no)pyrido[3,4-d]pyrimidin-2-yl)ami- no)tetrahydro-2H-pyran-4-yl)acryl- amide 575 522

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphennyl)-8-((tetrahydrofuran- 3-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 589 523

N-((3S,4S)-3-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-((tetrahydrofuran- 3-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 557 524

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((tetrahydro-2H- pyran-4-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 603 525

N-((3S,4S)-3-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-((tetrahydro-2H- pyran-4-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 571 526

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-methylpyrroli- din-3-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 616 527

N-((3S,4S)-3-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-(((1-methylpyrroli- din-3-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 584 528

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-methylpyrroli- din-2-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 616 529

N-((3S,4S)-3-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-(((1-methylpyrroli- din-2-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 584 530

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((1-methylpyrroli- din-3-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 602 531

N-((3S,4S)-3-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-((1-methylpyrroli- din-3-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 570 532

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-methylazeti- din-3-yl)methyl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 602 533

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((1-methylazeti- din-3-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 588 534

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((1-methylpiperi- din-4-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 616 535

N-((3S,4S)-3-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-((1-methylpiperi- din-4-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 584 536

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-methylpiperi- din-4-yl)methyl)amino)pyrido[3,4-d] pyrimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 630 537

N-((3S,4S)-3-(((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((3,3-difluorocyclo- butyl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 609 538

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((3,3-difluorocyclo- pentyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 623 539

N-((3S,4S)-3-((8-((cyclopentylmeth- yl)amino)-6-(2,6-dichloro-3,5-dimeth- oxyphenyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 601 540

N-((3S,4S)-3-((8-(benzylamino)-6- (2,6-dichloro-3,5-dimethoxyphenyl)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 609 541

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(phenethylamino)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 623 542

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(phenylamino)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 595 543

N-((3S,4S)-3-((8-((3-aminobenzyl)a- mino)-6-(2,6-dichloro-3,5-dimethoxy- phenyl))pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydro-2H-pyran-4-yl)acryl- amide 624 544

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-methyl-1H- pyrazol-4-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 613 545

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(((1-methyl-1H- pyrazol-4-yl)methyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 581 546

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-(2-hydroxy- ethyl)-1H-pyrazol-4-yl)methyl)amino)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 643 547

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-(2-methoxy- ethyl)-1H-pyrazol-4-yl)methyl)amino)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydroxy-2H-pyran-4-yl)acrylamide 657 548

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(neopentylamino)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 589 549

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((3-(isopropyl- amino)propyl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 618 550

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((4-(isopropyl- amino)butyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 632 551

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((4-(dimethyl- amino)butyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 618 552

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((4-(pyrrolidin-1- yl)butyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 644 553

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-(4-methyl- piperazin-1-yl)ethyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 645 554

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-morpholinoeth- yl)amino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 632 555

N-((3S,4S)-3-((8-((2-(3-aminopyrroli- din-1-yl)ethyl)amino)-6-(2,6-dichloro- 3,5-dimethoxyphenyl)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 631 556

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((2-(3-(dimethyl- amino)pyrrolidin-1-yl)ethyl)amino) pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydro-2H-pyran-4- yl)acrylamide 659 557

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxypehnyl)-8-((2-(2-(dimethyl- amino)ethoxy)ethyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 634 558

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((4-(2-(hydroxy- methyl)pyrrolidin-1-yl)butyl)amino)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 674 559

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((4-(3,3-difluoro- pyrrolidin-1-yl)butyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 680 560

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((4-(3-methoxy- pyrrolidin-1-yl)butyl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 674 561

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-methoxypyrido[3,4- d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 534 562

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-ethoxypyrido[3,4- d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 548 563

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-isopropoxypyrdo[3,4- d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 562 564

N-((3S,4S)-3-((8-(cyclopropylmeth- oxy)-6-(2,6-dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydro-2H-pyran-4-yl)acryl- amide 574 565

N-((3S,4R)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)-1-methylpyrrolidin- 3-yl)acrylamide 503 566

N-((3S,4R)-1-acetyl-4-((6-(2,6-di- chloro-3,5-dimethoxyphenyl)pyrido[3,4- d]pyrimidin-2-yl)amino)pyrrolidin- 3-yl)acrylamide 531 567

N-((3S,4R)-1-acetyl-4-((6-(2,6-dichloro- 3,5-dimethoxyphenyl)-8-(methyl- amino)pyrido[3,4-d]pyrimidin-2-yl)a- mino)pyrrolidin-3-yl)acrylamide 560 568

N-((3S,4R)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)-1-(2-(dimethyl- amino)ethyl)pyrrolidin-3-yl)acrylamide 560 569

(3S,4R)-3-acrylamido-4-((6-(2,6-di- chloro-3,5-dimethoxyphenyl)pyrido[3,4- d]pyrimidin-2-yl)amino)-N-meth- ylpyrrolidine-1-carboxamide 546 570

N-((3S,4R)-4-((8-((cyclopropylmeth- yl)amino)-6-(2,6-dichloro-3,5-dimeth- oxyphenyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)-1-methylpyrrolidin- 3-yl)acrylamide 572 571

(3S,4R)-3-acrylamido-4-((8-((cyclo- propylmethyl)amino)-6-(2,6-dichloro- 3,5-dimethoxyphenyl)pyrido[3,4-d]py- rimidin-2-yl)amino)-N-methyl- pyrrolidine-1-carboxamide 615 572

N-((3S,4R)-1-acetyl-4-((8-((cyclo- propylmethyl)amino)-6-(2,6-dichloro- 3,5-dimethoxyphenyl)pyrido[3,4-d] pyrimidin-2-yl)amino)pyrrolidin- 3-yl)acrylamide 600 573

N-((3S,4R)-4-((8-((cyclopropylmeth- yl)amino)-6-(2,6-dichloro-3,5-dimeth- oxyphenyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)-1-(oxetan-3-yl)pyrrolidin- 3-yl)acrylamide 614 574

N-((3S,4R)-4-((8-((cyclopropylmeth- yl)amino)-6-(2,6-dichloro-3,5-dimeth- oxyphenyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)-1-(2-(dimethylamino)eth- yl)pyrrolidin-3-yl)acrylamide 629 575

N-((3S,4R)-4-((8-((cyclopropylmeth- yl)amino)-6-(2,6-dichloro-3,5-dimeth- oxyphenyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)-1-(1H-pyrazol-4-yl)pyrroli- din-3-yl)acrylamide 624 576

N-((3S,4R)-4-((8-((cyclopropylmeth- yl)amino)-6-(2,6-dichloro-3,5-dimeth- oxyphenyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)-1-(1-methyl-1H-pyrazol- 4-yl)pyrrolidin-3-yl)acrylamide 638 577

N-((3S,4R)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((tetrahydrofuran- 2-yl)methyl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)-1-methyl- pyrrolidin-3-yl)acrylamide 602 578

(3S,4R)-3-acrylamido-4-((6-(2,6-di- chloro-3,5-dimethoxphenyl)-8-(((tetra- hydrofuran-2-yl)methyl)amino)pyri- do[3,4-d]pyrimidin-2-yl)amino)-N- methylpyrrolidine-1-carboxamide 645 579

N-((3S,4R)-1-acetyl-4-(((6-(2,6-di- chloro-3,5-dimethoxyphenyl)-8-(((tetra- hydrofuran-2-yl)methyl)amino)pyri- do[3,4-d]pyrimidin-2-yl)amino)pyrroli- din-3-yl)acrylamide 630 580

N-((3S,4R)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(((tetrahydrofuran- 2-yl)methyl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)-1-(oxetan- 3-yl)pyrrolidin-3-yl)acrylamide 644 581

N-((3S,4R)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((tetrahydrofuran- 2-yl)methyl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)-1-(2-(dimethyl- amino)ethyl)pyrrolidin-3-yl)acrylamide 659 582

N-((3S,4R)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((tetrahydrofuran- 2-yl)methyl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)-1-(1H-pyrazol- 4-yl)pyrrolidin-3-yl)acrylamide 654 583

N-((3S,4R)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((tetrahydrofuran- 2-yl)methyl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)-1-(1-methyl-1H- pyrazol-4-yl)pyrrolidin-3-yl)acryl- amide 668 584

N-((3S,4R)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(oxetan-3-ylamino)py- rido[3,4-d]pyrimidin-2-yl)amino)- 1-methylpyrrolidin-3-yl)acrylamide 574 585

(3S,4R)-3-acrylamido-4-((6-(2,6-di- chloro-3,5-dimethoxyphenyl)-8-(oxetan- 3-ylamino)pyrido[3,4-d]pyrimidin- 2-yl)amino)-N-methylpyrrolidine- 1-carboxamide 617 586

N-((3S,4R)-1-acetyl-4-((6-(2,6-di- chloro-3,5-dimethoxyphenyl)-8-(oxetan-3- ylamino)pyrido[3,4-d]pyrimidin-2-yl) amino)pyrrolidin-3-yl)acrylamide 602 587

N-((3S,4R)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(oxetan-3-yl- amino)pyrido[3,4-d]pyrimidin-2-yl)ami- no)-1-(oxetan-3-yl)pyrrolidin-3- yl)acrylamide 616 588

N-((3S,4R)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(oxetan-3-yl- amino)pyrido[3,4-d]pyrimidin-2-yl)a- mino)-1-(2-dimethylamino)ethyl)pyrroli- din-3-yl)acrylamide 631 589

N-((3S,4R)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(oxetan-3-yl- amino)pyrido[3,4-d]pyrimidin-2-yl)a- mino)-1-(1H-pyrazol-4-yl)pyrrolidin- 3-yl)acrylamide 626 590

N-((3S,4R)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(oxetan-3-yl- amino)pyrido[3,4-d]pyrimidin-2-yl)ami- no)-1-(1-methyl-1H-pyrazol- 4-yl)pyrrolidin-3-yl)acrylamide 640 591

N-((3S,4R)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((tetrahydrofuran- 3-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)-1-methylpyrrolidin- 3-yl)acrylamide 588 592

(3S,4R)-3-acrylamido-4-((6-(2,6-di- chloro-3,5-dimethoxyphenyl)-8-((tetra- hydrofuran-3-yl)amino)pyrido[3,4- d]pyrimidin-2-yl)amino)-N-methyl- pyrrolidine-1-carboxamide 631 593

N-((3S,4R)-1-acetyl-4-((6-(2,6-di- chloro-3,5-dimethoxyphenyl)-8-((tetra- hydrofuran-3-yl)amino)pyrido[3,4-d]py- rimidin-2-yl)amino)pyrrolidin-3- yl)acrylamide 616 594

N-((3S,4R)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((tetrahydrofuran- 3-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)-1-(oxetan-3- yl)pyrrolidine-3-yl)acrylamide 630 595

N-((3S,4R)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((tetrahydrofuran- 3-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)-1-(2-(dimethylamino)eth- yl)pyrrolidin-3-yl)acrylamide 645 596

N-((3S,4R)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((tetrahydrofuran- 3-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)-1-(1H-pyrazol-4- yl)pyrrolidine-3-yl)acrylamide 640 597

N-((3S,4R)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((tetrahydrofuran- 3-yl)amino)pyrido[3,4-d]pyrimidin- 2-yl)amino)-1-(1-methyl-1H-pyrazol- 4-yl)pyrrolidin-3-yl)acrylamide 654 598

N-((3R,4S)-4-((8-(((R)-1-cyclopropopyl- ethyl)amino)-6-(2,6-dichloro-3,5-di- methoxyphenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 573 599

N-((3R,4S)-4-((8-(((R)-1-cylopropyl- ethyl)amino)-6-(2,6-difluoro-3,5-di- methoxyphenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 541 600

N-((3R,4S)-4-((8-(((S)-1-cyclopropyl- ethyl)amino)-6-(2,6-dichloro-3,5-di- methoxyphenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 573 601

N-((3R,4S)-4-((8-(((S)-1-cyclopropyl- ethyl)amino)-6-(2,6-difluoro-3,5-di- methoxyphenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 541 602

N-((3R,4S)-4-((6-(26-dichloro-3,5-di- methoxyphenyl)-8-(((R)-3,3-dimeth- ylbutan-2-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 589 603

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-(((R)-3,3-dimeth- ylbutan-2-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 557 604

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((S)-3,3-dimeth- ylbutan-2-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 589 605

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-(((S)-3,3-dimeth- ylbutan-2-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 557 606

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-methylpyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 504 607

N-((3R,4)S-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-ethylpyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 518 608

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-isopropylpyrido[3,4- d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 532 609

N-((3R,4S)-4-((8-cyclopropyl-6-(2,6- dichloro-3,5-dimethoxyphenyl)pyri- do[3,4-d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 530 610

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-neopentylpyrido[3,4- d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 560 611

N-((3R,4S)-4-((8-(cyclopropylmeth- yl)-6-(2,6-dichloro-3,5-dimethoxyphen- yl)pyrido[3,4-d]pyrimidin-2-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 544 612

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((tetrahydrofuran- 3-yl)methyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl) acrylamide 574 613

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((tetrahydrofuran- 2-yl)methyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl) acrylamide 574 614

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(tetrahydro-2H- pyran-4-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 574 615

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((1-methylpyrroli- din-3-yl)methyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 587 616

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-((1-methylpyrroli- din-2-yl)methyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3-yl) acrylamide 587 617

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(1-methylpiperidin- 4-yl)pyrido[3,4-d]pyrimidin-2-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 587 618

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(methoxymethyl)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 534 619

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(2-methoxyethyl) pyrido[3,4-d]pyrimidin-2-yl)amino) tetrahydrofuran-3-yl)acrylamide 548 620

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(2-(isopropylami- no)ethyl)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acrylamide 575 621

N-((3R,4S)-4-((8-((cyclopropyl- amino)methyl)-6-(2,6- dichloro-3,5-dimeth- oxyphenyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl)acryl- amide 559 622

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(methylsulfon- amidomethyl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 597 623

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(((1-methylethyl)sul- fonamido)methyl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran- 3-yl)acrylamide 625 624

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(2,2,2-trifluoroeth- yl)pyrido[3,4-d]pyrimidin-2-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 572 625

N-((3R,4S)-4-((8-benzyl-6-(2,6-di- chloro-3,5-dimethoxyphenyl)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 580 626

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-phenylpyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 566 627

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(pyridin-4-yl)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 567 628

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(pyridin-3-yl)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 567 629

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(1-methyl-1H- pyrazol-4-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 570 630

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((1-methyl-1H- pyrazol-4-yl)methyl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 584 631

N-((3R,4S)-4-((8-(1-cyclopropyl-1H- pyrazol-4-yl)-6-(2,6-dichloro-3,5-di- methoxyphenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 596 632

N-((3R,4S)-4-((8-(1-(cyclopropyl- methyl)-1H-pyrazol-4-yl)-6-(2,6-dichloro- 3,5-dimethoxyphenyl)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 610 633

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(1-(2-methoxyeth- yl)-1H-pyrazol-4-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 614 634

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(1-(2-hydroxy- ethyl)-1H-pyrazol-4-yl)pyrido[3,4-d]py- rimidin-2-yl)amio)tetrahydro- furan-3-yl)acrylamide 600 635

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxphenyl)-8-(1-(tetrahydrofuran- 3-yl)-1H-pyrazol-4-yl)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 626 636

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-phenethylpyrido[3,4- d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 594 637

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(1-methyl-1H-py- razol-4-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 538 638

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(1-(2-methoxy- ethyl)-1H-pyrazol-4-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydr- furan-3-yl)acrylamide 582 639

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-(1-(2-hydroxyeth- yl)-1H-pyrazol-4-yl)pyrido[3,4-d] pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 568 640

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- methoxyphenyl)-8-ethylpyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 532 641

N-((3S,4S)-3-((8-(cyclopropylmeth- yl)-6-(2,6-dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydro-2H-pyran-4- yl)acrylamide 558 642

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((tetrahydrofuran- 3-yl)methyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 588 643

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(tetrahydro-2H- pyran-4-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 588 644

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(1-methyl-1H- pyrazol-4-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran-4-yl) acrylamide 584 645

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((1-methyl-1H- pyrazol-4-yl)methyl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 598 646

N-((3S,4S)-3-((8-(1-cyclopropyl-1H- pyrazol-4-yl)-6-(2,6-dichloro-3,5-di- methoxyphenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 610 647

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(1-(2-methoxy- ethyl)-1H-pyrazol-4-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 628 648

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(2-(isopropyl- amino)ethyl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 589 649

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-ethylpyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 500 650

N-((3S,4S)-3-((8-(cyclopropylmeth- yl)-6-(2,6-difluoro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 526 651

N-((3S,4S)-3-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-((tetrahydrofuran- 3-yl)methyl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 556 652

N-((3S,4S)-3-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-(tetrahydro-2H- pyran-4-yl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 556 653

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxypehnyl)-8-(1-methyl-1H- pyrazol-4-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 552 654

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(1-(2-methoxy- ethyl)-1H-pyrazol-4-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 596 655

N-((3R,4S)-4-((8-(cyclopropylamino)- 6-(2,6-dichloro-3,5-dimethoxyphen- yl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3- yl)acrylamide 545 656

N-((3R,4S)-4-((8-(cyclopropylamino)- 6-(2,6-difluoro-3,5-dimethoxyphen- yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3- yl)acrylamide 513 657

N-((3R,4S)-4-((8-(azetidin-1-yl)-6- (2,6-dichloro-3,5-dimethoxyphenyl)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 545 658

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3-methoxyazeti- din-1-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 575 659

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(3-methoxyazeti- din-1-yl)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acryl- amide 543 660

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3-(dimethylami- no)azetidin-1-yl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 588 661

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3-(trifluorometh- yl)azetidin-1-yl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 613 662

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3,3-dimethylaze- tidin-1-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 573 663

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3,3-difluoroaze- tidin-1-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 581 664

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3-hydroxy-3-meth- ylazetidin-1-yl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 575 665

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(3-methoxy-3- methylazetidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 589 666

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(3-methoxy-3- methylazetidin-1-yl)pyrido[3,4-d]pyri- midin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 557 667

N-((3R,4S)-4-((8-(3-cyano-3-methyl- azetidin-1-yl)-6-(2,6-dichloro-3,5-di- methoxyphenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 584 668

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(2-oxa-6-aza- spiro[3.3]heptan-6-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 587 669

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(2-oxa-6-aza- spiro[3.3]heptan-6-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 555 670

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(1-oxa-6-aza- spiro[3.3]heptan-6-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 587 671

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(1-oxa-6-aza- spiro[3.3]heptan-6-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 555 672

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(2- azaspiro[3.3]heptan-2-yl)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydrofuran- 3-yl)acrylamide 585 673

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8- (2-azaspiro[3.4]octan-2-yl)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 599 674

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(6-oxa-2- azaspiro[3.4]octan-2-yl)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 601 675

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(7-oxa- 2-azaspiro[3.5]nonan-2- yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acrylamide 615 676

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(pyrrolidin-1- yl)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acrylamide 559 677

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3-methoxypyrro- lidin-1-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 589 678

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-(3-methoxypyrro- lidin-1-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 557 679

N-((3R,4S)-4-((8-(3-cyanopyrrolidin- 1-yl)-6-(2,6-dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acryl- amide 584 680

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3,3-difluoro- pyrrolidin-1-yl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl)acryl- amide 595 681

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3-methoxy-3- methylpyrrolidin-1-yl)pyrido[3,4-d]py- rimidn-2-yl)amino)tetrahydrofuran- 3-yl)acrylamide 603 682

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(3-methoxy-3- methylpyrrolidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 571 683

N-((3R,4S)-4-((8-(3-cyano-3-methyl- pyrrolidin-1-yl)-6-(2,6-dichloro-3,5- dimethoxyphenyl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 598 684

N-((3R,4S)-4-((8-(3-aza- bicyclo[3.1.0]hexan-3-yl)-6-(2,6- dichloro-3,5-dimethoxyphen- yl)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acrylamide 571 685

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(2-oxa-7- azaspiro[4.4]nonan-7-yl)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 615 686

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-morpholino- pyrido[3,4-d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 575 687

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-morpholino- pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acrylamide 543 688

N-((3R,4S)-4-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(2-methyl- morpholino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acrylamide 589 689

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-(2-methyl- morpholino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 557 690

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(2,6-dimethyl- morpholino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 603 691

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(2,6-dimethyl- morpholino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 571 692

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(4-hydroxypiperi- din-1-yl)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acryl- amide 589 693

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(4-methoxy- piperidin-1-l)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl)acryl- amide 603 694

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(4-methoxypiper- idin-1-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3-yl)acryl- amide 571 695

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3-methoxy- piperidin-1-yl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl)acryl- amide 603 696

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(4-hydroxy-4- methylpiperidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 603 697

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(4-methoxy-4- methylpiperidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 617 698

N-((3R,4S)-4-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-(4-methoxy-4- methylpiperidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 585 699

N-((3R,4S)-4-((8-(4-cyano-4-methyl- piperidin-1-yl)-6-(2,6-dichloro-3,5-di- methoxyphenyl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofurna-3-yl) acrylamide 612 700

N-(2-(((3S,4R)-4-acrylamidotetrahy- drofuran-3-yl)amino)-6-(2,6-dichloro- 3,5-dimethoxyphenyl)pyrido[3,4- d]pyrimidin-4-8-yl)cyclopropanecarbox- amide 573 701

N-(2-(((3S,4R)-4-acrylamidotetra- hydrofuran-3-yl)amino)-6-(2,6-dichloro- 3,5-dimethoxyphenyl)pyrido[3,4-d]py- rimidin-8-yl)tetrahydrofuran-2- carboxamide 603 702

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(methylsulfonami- do)pyrido[3,4-d]pyrimidin-2-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 583 703

N-((3S,4S)-3-((8-(cyclopropylamino)- 6-(2,6-dichloro-3,5-dimethoxyphenyl)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 559 704

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(3-methoxyazeti- din-1-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 589 705

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(3,3-difluoro- azetidin-1-yl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 595 706

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3-methoxy-3- methylazetidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 603 707

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(2-oxa-6-aza- spiro[3.3]heptan-6-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 601 708

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(6-oxa-2- azaspiro[3.4]octan-2-yl)pyrido[3,4- d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 615 709

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(7-oxa-2- azaspiro[3.5]nonan-2-yl)py- rido[3.4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 629 710

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3-methoxy- pyrrolidin-1-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 603 711

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3-methoxy-3- methylpyrrolidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 617 712

N-((3S,4S)-3-((6-(2,6-dichloro-3,5-di- methoxyphenyl)-8-(2,6-dimethyl- morpholino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 617 713

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(4-hydroxy-4- methylpiperidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 617 714

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(4-methoxy-4- methylpiperidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 631 753

N-((3R,4S)-4-((8-chloro-6-(2,6-di- chloro-3,5-dimethoxyphenyl)py- rido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro- furan-3-yl)acrylamide 524 754

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- bis(methoxy-d₃)phenyl)-8-ethoxy- pyrido[3,4-d]pyrimidin-2- yl)amino)tetra- hydrofuran-3-yl)acrylamide 540 755

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((3,5-dimethoxy- benzyl)oxy)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl) acrylamide 656 756

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3,6-dihydro-2H- pyran-4-yl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydrofuran-3-yl)acryl- amide 572 758

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxypehnyl)-8-((3-hydroxy-2,2- bis(hydroxymethyl)propyl)amino)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 623 759

N-((3R,4S)-4-((8-(3,3-bis(hydroxy- methyl)azetidin-1-yl)-6-(2,6-dichloro- 3,5-dimethoxyphenyl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran- 3-yl)acrylamide 605 760

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3-hydroxy-3- methylpyrrolidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetarhydrofuran-3- yl)acrylamide 589 761

N-((3R,4S)-4-((6-(2-chloro-3,5-dimeth- oxyphenyl)-8-(1-methyl-1H-pyrazol- 4-yl)pyrido[3,4-d]pyrimidin-2-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 536 762

N-((3R,4S)-4-((8-(6-oxa-3-aza- bicyclo[3.1.1]heptan-3-yl)-6-(2,6-di- chloro-3,5-dimethoxyphenyl)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 587 763

N-((3R,4S)-4-((8-(2-oxa-5- azabicyclo[2.2.1]heptan-5-yl)-6-(2,6- dichloro-3,5-dimethoxyphenyl)py- rido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acrylamide 587 764

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(methylamino)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 487 765

N-((3R,4S)-4-((8-amino-6-(2,6-di- chloro-3,5-dimethoxyphenyl)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 505 766

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- bis(methoxy-d3)phenyl)-8-((methyl- d3)amino)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydrofuran-3-yl)acrylamide 528 767

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(ethylamino)pyri- do[3,4-d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 501 768

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(3,3-difluoro- azetidin-1-yl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 549 769

N-((3R,4S)-4-((8-(6-oxa-3- azabicyclo[3.1.1]heptan-3-yl)-6-(2,6- difluoro-3,5-dimethoxy- phenyl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydrofuran-3- yl)acrylamide 555 770

N-((3R,4S)-4-((6-(2-fluoro-3-meth- oxyphenyl)-8-(methylamino)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 439 771

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((methyl-d₃)ami- no)pyrido[3,4-d]pyrimidin-2-yl)ami- no)tetrahydrofuran-3-yl)acrylamide 522 772

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(3-hydroxy-3- methylpyrrolidin-1-yl)pyrido[3,4-d]py- rimidin-2-l)amino)tetrahydrofuran-3- yl)acrylamide 557 773

N-((3R,4S)-4-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(3-hydroxy-3-meth- ylazetidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 543 774

N-((3R,4S)-4-((8-(azetidin-1-yl)-6-(2,6- difluoro-3,5-dimethoxyphenyl)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 513 775

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(3-methoxyazeti- din-1-yl)pyrido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydro-2H-pyran-4-yl)acryl- amide 557 776

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(7-oxa-2-azaspiro [3.5]nonan-2-yl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydrofuran-3- yl)acrylamide 615 777

N-((3R,4S)-4-((6-(2,6-difluoro-3-meth- oxyphenyl)-8-(methylamino)pyri- do[3,4-d]pyrimidin-2-yl)amino)tetra- hydrofuran-3-yl)acrylamide 457 778

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((S)-3-hydroxy-3- methylpyrrolidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydrofuran- 3-yl)acrylamide 589 779

N-((3R,4S)-4-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-((R)-3-hydroxy- 3-methylpyrrolidin-1-yl)pyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- furan-3-yl)acrylamide 589 780

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-morpholino- pyrido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 589 781

N-((3S,4S)-3-((8-(6-oxa-3- azabicyclo[3.1.1]heptan-3-yl)-6- (2,6-dichloro-3,5-dimethoxy- phenyl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 601 782

N-((3S,4S)-3-((8-(2-oxa-5- azabicyclo[2.2.1]heptan-5-yl)-6-(2,6- dichloro-3,5-dimethoxyphenyl)py- rido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydro-2H-pyran- 4-yl)acrylamide 601 783

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3-hydroxy-3- methylpyrrolidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 603 784

N-((3S,4S)-3-((8-(azetidin-1-yl)-6-(2,6- dichloro-3,5-dimethoxyphenyl)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 559 785

N-((3S,4S)-3-((6-(2,6-dichloro-3,5- dimethoxyphenyl)-8-(3-hydroxy-3- methylazetidin-1-yl)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 589 786

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(methylamino)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 501 787

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(ethylamino)pyri- do[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 515 788

N-((3S,4S)-3-((8-(cyclopropylamino)- 6-(2,6-difluoro-3,5-dimethoxyphenyl)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 527 789

N-((3S,4)S-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-morpholinopy- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 557 790

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(3-methoxy-3- methylazetidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 571 791

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(3,3-difluoroazet- idin-1-yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 563 792

N-((3S,4S)-3-((8-(azetidin-1-yl)-6-(2,6- difluoro-3,5-dimethoxyphenyl)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 527 793

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(3-hydroxy-3- methylazetidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 557 794

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(3-methoxy- pyrrolidin-1-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 571 795

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(4-methoxy- piperidin-1-yl)pyrido[3,4-d]pyrimidin- 2-yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 585 796

N-((3S,4S)-3-((8-(6-oxa-3-aza- bicyclo[3.1.1]heptan-3-yl)-6-(2,6- difluoro-3,5-dimethoxyphenyl)py- rido[3,4-d]pyrimidin-2-yl)a- mino)tetrahydro-2H-pyran-4- yl)acrylamide 569 797

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-((2,2,2-trifluoro- ethyl)amino)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 569 798

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-((3,3-dimethyl- butan-2-yl)amino)pyrido[3,4-d]pyrimi- din-2-yl)amino)tetrahydro-2H-pyran- 4-yl)acrylamide 571 799

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-methoxypyrido[3,4- d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 502 800

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-methylpyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 486 801

N-((3S,4)S-3-((8-cyclopropyl-6-(2,6- difluoro-3,5-dimethoxyphenyl)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 512 802

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(piperidin-4-yl)py- rido[3,4-d]pyrimidin-2-yl)amino)tetra- hydro-2H-pyran-4-yl)acrylamide 555 803

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(1H-pyrazol-4- yl)pyrido[3,4-d]pyrimidin-2- yl)amino)tetrahydro-2H-pyran-4- yl)acrylamide 538 804

N-((3S,4S)-3-((6-(2,6-difluoro-3,5- dimethoxyphenyl)-8-(1-(2-hydroxyeth- yl)-1H-pyrazol-4-yl)pyrido[3,4-d]py- rimidin-2-yl)amino)tetrahydro-2H- pyran-4-yl)acrylamide 582 805

N-((3S,4S)-3-((6-(2,6-difluoro-3,5-di- methoxyphenyl)-8-phenylpyrido[3,4- d]pyrimidin-2-yl)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 548 806

N-((3S,4S)-3-((8-chloro-6-(2,6-di- fluoro-3,5-dimethoxyphenyl)pyrido[3,4- d]pyrimidin-2-yL)amino)tetrahydro- 2H-pyran-4-yl)acrylamide 506

Example 715 Preparation of N-(5-(6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)-1-(2-methoxyethyl)-1H-pyrazol-4-yl)acrylamide

Step 1: Preparation of 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(1-(2-methoxyethyl)-4-nitro-1H-pyrazol-5-yl)pyrido[3,4-d]pyrimidine

1-(2-methoxyethyl)-4-nitro-H-pyrazole (84 mg, 0.49 mmol) and 2-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidine (200 mg, 0.54 mmol) were dissolved into DMA (15 mL), then CuI (112 mg, 0.59 mmol), PivOH (15 mg, 0.15 mmol), K₂CO₃ (88 mg, 0.64 mmol) and Pd(PPh₃)₂Cl₂ (34 mg, 0.05 mmol) were added, the mixture was heated to 140° C. under N₂ and stirred for 1 h. The reaction was completed, and the mixture was concentrated to remove the solvent by reduced pressure and separated by fast silica gel column (PE/EA 2:1) to obtain compound 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(1-(2-methoxyethyl)-4-nitro-1H-pyrazol-5-yl)pyrido[3,4-d]pyrimidine (103 mg, yield 42%). MS m/z (ESI): 505 [M+1]⁺.

Step 2: Preparation of 5-(6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)-1-(2-methoxyethyl)H-pyrazolyl-4-amine

6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(1-(2-methoxyethyl)-4-nitro-1H-pyrazol-5-yl)pyrido[3,4-d]pyrimidine (103 mg, 0.20 mmol) was dissolved in the mixture of EtOH and H₂O (10/3 mL), then Fe powder (114 mg, 2.04 mmol) and NH₄Cl (109 mg, 2.04 mmol) were added, the mixture was heated to reflux and stirred for 2 h. After the reaction was completed, the reaction liquid was extracted for three times with dichloromethane. The organic phases were combined, washed with water, then a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtrated and concentrated. The crude product was separated by fast silica gel column chromatography (CH₂Cl₂/MeOH 10:1) to obtain compound 5-(6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)-1-(2-methoxyethyl)-1H-pyrazolyl-4-amine (12 mg, yield 12%). MS m/z (ESI): 476 [M+1]⁺.

Step 3: Preparation of N-(5-(6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl 1-2-methoxyethyl)-1H-pyrazol-4-yl)acrylamide

5-(6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)-1-(2-methoxyethyl)-1H-pyrazolyl-4-amine (12 mg, 0.025 mmol) was dissolved in the mixture of THF and H₂O (4:1, 4 mL), then NaHCO₃ (11 mg, 0.13 mmol) was added, the mixture was cooled under ice water bath, Acryloyl chloride (2.3 mg, 0.025 mmol) as added, and the mixture was stirred at 0° C. for 10 min. After the reaction was completed, the reaction liquid w as concentrated by reduced pressure, separated by silica gel column chromatography (CH₂Cl₂/MeOH 10:1) to obtain compound N-(5-(-(2,6-dichloro-3,5-dimethoxyphenyl)pyrido[3,4-d]pyrimidin-2-yl)-1-(2-methoxyethyl)-1H-pyrazol-4-yl)acrylamide (4.8 mg, yield 36%). MS m/z (ESI): 529 [M+1]⁺.

¹H NMR (400 MH-z, CDCl₃) δ 10.71 (s, 1H), 9.63 (s, 1H) 9.60 (s, 1H), 8.61 (s, 1H), 7.80 (s, 1H), 6.72 (s, 1H), 6.49 (d, J=16.7 Hz, 1H), 6.40 (dd, J=16.9, 9.7 Hz, 1H), 5.84 (d, J=9.7 Hz 1H), 5.21 (t, J=6.0 Hz, 2H), 4.00 (s, 7H), 3.89 (t, J=5.9 Hz, 2H), 3.35 (s, 3H).

Examples 716-729 were prepared by referring to the synthesis method of Example 715.

Example MS: m/z No. Compound structure Compound name [M + 1]⁺ 716

N-(5-(7-(2,6-dichloro-3,5-dimethoxyphenyl)- 5-oxo-5,6-dihydro-2,6-naphthyridin-3- yl)-1-(2-methoxyethyl)-1H-pyrazol-4-yl) acrylamide 544 717

N-(5-(7-(2,6-dichloro-3,5-dimethoxyphenyl)- 6-methyl-5-oxo-5,6-dihydro-2,6- naphthyridin-3-yl)-1-(2-methoxyethyl)-1H- pyrazol-4-yl)acrylamide 558 718

N-(5-(7-(2-chloro-6-fluoro-3,5- dimethoxyphenyl)- 6-methyl-5-oxo-5,6-dihydro-2,6- naphthyridin-3-yl)-1-(2-methoxyethyl)- 1H-pyrazol-4-yl)acrylamide 542 719

N-(5-(6-(2-(tert-butylamino)-2-oxoethyl)- 7-(2,6-dichloro-3,5-dimethoxyphenyl)-5- oxo-5,6-dihydro-2,6-naphthyridin-3-yl)-1- (2-methoxyethyl)-1H-pyazol-4-yl) acrylamide 657 720

N-(5-(6-(cyclopropylmethyl)-7-(2,6-dichloro- 3,5-dimethoxyphenyl)-5-oxo-5,6-dihydro- 2,6-naphthyridin-3-yl)-1-(2-methoxyethyl)- 1H-pyrazol-4-yl)acrylamide 598 721

N-(5-(6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-oxo-7,8-dihydropyrido[3,4-d]pyrimidin- 2-yl)-1-(2-methoxyethyl)-1H-pyrazol- 4-yl)acrylamide 545 722

N-(5-(6-(2,6-dichloro-3,5-dimethoxyphenyl)- 7-methyl-8-oxo-7,8-dihydropyrido [3,4-d]pyrimidin-2-yl)-1-(2-methoxyethyl)- 1H-pyrazol-4-yl)acrylamide 559 723

N-(5-(7-(2,6-dichloro-3,5-dimethoxyphenyl)- 2,6-naphthyridin-3-yl)-1-(2- methoxyethyl)-1H-pyrazol-4-yl)acrylamide 528 724

N-(5-(7-(2,6-dichloro-3,5-dimethoxyphenyl)- 2,6-naphthyridin-3-yl)-1-(2-methoxyethyl)- 1H-pyrazol-4-yl)acrylamide 601 725

N-(5-(7-(2,6-dichloro-3,5-dimethoxyphenyl)- 5-methoxy-2,6-naphthyridin-3-yl)-1- (2-methoxyethyl)-1H-pyrazol-4-yl) acrylamide 558 726

N-(5-(3-(2,6-dichloro-3,5-dimethoxyphenyl)- 1-oxo-1H-pyrano[4,3-c]pyridin-7-yl)- 1-(2-methoxyethyl)-1H-pyrazol-4-yl) acrylamide 545 727

N-(5-(6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-methoxypyrido[3,4-d]pyrimidin-2-yl)- 1-(2-methoxyethyl)-1H-pyrazol-4-yl) acrylamide 560 728

N-(5-(6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-((2-methoxyethyl)amino)pyrido[3,4-d] pyrimidin-2-yl)-1-(2-methoxyethyl)- 1H-pyrazol-4-yl)acrylamide 602 729

N-(5-(8-((cyclopropylmethyl)amino)-6-(2,6- dichloro-3,5-dimethoxyphenyl)pyrido [3,4-d]pyrimidin-2-yl)-1-(2-methoxyethyl)- 1H-pyrazol-4-yl)acrylamide 598

Example 730 Preparation of N-((3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-7-yl)methyl)acrylamide

Step 1: Preparation of 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-7-carbonitrile

7-chloro-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methyl-1,6-naphthyridin-2(1H)-one (250.0 mg, 0.626 mmol), Zn(CN)₂ (110 mg, 0.938 mmol) and 1,1′-bis(diphenylphosphino)ferrocene (34.7 mg, 0.063 mmol) were added to the mixture of DMF and H₂O (5 mL, 100:1), then Pd₂(dba)₃ (28.7 mg, 0.031 mmol) was added under N₂, the mixture was heated to 12 0° C. and stirred for 20 h. The reaction was completed, and the mixture was cooled to room temperature, diluted with water and extracted with EtOAc. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtrated, concentrated and separated by silica gel column chromatography (Eluent: PE/EtOAc=10-25%) to obtain compound 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-7-carbonitrile (75 mg, yield: 28%). MS m/z (ESI): 390.0 [M+H]⁺.

Step 2: Preparation of 7-(aminomethyl)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-meth yl-1,6-naphthyridin-2(1H)-one

3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methyl-2-carbonyl-1,2-dihydro-1,6-naphthyridin-7-carbonitrile (15 mg, 0.038 mmol) was dissolved in methanol (3 mL), and concentrated hydrochloric acid (15 mL) and 10% Pd/C (catalytic amount) were added, the mixture was stirred at room temperature for 2 h under H₂, the reaction was completed. The reaction liquid was filtrated and evaporated in vacuo to obtain the crude product 7-(aminomethyl)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methyl-1,6-naphthyridin-2(H)-one, which can be directly used in the next reaction. MS m/z (ESI): 394.0 [M+H]⁺.

Step 3: Preparation of N-((3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-7-yl)methyl)acrylamide

At 0° C., acryloyl chloride (3.8 mg, 0.042 mmol) was added to a solution of 7-(aminomethyl)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methyl-, 6-naphthyridin-2(H)-one (the crud e product, 0.038 mmol) and NaHCO₃ (19.0 mg, 0.230 mmol) in the mixture of THF and H₂O (0.8 mL/0.2 mL), the mixture was stirred for 10 min At 0° C. The reaction liquid was diluted with EtOAc (5 mL), washed with saturated brine, dried over anhydrous sodium sulfate, filtrated, concentrated and separated by a preparative TLC (Eluent: CH₂Cl₂/MeOH=10:1) to obtain compound N-((3-(2,6-dichloro-3,5-dimethoxyphenyl)--methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-7-yl)methyl)acrylamide (1.1 mg, two-step yield: 6%).

¹H NMR (400 MHz, Chloroform-d) δ 8.75 (s, 1H), 7.68 (s, 1H), 7.40 (s, 1H), 6.65 (s, 1H), 6.38-6.32 (m, 1H), 6.27-6.21 (m, 1H), 5.73-5.69 (m, 1H), 5.30 (s, 1H), 4.81 (d, J=5.6 Hz, 2H), 3.96 (s, 6H), 3.78 (s, 3H):

MS m/z (ESI): 448.0 [M+H]⁺.

Examples 731-751 were prepared referring to the synthesis method of Example 730.

Example MS: m/z No. Compound structure Compound name [M + 1]⁺ 731

N-((3-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-oxo-1-(2,2,2-trifluoroethyl)- 1,2-dihydro-1,6-naphthyridin- 7-yl)methyl)acrylamide 516 732

N-((3-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-oxo-1-(tetrahydrofuran- 3-yl)-1,2-dihydro-1,6-naphthyridin- 7-yl)methyl)acrylamide 504 733

N-((3-(2,6-dichloro-3,5-dimethoxyphenyl)- 1-(2-methoxyethyl)-2-oxo- 1,2-dihydro-1,6-naphthyridin-7-yl) methyl)acrylamide 492 734

N-((7-(2,6-dichloro-3,5-dimethoxyphenyl)- 2,6-naphthyridin-3-yl) methyl)acrylamide 418 735

N-((6-(2,6-dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidin-2- yl)methyl)acrylamide 419 736

N-((3-(2,6-dichloro-3,5-dimethoxyphenyl)- 1-oxo-1H-pyrano[4,3-c] pyridin-7-yl)methyl)acrylamide 435 737

N-((7-(2,6-dichloro-3,5-dimethoxyphenyl)- 5-oxo-5,6-dihydro-2,6- naphthyridin-3-yl)methyl)acrylamide 434 738

N-((7-(2,6-dichloro-3,5-dimethoxyphenyl)- 6-methyl-5-oxo-5,6-dihydro- 2,6-napthyridin-3-yl)methyl) acrylamide 448 739

N-((7-(2,6-dichloro-3,5-dimethoxyphenyl)- 5-methoxy-2,6-naphthyridin- 3-yl)methyl)acrylamide 448 740

N-((6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-oxo-7,8-dihydropyrido [3,4-d]pyrimidin-2-yl)methyl) acrylamide 435 741

N-((6-(2,6-dichloro-3,5-dimethoxyphenyl)- 7-methyl-8-oxo-7,8-dihydropyrido [3,4-d]pyrimidin-2-yl)methyl)acrylamide 449 742

N-((6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-methoxypyrido[3,4-d] pyrimidin-2-yl)methyl)acrylamide 449 743

N-((6-(2,6-dichloro-3,5-dimethoxyphenyl) thieno[2,3-d]pyrimidin-2-yl) methyl)acrylamide 424 744

N-((2-(2,6-dichloro-3,5-dimethoxyphenyl) thiazolo[5,4-d]pyrimidin-5- yl)methyl)acrylamide 425 745

N-((2-(2,6-dichloro-3,5-dimethoxyphenyl) thiazolo[4,5-c]pyridin-6-yl) methyl)acrylamide 424 746

N-((2-(2,6-dichloro-3,5-dimethoxyphenyl)- 4-oxo-4H-pyrano[2,3-c] pyridin-6-yl)methyl)acrylamide 435 747

N-((6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-oxo-8H-pyrano[3,2-d] pyrimidin-2-yl)methyl)acrylamide 436 748

N-((6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-oxo-5,8-dihydropyrido [3,2-d]pyrimidin-2-yl)methyl) acrylamide 435 749

N-((6-(2,6-dichloro-3,5-dimethoxyphenyl)- 8-((2-methoxyethyl)amino) pyrido[3,4-d]pyrimidin-2-yl) methyl)acrylamide 492 750

N-((8-((cyclopropylmethyl)amino)- 6-(2,6-dichloro-3,5-dimethoxyphenyl) pyrido[3,4-d]pyrimidin-2-yl) methyl)acrylamide 488 751

N-((7-(2,6-dichloro-3,5-dimethoxyphenyl)- 5-((2-methoxyethyl)amino)- 2,6-naphthyridin-3-yl)methyl) acrylamide 491

Biological Test and Evaluation

I. In Vitro Biochemical Kinase Analysis of FGFR4

FGFR4 Caliper Assay was used in the present invention to determine the inhibitory activities of the compounds against FGFR4. The detailed experimental procedure was as follows.

1. The kinase reaction in the present invention was carried out in a 384-well plate, and 12.5 μM of FGFR4, 65 μM of ATP and 1 μM of peptide (5 Fluo Ahx KKKKEEIYFFFG NH2) were respectively added into the following reaction system.

2. A reaction system is a mixture solution of 50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween 20, 0.02% BSA, 0.6% DMSO, 10 mM beta glycerol phosphate and 10 μM sodium orthovanadate and 16 mM MgCl₂.

3. The reaction system was incubated at 30° C. for 40 minutes.

4. The reaction was terminated by adding a stop solution (100 mM HEPES, pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA and 0.015% Brij35).

5. The culture plate with the terminated kinase reaction was transferred to the Caliper LC 3000 workstation to read the data, the phosphorylated and unphosphorylated peptides were separated by using the Caliper microfluid migration shift technique, and the analyte was transferred by allowing a constant buffer flow through the chip, the migration of the substrate peptide was monitored by the labeled fluorescent signal, and the kinase activity was calculated by using the amount of the phosphate-based peptide formed.

6. Finally, IC₅₀ values were determined by non-linear regression analysis of percent inhibition at different compound concentrations. The test results for the enzymatic activities of the compounds of the specific examples were shown in Table 1.

II. FGFR4 Cell Proliferation Experiment

Cell Titer Glo (CTG) experiment was used in the present invention to evaluate the functional effects of the compounds on cell proliferation. Huh7 hepatocellular carcinoma cells (Catalog No. TChU182) from the Chinese Academy of Sciences cell bank were cultured in DMEM with high glucose (Gibco, cat. No. 1773536), 10% fetal bovine serum (Gibco, 10099-141) at 37° C., in a 5% CO₂ incubator. Compound-mediated inhibition of cell proliferation/survival was assessed by quantification of cellular ATP levels using CTG reagent (Promega, #G7573). The specific experimental procedure was as follows:

1. The cells were seeded into a tissue culture medium-treated 96-well plate (Costar #3904) at 3500 cells/well/90 μL of fresh medium:

2. 10 μL of medium containing a compound concentration of 10 fold of its final test concentration was added;

3. The dose effect was evaluated by a 5-fold serial dilution of the test compound, starting from 10 μM.

4. After cells incubation for 3 days at 37° C. under 5% CO₂, the effect of the inhibitor on cell proliferation was quantified after adding 50 μL of CTG and testing with luminescence.

5. The concentration of the compound (EC₅₀) leading to half maximal growth inhibition and the concentration of compound (Absolute IC₅₀) leading to absolute half growth inhibition were determined using a four-parameter curve fit in Graphpad Prism in a plate reader (M1000, Tecan). The test results of cell activities for the compounds of specific examples were shown in Table 1.

TABLE 1 The results of enzymatic activity and cell activity tests Enzymatic Cell activity activity HuH-7 Example FGFR4 HuH-7 Absolute No. IC₅₀ (nM) EC₅₀ (nM) IC₅₀ (nM) ¹H-NMR Example 1 13.9 1527 2446 ¹H NMR (400 MHz, CDCl₃) δ 8.60 (s, 1H), 8.30 (d, J = 8.1 Hz, 1H), 7.31 (s, 1H), 7.10-7.05 (m, 2H), 6.68 (s, 1H), 6.52-6.48 (m, 1H), 6.44 (s, 1H), 6.39 (s, 1H), 6.33 (d, J = 1.4 Hz, 1H), 6.19 (d, J = 10.2 Hz, 1H), 5.68 (dd, J = 10.2, 1.4 Hz, 1H), 3.99 (s, 6H), 3.25 (s, 3H), 2.21 (s, 3H). Example 5 26.1 >10000 >10000 ¹H NMR (400 MHz, CDCl₃) δ 9.21 (s, 1H), 8.72 (s, 1H), 8.23 (s, 3H), 7.34 (t, J = 7.8 Hz, 1H), 7.12 (d, J = 7.7 Hz, 1H), 7.02 (s, 1H), 6.70 (s, 1H), 6.42-6.25 (m, 2H), 5.71 (d, J = 9.8 Hz, 1H), 3.97 (s, 6H), 2.25 (s, 3H). Example 7 28.9 >10000 >10000 ¹H NMR (400 MHz, CDCl₃) δ 8.53 (s, 1H), 8.13 (s, 1H), 7.92 (s, 1H), 7.32 (t, J = 8.0 Hz, 1H), 7.13 (d, J = 7.6 Hz, 1H), 6.94 (s, 1H), 6.75 (s, 1H), 6.67 (s, 1H), 6.54 (s, 1H), 6.39 (d, J = 16.7 Hz, 1H), 6.25-6.13 (m, 1H), 5.73 (d, J = 10.0 Hz, 1H), 3.96 (s, 6H), 2.22 (s, 3H). Example 9 138 89 1049 ¹H NMR (400 MHz, CDCl₃) δ 8.91 (s, 1H), 8.42 (s, 1H), 8.20 (s, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.20 (s, 1H), 7.12 (d, J = 7.6 Hz, 1H), 6.65 (s, 2H), 6.35 (d, J = 15.3 Hz, 2H), 6.16 (dd, J = 17.2, 9.9 Hz, 1H), 5.68 (d, J = 10.2 Hz, 1H), 3.97 (s, 9H), 2.23 (s, 3H). Example 105.3 3515 4817 ¹H NMR (400 MHz, CDCl₃) δ 9.16 (s, 1H), 8.38 (d, J = 8.2  10 Hz, 1H), 8.17 (s, 1H), 7.36 (t, J = 7.9 Hz, 1H), 7.13 (d, J = 7.7 Hz, 1H), 6.98 (s, 1H), 6.64 (s, 1H), 6.56 (s, 1H), 6.37 (d, J = 16.8 Hz, 1H), 6.20 (dd, J = 16.9, 10.2 Hz, 1H), 5.70 (d, J = 10.2 Hz, 1H), 4.07 (s, 3H), 3.96 (s, 6H), 2.25 (s, 3H). Example 100.7 4717 4717 ¹H NMR (400 MHz, CDCl₃) δ 8.76 (s, 1H), 8.27 (d, J = 8.2  11 Hz, 1H), 8.14 (s, 1H), 7.49 (s, 1H), 7.33 (t, J = 7.9 Hz, 1H), 7.11 (d, J = 7.6 Hz, 1H) 6.94 (s, 1H), 6.69 (s, 1H), 6.43- 6.34 (m, 1H), 6.26 (dd, J = 16.9, 10.1 Hz, 1H), 5.72 (dd, J = 10.1, 1.4 Hz, 1H), 3.98 (s, 6H), 3.51 (t, J = 6.4 Hz, 2H), 3.22 (s, 3H), 2.24 (s, 3H), 1.27 (d, J = 7.0 Hz, 2H). Example 43.8 3352 3352 ¹H NMR (400 MHz, CDCl₃) δ 8.38 (s, 1H), 8.02 (s, 1H),  12 7.57 (s, 1H), 7.33 (t, J = 7.9 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 6.64 (s, 1H), 6.41 (d, J = 16.6 Hz, 1H), 6.26 (dd, J = 16.6, 9.8 Hz, 1H), 6.07 (s, 1H), 5.74 (d, J = 9.8 Hz, 1H), 3.95 (s, 6H), 2.08 (s, 3H). Example 8.0 181.5 513.1 ¹H NMR (400 MHz, Methanol-d₄) δ 9.05 (s, 1H), 8.98  13 (s, 1H), 7.72 (s, 1H), 7.68-7.66 (d, J = 8.0 Hz, 1H), 7.32-7.24 (m, 2H), 6.91 (s, 1H), 6.47(s, 1H), 6.35-6.23 (m, 2H), 5.66-5.63 (dd, J = 8 Hz, 1H), 3.97(s, 6H), 2.30(s, 3H). Example 53.3 54.2 268.5 ¹H NMR (400 MHz, CDCl₃) δ 10.72 (s, 1H), 9.31-9.24  64 (m, 2H), 8.24 (s, 1H), 7.64 (s, 1H), 6.70 (s, 1H), 6.42- 6.33 (m, 2H), 5.75 (dd, J = 9.0, 2.6 Hz, 1H), 5.38-5.32 (m, 1H), 3.99 (s, 6H), 3.87 (s, 3H). Example 246.6 >10000 >10000 ¹H NMR (400 MHz, CDCl₃) δ 8.77 (s, 1H), 8.08 (s, 1H),  75 7.97 (s, 1H), 6.89 (s, 1H), 6.75 (s, 1H), 6.62 (s, 1H), 6.54- 6.50 (m, 1H), 6.28 (d, J = 16.6 Hz, 1H), 6.13-6.03 (m, 1H), 5.70-5.57 (m, 1H), 3.91 (s, 61H), 3.49-3.38 (m, 4H), 3.25 (s, 3H), 2.54-2.39 (m, 4H), 2.08 (s, 3H), 1.31 (s, 3H). Example 24.0 23.8 62.6 ¹H NMR (400 MHz, CDCl₃) δ 9.03 (s, 1H), 8.17 (s, 1H)  76 6.77 (s, 1H), 6.63 (s, 1H), 6.38 (d, J = 16.6 Hz, 2H), 6.33- 6.24 (m, 1H), 5.70 (d, J = 10.1 Hz, 1H), 3.95 (s, 6H), 3.87 (s, 3H), 3.53-3.36 (m, 2H), 1.19-1.10 (m, 1H), 0.55-0.41(m, 2H), 0.42-0.29 (m, 2H). Example 80.5 179.4 332.8 ¹H NMR (400 MHz, CDCl₃) δ 9.21 (s, 1H), 9.16 (s, 1H), 118 7.55 (s, 1H), 6.68 (s, 1H), 6.45 (d, J = 7.3 Hz, 1H), 6.27 (dd, J = 17.0, 1.4 Hz, 1H), 6.07 (dd, J = 16.9, 10.3 Hz, 1H), 5.63 (dd, J = 10.2, 1.4 Hz, 1H), 4.94 (dd, J = 11.6, 4.9 Hz, 1H), 4.90-4.79 (m, 1H), 4.34-4.19 (m, 2H), 3.98 (s, 6H), 3.90-3.79 (m, 2H). Example 166.0 78.1 457.1 ¹H NMR (400 MHz, CDCl₃) δ 9.17 (s, 2H), 7.56 (s, 1H), 119 6.68 (s, 1H), 6.25 (dd, J = 16.9, 1.4 Hz, 1H), 6.01 (dd, J = 17.0, 10.3 Hz, 1H), 5.60 (dd, J = 10.3, 1.4 Hz, 1H), 4.55 (s, 1H), 4.35 (s, 1H), 4.11-4.00 (m, 2H), 3.98 (s, 6H), 3.78 (d, J = 12.1 Hz, 1H), 3.64 (dd, J = 3.4, 10.9 Hz, 1H), 2.24-2.20 (m, 2H), 2.02-1.99 (m, 2H). Example 303.0 155.6 754.2 1H NMR (400 MHz, CDCl₃) δ 9.20 (s, 1H), 9.14 (s, 1H), 120 7.71 (s, 1H), 6.73 (t, J = 8.0 Hz, 1H), 6.46 (d, J = 7.0 Hz, 1H), 6.26 (d, J = 16.9 Hz, 2H), 6.04 (dd, J = 17.0, 10.3 Hz, 1H), 5.62 (d, J = 10.2 Hz, 1H), 4.93 (d, J = 6.0 Hz, 1H), 4.86 (t, J = 6.2 Hz, 1H), 4.28 (ddd, J = 18.7, 9.4, 6.2 Hz, 2H), 3.93 (s, 6H), 3.85 (ddd, J = 15.4, 9.5, 4.9 Hz, 2H). Example 182.6 171.9 401.4 ¹H NMR (400 MHz, CDCl₃) δ 9.20 (d, J = 9.2 Hz, 2H), 121 7.94 (s, 1H), 6.82 (d, J = 2.8 Hz, 1H), 6.60 (d = 2.7 Hz, 1H), 6.48-6.43 (m, 1H), 6.24 (t, J = 1.9 Hz, 1H), 6.18 (dd, J = 17.3, 10.4 Hz, 1H), 6.12-6.04 (m, 1H), 5.63 (dt, J = 10.3, 1.6 Hz, 1H), 4.97-4.85 (m, 3H), 4.28 (ddd, J = 20.2, 9.5, 6.3 Hz, 3H), 3.98 (s, 3H), 3.94 (s, 3H). Example 61.6 302.7 556 ¹H NMR (400 MHz, DMSO-d₆) δ 9.12 (s, 1H), 9.02 (s, 124 1H), 8.11-8.09 (d, J = 8.0 Hz, 1H), 7.67 (s, 1H), 7.03 (s, 1H), 6.92 (s, 1H), 6.70-6.68 (dd, J = 8 Hz, 1H), 6.23-6.16 (dd, J = 16 Hz, 1H), 6.01-5.97 (dd, J = 16 Hz, 1H), 5.52-5.48 (dd, J = 16 Hz, 1H), 4.75-4.68 (m, 1H), 4.59-4.52 (m, 1H), 4.15-4.11 (m, 1H), 4.06-4.03 (m, 1H), 3.98 (s, 6H), 3.74-3.67 (m, 2H). Example 22.0 31.5 53.7 ¹H NMR (400 MHz, CDCl₃) δ 8.68(s, 1H), 6.82 (s, 1H), 126 6.76 (s, 1H), 6.62(s, 1H), 6.44 (s, 1H), 6.22-6.18 (dd, J = 16 Hz, 1H), 6.00-5.94 (dd, J = 16 Hz, 1H), 5.55-5.52(dd, J = 8 Hz, 1H), 4.92-4.85 (m, 1H), 4.56-4.50 (m, 1H), 4.30-4.21 (m, 2H), 3.98 (s, 6H), 3.87-3.84 (dd, J = 12 Hz, 1H), 3.77-3.74 (dd, J = 12 Hz, 1H), 4.42-4.39 (m, 2H), 1.23-1.19 (m, 1H), 0.59-0.53 (m, 2H), 0.33-0.29 (m, 2H), Example 12.4 5.4 10.0 ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 6.80 (brs, 1H), 421 6.68 (s, 1H), 6.62 (s, 1H), 6.38 (brs, 1H), 6.21 (dd, J = 17.0, 1.5 Hz, 1H), 6.02 (dd, J = 17.0, 10.2 Hz, 1H),, 5.56 (dd, J = 10.1, 1.5 Hz, 1H), 4.93-4.83 (m, 2H), 4.30- 4.18(m, 2H), 3.96 (s, 6H), 3.90 (dd, J = 9.7, 3.2 Hz, 1H), 3.79 (dd, J = 9.2, 5.2 Hz, 1H), 3.52-3.37 (m, 2H), 0.88 (t, J = 6.0 Hz, 1H), 0.57-0.48 (m, 2H), 0.36-0.26 (m, 2H). Example 22.5 47.0 238.5 ¹H NMR (400 MHz, CDCl₃) δ 8.92 (s, 1H), 6.74 (s, 1H), 422 6.67 (s, 2H), 6.22 (d, J = 15.4 Hz, 1H), 5.56 (d, J = 10.4 Hz, 1H), 4.89 (s, 2H), 4.29-4.17 (m, 2H), 3.98 (s, 6H), 3.96-3.80 (m, 4H), 3.76-3.65 (m, 2H), 3.35 (s, 3H). Example 31.7 98.0 347.6 ¹H NMR (400 MHz, CDCl₃) δ 9.13 (s, 1H), 7.17 (s, 1H), 423 6.75 (s, 1H), 6.66 (s, 1H), 6.26 4 J = 16.9 Hz, 1H), 6.12 (dd, J = 17.0, 10.2 Hz, 1H), 5.61 (d, J = 10.2 Hz, 1H), 5.03- 4.93 (m, 1H), 4.93-4.85 (m, 1H), 4.31-4.20 (m, 2H), 4.14 (s, 3H), 3.98 (s, 6H), 3.88 (dd, J = 9.8, 4.0 Hz, 1H), 3.82 (dd, J = 9.3, 6.5 Hz, 1H). Example 11.0 18.5 37.2 ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 6.85 (s, 1H), 424 6.82 (t, J = 8.0 Hz, 1H), 6.15 (dd, J = 17.1, 2.5 Hz, 1H), 6.12-6.02 (m, 1H), 5.53 (dd, J = 9.5, 2.5 Hz, 1H), 4.99 (td, J = 6.3, 4.8 Hz, 1H), 4.87 (q, J = 6.5 Hz, 1H), 4.27 (dd, J = 9.4, 6.3 Hz, 1H), 4.16 (dd, J = 9.0, 6.9 Hz, 1H), 3.92 (m, 7H), 3.80 (dd, J = 9.0, 6.5 Hz, 1H), 3.45 (dd, J = 13.7, 7.0 Hz, 1H), 3.37 (d, J = 6.8 Hz, 1H), 1.33-1.24 (m, 1H), 0.55-0.41 (m, 2H), 0.42-0.29 (m, 2H). Example 7.7 NT NT ¹H NMR (400 MHz, CDCl₃) δ 8.93 (s, 1H), 6.68 (s, 1H), 425 6.61 (s, 1H), 6.22 (d, J = 16.6 Hz, 2H), 6.00 (dd, J = 16.9, 10.2 Hz, 1H), 5.89 (s 1H), 5.57 (d, J = 10.2 Hz, 1H), 4.89 (s, 2H), 4.30-4.20 (m, 2H), 3.90 (d, J = 9.8 Hz, 1H), 3.82- 3.72 (m, 1H), 3.42 (s, 2H), 1.26-1.21 (m, 1H), 0.58- 0.47 (m, 2H), 0.36-0.27 (m, 2H). Example 22.4 63.2 184.5 ¹H NMR (400 MHz, CDCl₃) δ 8.90 (s, 1H), 7.06 (s, 1H), 429 6.78 (s, 1H), 6.64 (s, 1H), 6.18 (d, J = 17.0 Hz, 1H), 6.11 (d, J = 7.2 Hz, 1H), 5.98 (dd, J = 17.0, 10.2 Hz, 1H), 5.81 (s, 1H), 5.56 (d, J = 10.3 Hz, 1H), 4.94-4.83 (m, 2H), 4.27 (dd, J = 9.6, 5.8 Hz, 1H), 4.20 (dd, J = 9.4, 6.1 Hz, 1H), 4.10 (s, 2H), 3.97 (s, 6H), 3.87 (dd, J = 9.6, 3.9 Hz, 1H), 3.81 (dd, J = 9.5, 5.0 Hz, 1H), 3.49-3.38 (m, 2H), 3.01 (q, J = 7.5 Hz, 2H), 1.27 (t, J = 7.4 Hz, 3H). Example 19.1 32.0 93.5 ¹H NMR (400 MHz, CDCl₃) δ 8.60 (s, 1H), 7.24 (s, 1H), 430 6.81 (brs, 1H), 6.63 (s, 1H), 6.57 (s, 1H), 6.26 (brs, 1H), 6.16-6.03 (m, 2H), 5.53 (d, J = 9.6 Hz 1H), 5.08 (s, 1H), 4.88 (s, 1H), 4.26-4.12 (m, 2H), 3.96 (d, J = 6.0 Hz, 6H), 3.93-3.88 (m, 2H), 3.81 (d, J = 10.1 Hz, 2H), 3.60 (d, J = 11.3 Hz, 2H), 3.42 (s, 1H), 2.94 (s, 3H). Example 519.1 NT NT ¹H NMR (400 MHz, CDCl₃) δ 12.21 (s, 1H), 8.90 (s, 1H), 431 7.72 (s, 1H), 7.52 (s, 1H), 6.78 (s, 1H), 6.67 (s, 1H), 6.22- 6.12 (m, 2H), 5.53 (d, J = 9.9 Hz, 1H), 5.00-4.88 (m, 2H), 4.33-4.27 (m, 2H), 4.26-4.19(m, 2H), 3.97 (s, 6H), 3.94-3.87 (m, 2H), 3.49 (s, 2H), 2.87 (s, 6H). Example 105.8 395.8 934.2 ¹H NMR (400 MHz, CDCl₃) δ8.66 (s, 1H), 6.99 (s, 1H), 432 6.91 (s, 1H), 6.63 (s, 1H), 6.59 (s, 1H), 6.33 (d, J = 6.4 Hz, 1H), 6.18 (d, J = 5.9 Hz, 2H), 5.59-5.49 (m, 1H), 4.99 (s, 2H), 4.30-4.23(m, 2H), 3.97 (s, 6H), 3.92-3.87 (m, 1H), 3.77-3.71 (m, 1H), 3.25 (s, 2H), 2.77 (s, 6H), 2.25 (s, 2H), 1.70 (s, 2H). Example 7.6 19.3 26.1 ¹H NMR (400 MHz, CDCl₃) δ 8.88 (s, 1H), 6.67 (s, 1H), 433 6.62 (s, 1H), 6.30 (brs, 1H), 6.19 (d, J = 16.9 Hz, 1H), 5.97 (dd, J = 17.0, 10.3 Hz, 1H), 5.88 (brs, 1H), 5.54 (d, J = 10.4 Hz, 1H), 4.95-4.83 (m, 2H), 4.29-4.18 (m, 2H), 3.95 (s, 614), 3.89 (dd, J = 9.7, 3.0 Hz, 1H), 3.77 (dd, J = 9.3, 5.5 Hz, 1H), 3.14 (d, J = 4.4 Hz, 3H). Example 8.4 9.6 18.2 ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 6.67 (s, 1H), 434 6.62 (s, 1H), 6.51 (s, 1H), 6.27-6.15 (m, 2H), 5.97 (dd, J = 16.9, 10.3 Hz, 1H), 5.79 (s, 1H), 5.56 (dd, J = 10.3, 1.4 Hz, 1H), 4.97-4.82 (m, 2H), 4.29-4.18 (M, 2H), 3.96 (s, 6H), 3.89 (dd, J = 9.6, 3.2 Hz, 1H), 3.76 (dd, J = 9.2, 5.5 Hz, 1H), 3.65-3.50 (m, 2H), 1.32 (t, J = 7.2 Hz, 3H). Example 67.0 80 148.5 ¹H NMR (400 MHz, CDCl₃) δ 8.96 (s, 1H), 6.85 (s, 1H), 435 6.79 (s, 1H), 6.64 (s, 1H), 6.19 (d, J = 16.9 Hz, 1H), 6.13 (s, 1H), 6.06 (s, 1H), 5.98 (dd, J = 17.0, 10.3 Hz, 1H), 5.56 (d, J = 10.2 Hz, 1H), 4.93 (dd, J = 11.7, 4.8 Hz, 2H), 4.51- 4.37 (m, 1H), 4.30-4.17 (m, 3H), 3.97 (s, 6H), 3.90 (dd, J = 9.7, 2.8 Hz, 1H), 3.78 (dd, J = 9.4, 5.0 Hz, 1H). Example >10000 NT NT ¹H NMR (400 MHz, CDCl₃) δ 9.33 (s, 1H), 6.59 (s, 1H), 436 6.56 (s, 1H), 6.45 (s, 1H), 6.22 (s, 1H), 6.14-6.00 (m, 1H), 5.62 (d, J = 10.2 Hz, 1H), 4.86 (s, 2H), 4.24 (s, 2H), 3.98-3.94 (m, 2H), 3.83 (s, 6H), 3.38 (s, 6H). Example 3.5 9.9 17.8 ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 6.84 (brs, 1H), 438A 6.70 (s, 1H), 6.63 (s, 1H), 6.42 (brs, 1H), 6.22 (dd, J = 17.0, 1.5 Hz, 1H), 6.11-6.01 (m, 1H), 5.85 (s, 1H), 5.57 (dd, J = 10.1, 1.5 Hz, 1H), 4.93-4.81 (m, 2H), 4.30-4.16 (m, 3H), 3.96 (s, 6H), 3.92-3.82 (m, 3H), 3.82-3.74 (m, 2H), 3.58-3.45 (m, 1H), 1.95-1.85 (m, 2H), 1.70-1.64 (m, 2H). Example 9.1 15.8 35.1 ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 6.74 (s, 1H), 438B 6.69 (s, 1H), 6.62 (s, 1H), 6.25 (dd, J = 16.9, 1.4 Hz, 1H), 6.20 (s, 1H), 6.03 (dd, J = 16.9, 10.3 Hz, 1H), 5.81 (s, 1H), 5.61 (d, J = 10.4 Hz, 1H), 4.93-4.81 (m, 2H), 4.31-4.16 (m, 3H), 3.96 (s, 6H), 3.93-3.84 (m, 2H), 3.82-3.72 (m, 3H), 3.59 (dd, J = 13.3, 6.7 Hz, 1H), 1.91-1.85 (m, 2H), 1.70-1.63 (m, 2H). Example 4.6 NT NT ¹H NMR (400 MHz, CDCl₃) δ 8.88 (s, 1H), 6.72 (brs, 1H), 439 6.69 (s, 1H), 6.63 (s, 1H), 6.35 (brs, 1H), 6.19 (d, J = 17.1 Hz, 1H), 6.00 (dd, J = 17.0, 10.2 Hz, 1H), 5.89 (s, 1H), 5.55 (dd, J = 10.3, 1.5 Hz, 1H), 4.96-4.82 (m, 2H), 4.31- 4.17 (m, 2H), 3.96 (s, 6H), 3.93-3.82 (m, 2H), 3.81- 3.71 (m, 2H), 3.66 (dd, J = 8.9, 5.3 Hz, 1H), 3.63-3.51 (m, 2H), 2.82-2.69 (m, 1H), 2.13-2.00 (m, 1H), 1.77- 1.72 (m, 1H). Example 8.2 15.9 70.8 ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 6.73 (s, 1H), 443 6.63 (s, 1H), 6.24-6.16 (m, 1H), 6.13 (brs, 1H), 5.96 (dd, J = 17.2, 10.3 Hz, 1H), 5.79 (brs, 1H), 5.59-5.51 (m, 1H), 4.95-4.84 (m, 2H), 4.71 (s, 1H), 4.30-4.15 (m, 2H), 4.13-4.04 (m, 1H), 4.05-3.98 (m, 1H), 3.97 (s, 6H), 3.92-3.82 (m, 3H), 3.76 (dd, J = 9.3, 5.7 Hz, 1H), 2.45- 2.31 (m, 1H), 2.18-2.05 (m, 1H). Example 7.0 NT NT ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 6.70 (s, 1H), 444 6.63 (s, 1H), 6.42-6.33 (m, 1H), 6.20 (dd, J = 17.0, 1.4 Hz, 1H), 6.17-6.13 (m, 1H), 5.97 (dd, J = 17.0, 10.3 Hz, 1H), 5.75 (d, J = 6.5 Hz, 1H), 5.57 (dd, J = 10.4, 1.4 Hz, 1H), 4.95-4.82 (m, 2H), 4.29-4.18 (m, 3H), 4.03-3.98 (m, 2H), 3.97 (s, 6H), 3.89 (dd, J = 9.6, 3.6 Hz, 1H), 3.76 (dd, J = 9.3, 5.8 Hz, 1H), 3.58-3.48 (m, 2H), 2.24-2.10 (m, 2H), 1.73-1.64 (m, 2H). Example 42.2 20.3 53.3 ¹H NMR (400 MHz, CDCl₃) δ 8.92 (s, 1H), 6.88 (brs, 1H), 452 6.77 (s, 1H), 6.64 (s, 1H), 6.17 (d, J = 16.8 Hz, 1H), 5.95 (m, 2H), 5.55 (d, J = 10.2 Hz, 1H), 5.02-4.94 (m, 1H), 4.90 (s, 1H), 4.46 (s, 1H), 4.31-4.18 (m, 2H), 3.97 (s, 6H), 3.91 (d, J = 10.8 Hz, 1H), 3.73 (t, J = 8.1 Hz, 1H), 3.11 (s, 2H), 2.80 (s, 1H), 2.69 (s, 1H). Example 66.9 40.8 89.2 ¹H NMR (400 MHz, CDCl₃) δ 8.88 (s, 1H), 6.67 (s, 1H), 454 6.63 (s, 1H), 6.21 (d, J = 17.0 Hz, 1H), 6.09-5.97 (m, 1H), 5.57 (d, J = 10.2 Hz, 1H), 4.89-4.81 (m, 2H), 4.27- 4.20 (m, 2H), 3.96 (s, 6H), 3.92-3.90 (m, 1H), 3.81- 3.77 (m, 1H), 3.59-3.48 (m, 2H), 2.30 (dd, J = 15.2, 7.9 Hz, 1H), 1.83-1.76 (m, 2H), 1.59 (brd, J = 31.7 Hz, 4H), 1.28 (brs, 3H). Example 82.4 163 299 ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 7.47-7.11 456 (m, 6H), 6.70 (s, 1H), 6.63 (s, 1H), 6.22 (d, J = 17.1 Hz, 2H), 6.09-5.75 (m, 2H), 5.58 (d, J = 10.3 Hz, 1H), 4.89- 4.60 (m, 2H), 4.22-4.15 (m, 2H), 3.96 (s, 6H), 3.83-3.75 (m, 3H), 3.03 (q, J = 6.8 Hz, 2H). Example 17.3 23.8 58.0 ¹H NMR (400 MHz, DMSO-d₆) δ 9.02 (s, 1H), 7.58 (s, 459 1H), 7.38 (s, 1H), 6.98 (s, 1H), 6.71 (s, 1H), 6.14 (dd, J = 17.1, 10.2 Hz, 1H), 5.94 (dd, J = 17.2, 2.2 Hz, 1H), 5.47 (dd, J = 10.4, 2.0 Hz, 1H), 4.86 (s, 1H), 4.67 (q, J = 6.1 Hz, 1H), 4.39 (td, J = 14.6, 13.6, 5.3 Hz, 2H), 4.12 (t, J = 7.9 Hz, 1H), 4.02 (dd, J = 8.8, 6.5 Hz, 1H), 3.97 (s, 6H), 3.81-3.68 (m, 4H), 3.66 (dd, J = 8.8, 5.9 Hz, 1H), 3.33 (s, 3H). Example 14.5 24.6 38.3 ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 6.66 (s, 1H), 462 6.64 (s, 1H), 6.62 (s, 1H), 6.30 (s, 1H), 6.23 (dd, J = 16.9, 1.4 Hz, 1H), 6.01 (dd, J = 16.9, 10.3 Hz, 1H), 5.84 (s, 1H), 5.59 (dd, J = 10.3, 1.4 Hz, 1H), 4.93-4.77 (m, 2H), 4.29- 4.19 (m, 2H), 3.96 (s, 6H), 3.91 (dd, J = 9.5, 4.0 Hz, 1H), 3.79 (dd, J = 9.3, 5.5 Hz, 1H), 3.51 (dd, J = 13.1, 6.5 Hz, 1H), 3.36 (dd, J = 13.2, 5.9 Hz, 1H), 0.99 (s, 9H). Example 46.4 NT NT ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 6.67 (s, 1H), 465 6.62 (s, 1H), 6.18 (d, J = 17.1 Hz, 1H), 6.06 (d, J = 10.1 Hz, 1H), 5.86 (s, 1H), 5.54 (d, J = 10.1 Hz, 1H), 4.96- 4.83(m, 2H), 4.30-4.19 (m, 2H), 3.96 (s, 6H), 3.89 (dd, J = 9.6, 3.7 Hz, 1H), 3.81 (dd, J = 9.2, 5.6 Hz, 1H), 3.59 (s, 2H), 2.76 (s, 2H), 2.53 (s, 6H), 1.26 (s, 4H). Example 62.0 131.9 677.8 ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 7.03 (s, 1H), 475 6.83 (d, J = 2.8 Hz, 1H), 6.54 (d, J = 2.8 Hz, 1H), 6.30 (s, 1H), 6.22 (dd, J = 16.8, 1.4 Hz, 1H), 6.00 (dd, J = 16.9, 10.3 Hz, 1H), 5.82 (s, 1H), 5.61-5.53 (m, 1H), 4.88 (q, J = 6.5, 6.0 Hz, 2H), 4.33-4.18 (m, 2H), 3.92 (s, 3H), 3.89 (s, 1H), 3.84 (s, 3H), 3.81-3.73 (m, 1H), 3.58-3.40 (m, 2H), 1.26 (s, 1H), 0.66-0.46 (m, 2H), 0.42-0.24 (m, 2H). Example 8797 2393 >10000 ¹H NMR (400 MHz, CDCl₃) δ 9.18 (s, 1H), 7.71 (d, J = 4.2 498 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 6.93 (s, 1H), 6.67 (s, 1H), 6.17 (d, J = 16.9 Hz, 1H), 6.06 (d, J = 11.2 Hz, 1H), 5.55 (d, J = 10.1 Hz, 1H), 4.95 (s, 1H), 4.63 (s, 1H), 4.39 (s, 2H), 4.31 (t, J = 6.7 Hz, 1H), 4.24 (s, 2H), 3.98 (s, 6H), 3.92 (s, 1H), 0.88 (t, J = 7.0 Hz, 1H), 0.76-0.65 (m, 2H), 0.47 (s, 2H). Example 15.7 17.8 49.9 ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 6.68 (s, 1H), 501 6.64 (s, 1H), 6.17 (d, J = 16.7 Hz, 1H), 5.96 (d, J = 12.1 Hz, 1H), 5.55 (d, J = 10.5 Hz, 1H), 4.75-4.60 (m, 1H), 4.40-4.25 (m, 1H), 4.10-4.02 (m, 1H), 4.01-3.90 (m, 3H), 3.96 (s, 6H), 3.77 (d, J = 11.9 Hz, 1H), 3.62 (t, J = 12.2 Hz, 2H), 1.98-1.86 (m, 2H), 0.88 (s, 1H), 0.55 (s, 2H), 0.35 (s, 2H). Example 29 75.2 115.9 ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 6.67 (s, 1H), 510 6.62 (s, 1H), 6.48 (s, 1H), 6.20 (dd, J = 16.9, 1.4 Hz, 2H), 6.05 (d, J = 8.5 Hz, 1H), 5.91 (dd, J = 16.9, 10.3 Hz, 1H), 5.54 (d, J = 10.4, 1.4 Hz, 1H), 4.70 (d, J = 8.7 Hz, 1H), 4.38-4.27 (m, 1H), 4.12-4.05 (m, 1H), 3.99 (d, J = 11.2 Hz, 1H), 3.96 (s, 6H), 3.75 (dd, J = 12.0, 1.7 Hz, 1H), 3.65- 3.57 (m, 1H), 3.09 (d, J = 5.0 Hz, 3H), 1.97-1.86 (m, 2H). Example 23.4 25.7 41.1 ¹H NMR (400 MHz, CDCl₃) δ 9.18 (s, 1H), 7.44 (s, 1H), 606 6.67 (s, 1H), 6.30-6.24 (m, 1H), 6.17-6.08 (m, 1H), 5.63 (d, J = 10.7 Hz, 1H), 4.93 (s, 2H), 4.35-4.30 (m 1H), 4.25 (dd, J = 9.4, 6.1 Hz, 1H), 3.97 (s, 6H), 3.92 (dd, J = 9.6, 3.1 Hz, 1H), 3.87-3.82 (m, 1H), 2.98 (s, 3H). Example NT 36.6 56.1 ¹H NMR (400 MHz, CDCl₃) δ 9.07 (s, 1H), 6.64 (s, 1H), 609 6.55 (s, 1H), 6.25 (d, J = 16.8 Hz, 1H), 6.05 (dd, J = 16.9, 10.3 Hz, 1H), 5.86 (brs, 1H), 5.62 (dd, J = 10.3, 1.4 Hz, 1H), 4.90-4.87 (m, 2H), 4.82-4.78 (m, 1H), 4.31 (td, J = 10.3, 6.2 Hz, 2H), 3.97 (s, 6H), 3.95-3.68 (m, 2H), 3.28-3.24 (m, 1H), 1.27-1.21 (m, 2H), 1.10 (dd, J = 8.3, 3.0 Hz, 2H). Example 2.9 2.6 4.0 ¹H NMR (400 MHz, CDCl₃) δ 9.10 (s, 1H), 8.53 (s, 1H), 629 8.49 (s, 1H), 7.37 (s, 1H), 6.68 (s, 1H), 6.43 (d, J = 6.2 Hz, 1H), 6.20 (d, J = 16.9 Hz, 1H), 6.09 (s, 1H), 5.98 (dd, J = 17.0, 10.2 Hz, 1H), 5.57 (d, J = 10.3 Hz, 1H), 4.97-4.90 (m, 2H), 4.33-4.23 (m, 2H), 3.98 (s, 9H), 3.94 (dd, J = 9.8, 3.2 Hz, 1H), 3.82 (dd, J = 9.5, 4.8 Hz, 1H). Example 4.2 10.1 17.3 ¹H NMR (400 MHz, Methanol-d₄) δ 9.03 (s, 1H), 8.56 (s, 637 1H), 8.40 (s, 1H), 7.49 (s, 1H), 6.74 (t, J = 8.0 Hz, 1H), 6.03 (d, J = 5.9 Hz, 2H), 5.46 (t, J = 5.9 Hz, 1H), 4,87 (s, 2H), 4.20 (4, J = 7.8 Hz, 1H), 4.12 (dd, J = 9.1, 6.6 Hz, 1H), 3.93 (s, 3H), 3.86 (s, 6H), 3.83 (d, J = 4.0 Hz, 1H), 3.74 (dd, J = 9.2, 5.4 Hz, 1H). Example 8.0 28.0 68.4 ¹H NMR (400 MHz, CDCl₃) δ 8.88 (s, 1H), 6.74 (s, 1H), 655 6.70 (s, 1H), 6.62 (s, 1H), 6.19 (dd, J = 16.9, 1.4 Hz 2H), 5.95 (dd, J = 16.9, 10.3 Hz, 1H), 5.79 (s, 1H), 5.55 (dd, J = 10.3, 1.4 Hz, 1H), 4.93-4.81 (m, 2H), 4.29-4.17 (m, 2H), 3.96 (s, 6H), 3.88 (dd, J = 9.7, 3.3 Hz, 1H), 3.75 (dd, J = 9.2, 5.9 Hz, 1H), 3.01-2.84 (m, 1H), 0.87-0.79 (m, 2H), 0.76-0.69 (m, 1H), 0.68-0.58 (m, 1H). Example 6.5 9.6 13.3 ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 6.69 (s, 1H), 657 6.62 (s, 1H), 6.26 (dd-J = 16.8, 1.3 Hz, 2H), 6.06 (dd, J = 17.0, 10.3 Hz, 1H), 5.70-5.60 (n, 2H), 4.80-4.70 (m, 31-1), 4.60-4.45 (m, 3H), 4.29-4.15 (m, 2H), 3.95 (s, 6H), 3.87-3.73 (m, 2H), 2.42 (q, J = 7.6 Hz, 2H). Example 4.8 11.4 15.1 ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 6.73 (s, 1H), 658 6.63 (s, 1H), 6.24 (d, J = 16.8 Hz, 1H), 6.13 (d, J = 10.9 Hz, 1H), 5.61 (d, J = 10.1 Hz, 1H), 4.84-4.57 (m, 4H), 4.54-4.07 (m, 5H), 3.95 (s, 6H), 3.89-3.72 (m, 2H), 3.30 (s, 3H). Example 6.6 18.0 24.3 ¹H NMR (400 MHz, CDCl₃) δ 8.90 (s, 1H), 6.93 (s, 1H), 659 6.68 (t, J = 7.9 Hz, 1H), 6.34 (brs, 1H), 6.24 (dd, J = 16.8, 1.4 Hz, 1H), 6.05 (dd, J = 16.9, 10.3 Hz, 1H), 5.74 (brs, 1H), 5.62 (dd, J = 10.2, 1.4 Hz, 1H), 4.88-4.61 (m, 4H), 4.45-4.37 (m, 3H), 4.28-4.15 (m, 2H), 3.91 (s, 6H), 3.84 (dd, J = 9.5, 3.6 Hz, 1H), 3.77 (dd, J = 9.5, 5.1 Hz, 1H), 3.33 (s, 3H). Example 4.5 2.3 3.5 ¹H NMR (400 MHz, CDCl₃) δ 8.95 (s, 1H), 6.88 (s, 1H), 663 6.64 (s, 1H), 6.25 (d, J = 16.9 Hz, 2H), 6.06 (dd, J = 17.0, 10.3 Hz, 1H), 5.93 (s, 1H), 5.63 (d, J = 10.3 Hz, 1H), 4.88- 4.77 (m, 6H), 4.22 (dd, J = 9.5, 6.2 Hz, 2H), 3.96 (s, 6H), 3.82 (ddd, J = 17.2, 9.6, 5.0 Hz, 2H). Example 4.9 3.7 4.9 ¹H NMR (400 MHz, DMSO-d₆) δ 9.04 (s, 1H), 8.06 (d, J = 664 8.1 Hz, 1H), 7.23 (brs, 1H), 6.97 (s, 1H), 6.77 (s, 1H), 6.23 (dd, J = 17.1, 10.2 Hz, 1H), 6.02 (dd, J = 17.1, 2.1 Hz, 1H), 5.57 (d, J = 10.7 Hz, 1H), 5.55 (s, 1H), 4.74-4.58 (m, 2H), 4.21 (brs, 4H), 4.12-4.01 (m, 2H), 3.95 (s, 6H), 3.78- 3.66 (m, 2H), 1.46 (s, 3H). Example 5.7 9.9 11.8 ¹H NMR (400 MHz, DMSO-d₆) δ 9.06 (s, 1H), 8.06 (d, J = 665 8.3 Hz, 1H), 7.28 (s, 1H), 6.97 (s, 1H), 6.81 (s, 1H), 6.21 (dd, J = 17.1, 10.2 Hz, 1H), 6.00 (dd, J = 17.1, 2.2 Hz, 1H), 5.54 (dd, J = 10.1, 2.2 Hz, 1H), 4.76-4.60 (m, 2H), 4.17 (br s, 4H), 4.09 (d, J = 7.4 Hz, 1H), 4.05-4.00 (m, 1H), 3.95 (s, 6H), 3.75 (dd, J = 8.7, 5.9 Hz, 1H), 3.67 (dd, J = 9.0, 5.2 Hz, 1H), 3.21 (s, 3H), 1.49 (s, 3H). Example 4.5 3.2 4.6 ¹H NMR (400 MHz, CDCl₃) δ 8.90 (s, 1H), 6.93 (s, 1H), 666 6.68 (t, J = 7.9 Hz, 1H), 6.37 (s, 1H), 6.24 (d, J = 16.9 Hz, 1H), 6.04 (dd, J = 17.0, 10.3 Hz, 1H), 5.78 (s, 1H), 5.61 (d, J = 10.3 Hz, 1H), 4.84-4.73 (m, 2H), 4.56-4.41 (m, 2H), 4.41-4.26 (m, 2H), 4.26-4.17 (m, 2H), 3.91 (s, 6H), 3.85 (dd, J = 9.6, 3.5 Hz, 1H), 3.76 (dd, J = 9.4, 5.1 Hz, 1H), 3.30 (s, 3H), 1.56 (s, 3H). Example 14.7 16 22.6 ¹H NMR (400 MHz, CDCl₃) δ 8.82 (s, 1H), 6.70 (s, 1H), 668 6.66 (s, 1H), 6.56 (s, 1H), 6.16 (d, J = 17.0 Hz, 1H), 6.01 (dd, J = 17.1, 10.2 Hz, 1H), 5.53 (d, J = 10.0 Hz, 1H), 4.80-4.55(m, 8H), 4.18-4.15 (m, 2H), 3.88 (s, 6H), 3.84- 3.70 (m, 4H). Example 11.0 6.2 8.7 ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 6.71 (s, 1H), 675 6.63 (s, 1H), 6.38 (brs, 1H), 6.24 (d, J = 16.9 Hz, 1H), 6.05 (dd, J = 16.9, 10.2 Hz, 1H), 5.78 (brs, 1H), 5.61 (dd, J = 10.2, 1.3 Hz, 1H), 4.87-4.75 (m, 2H), 4.42-4.15 (m, 6H), 3.95 (s, 6H), 3.86 (dd, J = 9.5, 3.9 Hz, 1H), 3.78 (dd, J = 9.4, 5.4 Hz, 1H), 3.72-3.60 (m, 4H), 1.86 (t, J = 5.2 Hz, 4H). Example 7.4 3.7 5.3 ¹H NMR (400 MHz, CDCl₃) δ 8.80 (s, 1H), 6.63 (s, 1H), 677 6.54 (s, 1H), 6.41 (brs, 1H), 6.21 (d, J = 17.0 Hz, 1H), 5.99 (dd, J = 16.6, 10.2 Hz, 1H), 5.71 (brs, 1H), 5.53 (dd, J = 10.3, 3.5 Hz, 1H), 4.85-4.70 (m, 2H), 4.28-3.96 (m, 7H), 3.88 (s, 6H), 3.90-3.82 (m, 1H), 3.80-3.72 (m, 1H), 3.29 (d, J = 2.8 Hz, 3H), 2.07-1.94 (m, 2H). Example 6.5 13.3 16.5 ¹H NMR (400 MHz, CDCl₃) δ 8.92 (s, 1H), 6.94 (s, 1H), 678 6.56 (s, 1H), 6.50 (d, J = 7.4 Hz, 1H), 6.18 (d, J = 16.9 Hz, 1H) 5.98 (dd, J = 16.9, 10.3 Hz, 2H), 5.54 (d, J = 9.7 Hz, 1H), 4.82-4.69 (m, 2H), 4.74-4.64 (m, 2H), 4.19-4.12 (m, 2H), 3.89 (s, 6H), 3.87-3.76 (m, 7H), 3.76-3.67 (m, 1H), 2.20-2.10 (m, 1H), 2.08-1.95 (m, 1H). Example 8.2 5.4 8.8 ¹H NMR (400 MHz, CDCl₃) δ 8.92 (s, 1H), 6.94 (s, 1H), 686 6.56 (s, 1H), 6.50 (d, J = 7.4 Hz, 1H), 6.18 (d, J = 16.9 Hz, 1H), 5.98 (dd, J = 16.9, 10.3 Hz, 1H), 5.54 (d, J = 10.2 Hz, 1H), 4.81-4.73 (m, 1H), 4.70-4.67 (m, 1H), 4.20-4.12 (m, 2H), 3.89 (s, 6H), 3.88-3.67 (m, 10H), Example 6.3 6.9 10.0 ¹H NMR (400 MHz, CDCl₃) δ 9.03 (s, 1H), 7.25 (s, 1H), 687 6.70 (t, J = 7.9 Hz, 1H), 6.47 (brs, 1H), 6.25 (d, J = 16.9 Hz 1H), 6.06 (dd, J = 16.9, 10.2 Hz, 1H), 5.62 (d, J = 10.3 Hz, 1H), 4.88-4.81 (m, 1H), 4.78 (brs, 1H), 4.23 (dd, J = 9.5, 6.2 Hz, 2H), 3.93 (s, 6H), 3.92-3.81 (m, 9H), 3.81- 3.77 (m, 1H). Example 8.0 8.4 12.1 ¹H NMR (400 MHz, CDCl₃) δ 8.98 (s, 1H), 6.99 (s, 1H), 690 6.64 (s, 1H), 6.55 (d, J = 7.1 Hz, 1H), 6.26 (dd, J = 17.1, 1.3 Hz, 1H), 6.11-6.04 (m, 1H), 6.04 (s, 1H), 5.63 (d, J = 10.2 Hz, 1H), 4.86-4.73 (m, 2H), 4.68 (d, J = 12.8 Hz, 1H), 4.61 (d, J = 12.8 Hz, 1H), 4.29-4.20 (m, 2H), 3.97 (s, 6H), 3.94-3.85 (m, 3H), 3.82 (dd, J = 9.4, 5.0 Hz, 1H), 2.79-2.68 (m, 2H), 1.23 (dd, J = 6.3, 2.2 Hz, 6H). Example 5.6 1.3 2.1 ¹H NMR (400 MHz, CDCl₃) δ 8.99 (s, 1H), 6.99 (s, 1H) 693 6.63 (s, 1H), 6.53 (s, 1H), 6.23 (d, J = 16.9 Hz, 1H), 6.06 (dd, J = 17.0, 10.2 Hz, 1H), 5.94 (s, 1H), 5.60 (d, J = 10.2 Hz, 1H), 4,87-4.77 (m, 2H), 4.39 (d, J = 8.3 Hz, 1H), 4.30 (d, J = 13.2 Hz, 1H), 4.27-4.20 (m, 2H), 3.96 (s, 6H), 3.88 (dd, J = 9.5, 3.5 Hz, 1H), 3.81 (dd, J = 14.4, 5.1 Hz, 1H), 3.51-3.39 (m, 3H), 3.38 (s, 3H), 2.15-2.01 (m, 2H), 1.79-1.74 (m, 2H). Example 4.8 10.0 12.0 ¹H NMR (400 MHz, CDCl₃) δ 9.01 (s, 1H), 6.70 (t, J = 7.9 694 Hz, 1H), 6.22 (d, J = 16.8 Hz, 1H), 6.07 (dd, J = 17.0, 10.2 Hz, 1H), 5.59 (d, J = 10.2 Hz, 1H), 4.86-4.80 (m, 2H), 4.38-4.21 (m, 4H), 3.93 (s, 6H) 3.91-3.82 (m, 2H), 3.52-3.43 (m, 3H), 3.39 (s, 3H), 2.21-2.11 (m, 2H). Example 8.5 17.2 20.2 1H NMR (400 MHz, CDCl₃) δ 8.92 (s, 1H), 6.76 (s, 1H), 704 6.65 (brs, 1H), 6.62 (s, 1H), 6.25 (d, J = 16.9 Hz, 1H), 6.05 (dd, J = 16.8, 10.4 Hz, 1H), 5.61 (d, J = 10.3 Hz, 1H), 4.69 (brs, 1H), 4.55 (brs, 1H), 4.46-4.23 (m, 5H), 4.10-3.99 (m, 2H), 3.95 (s, 6H), 3.74 (d, J = 11.9 Hz, 1H), 3.61 (t, J = 11.8 Hz, 1H), 3.32 (s, 3H), 2.10-1.98 (m, 1H), 1.90- 1.80 (m, 1H). Example 62.7 1917.5 1917.5 ¹H NMR (400 MHz, CDCl₃) δ 10.71 (s, 1H), 9.63 (s, 1H), 715 9.60 (s, 1H), 8.61 (s, 1H), 7.80 (s, 1H), 6.72 (s, 1H), 6.49 (d, J = 16.7 Hz, 1H), 6.40 (dd, J = 16.9, 9.7 Hz, 1H), 5.84 (d-J = 9.7 Hz, 1H), 5.21 (t, J = 6.0 Hz, 2H), 4.00 (s, 7H), 3.89 (t, J = 5.9 Hz, 2H), 3.35 (s, 3H). Example 78.5 338.1 1211.5 ¹H NMR (400 MHz, DMSO-d₆) δ 9.75 (s, 1H), 9.71 (s, 723 1H), 9.68 (s, 1H), 8.37 (s, 1H), 8.21 (s, 1H), 8.05 (s, 1H), 7.15 (s, 1H), 6.51 (dd, J = 17.0, 10.2 Hz, 1H), 6.26 (dd, J = 17.1, 2.2 Hz, 1H), 5.75 (dd, J = 10.1, 2.1 Hz, 1H), 4.56 (t, J = 5.6 Hz, 2H), 4.06 (s, 6H), 3.70 (t, J = 5.6 Hz, 2H), 3.14 (s, 3H), Example 115.0 164 194 ¹H NMR (400 MHz, CDCl₃) δ 8.75 (s, 1H), 7.68 (s, 1H), 730 7.40 (s, 1H), 6.65 (s, 1H), 6.38-6.32 (m, 1H), 6.27-6.21 (m, 1H), 5.73-5.69 (m, 1H), 5.30 (s, 1H), 4.81 (d, J = 5.6 Hz, 2H), 3.96 (s, 6H), 3.78 (s, 3H). Example 990.9 1712 2631 ¹H NMR (400 MHz, CDCl₃) δ 8.82 (s, 1H), 6.68 (s, 1H), 752 6.66 (s, 1H), 6.59 (s, 1H), 6.13 (dd, J = 16.8, 1.4 Hz, 1H), 5.94 (dd, J = 17.0, 10.2 Hz, 1H), 5.51 (dd, J = 10.3, 1.4 Hz, 1H), 5.30 (s, 1H), 4.96-4.82 (m, 1H), 4.42 (s, 1H), 4.26 (dd, J = 9.8, 6.0 Hz, 1H), 4.18 (dd, J = 9.3, 7.4 Hz, 1H), 3.92 (s, 6H), 3.88-3.81 (m, 1H), 3.74 (dd, J = 9.2, 6.9 Hz, 1H), 3.13 (d, J = 4.6 Hz, 3H). Example 19 130 212 ¹H NMR (400 MHz, Methanol-d₄) δ 9.22 (s, 1H), 7.65 (s, 753 1H), 6.94 (s, 1H), 6.19 (dd, J = 17.1, 9.9 Hz, 1H), 6.10 (dd, J = 17.1, 2.2 Hz, 1H), 5.56 (dd, J = 9.9, 2.1 Hz, 1H), 5.01 (s, 2H), 4.29 (s, 1H), 4.17 (dd, J = 9.3, 6.2 Hz, 1H), 3.98 (s, 6H), 3.93-3.85 (m, 1H), 3.85-3.79 (m, 1H). Example 13.6 18.0 54.0 ¹H NMR (400 MHz, CDCl₃) δ 9.06 (d, J = 6.5 Hz, 1H), 754 7.11 (s, 1H), 6.64 (s, 1H), 6.25 (dd, J = 16.9, 1.5 Hz, 1H), 6.05 (dd, J = 17.0, 10.4 Hz, 1H), 5.60 (dd, J = 10.3, 1.5 Hz, 1H), 4.91 (brs, 1H), 4.79 (t, J = 6.5, 1H), 4.59 (q, J = 7.0, 2H), 4.35-4.19 (m, 2H), 3.93-3.68 (m, 2H) 1.48 (t, J = 7.1 Hz, 3H). Example 43.0 NT NT ¹H NMR (400 MHz, CDCl₃) δ 8.84 (s, 1H), 6.84 (s, 1H), 755 6.67 (s, 1H), 6.58-6.49 (m, 3H), 6.30 (d, J = 8.5 Hz, 2H), 6.10 (d, J = 17.0 Hz, 2H), 6.04-5.83 (m, 2H), 5.48 (d, J = 10.1 Hz, 1H), 4.72 (s, 3H), 4.63 (d, J = 14.8 Hz, 1H), 4.17- 4.04 (m, 2H), 3.89 (s, 6H), 3.78 (d, J = 6.2 Hz, 1H), 3.71 (s, 2H), 3.68 (s, 7H). Example 20.2 19 31 ¹H NMR (400 MHz, CDCl₃) δ 9.10 (s, 1H), 7.43 (s, 1H), 756 7.13 (s, 1H), 6.66 (s, 1H), 6.36 (s, 1H), 6.26 (dd, J = 16.9, 1.4 Hz, 1H), 6.04 (dd, J = 16.9, 10.3 Hz, 1H), 5.94 (s, 1H), 5.63 (dd, J = 10.3, 1.4 Hz, 1H), 4.89-4.78 (m, 2H), 4.45 (d, J = 2.8 Hz, 2H), 4.31-4.21 (m, 2H), 3.97 (s, 6H), 3.95- 3.92 (m, 2H), 3.90-3.87 (m, 1H), 3.81 (dd, J = 9.5, 4.8 Hz, 1H), 2.94-2.77 (m, 2H). Example 5.9 5.8 9.2 ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 6.71 (s, 1H), 758 6.62 (s, 1H), 6.42 (s, 1H), 6.20 (d, J = 17.0 Hz, 1H), 6.03- 5.91 (m 2H), 5.56 (d J = 10.3 Hz, 1H), 4.93 (d, J = 7.1 Hz, 1H), 4.81 (s, 1H), 4.67 (s, 1H), 4.41 (s, 1H), 4.25-4.05 (m, 3H), 4.25-4.12 (m, 3H), 3.97-3.80 (m, 10H), 3.68 (s, 3H). Example 5.7 42.2 61.1 ¹H NMR (400 MHz, CDCl₃) δ 8.89 (d, J = 11.1 Hz, 1H), 759 6.69 (s, 1H), 6.61 (s, 1H), 6.35-6.09 (m, 2H), 5.94 (dd, J = 17.0, 10.3 Hz, 1H), 5.59 (d, J = 10.1 Hz, 2H), 5.00 (p, J = 7.5 Hz, 1H), 4.83 (s, 1H), 4.31-4.18 (m, 1H), 4.16 (d, J = 8.1 Hz, 1H), 4.01-3.85 (m, 12H), 3.67 (d, J = 14.5 Hz, 2H). Example 2.9 5.5 6.7 ¹H NMR (400 MHz, CDCl₃) δ 8.86 (d, J = 5.2 Hz, 1H), 760 6.68 (d, J = 10.6 Hz, 1H), 6.61 (s, 1H), 6.42-6.21 (m, 1H), 6.14 (t, J = 18.1 Hz, 1H), 6.00-5.78 (m, 1H), 5.74 (s, 1H), 5.49 (dd, J = 29.1, 10.3 Hz, 1H), 4.91 (t, J = 7.6 Hz, 1H), 4.87-4.78 (m, 1H), 4.52-4.40 (m, 1H), 4.24-4.14 (m, 2H), 4.08 (d, J = 8.7 Hz, 1H), 3.95 (s, 6H), 3.92-3.83 (m, 2H), 3.80-3.70 (m, 2H), 2.03-1.89 (m, 2H), 1.54- 1.43 (m, 3H). Example 14.3 20.7 51.8 ¹H NMR (400 MHz, CDCl₃) δ 9.14 (s, 1H), 8.64 (s, 1H), 761 8.53 (s, 1H), 7.74 (s, 1H), 6.88 (d, J = 2.7 Hz, 1H), 6.61 (d, J = 2.7 Hz, 1H), 6.20 (d J = 16.9 Hz, 1H), 6.01 (s, 1H), 5.56 (d, J = 10.3 Hz, 1H), 5.01-4.91 (m, 2H), 4.32-4.23 (m, 2H), 4.02 (s, 3H), 3.99-3.95 (m, 1H), 3.95 (s, 3H), 3.87 (s, 3H), 3.84-3.82 (m, 1H). Example 5.2 3.2 4.2 ¹H NMR (400 MHz, CDCl₃) δ 8.94 (s, 1H), 6.83 (s, 1H), 762 6.63 (s, 1H), 6.30 (s, 1H), 6.22 (d, J = 17.1 Hz, 1H), 6.04 (dd, J = 16.9, 10.2 Hz, 1H), 5.81 (s, 1H), 5.60 (d, J = 10.2 Hz, 1H), 4.87-4.80 (m, 1H), 4.80-4.73 (m, 1H), 4.70 (d, J = 6.4 Hz, 2H), 4.60 (d, J = 13.8 Hz, 2H), 4.27 (d, J = 13.6 Hz, 1H), 4.23-4.15 (m, 2H), 4.10 (d, J = 13.7 Hz, 1H), 3.96 (s, 6H), 3.86 (dd, J = 9.6, 4.0 Hz, 1H), 3.75 (dd, J = 9.4, 5.8 Hz, 1H), 3.23 (q, J = 7.2 Hz, 1H), 2.08 (d, J = 8.6 Hz, 1H). Example 7.9 7.8 11.1 ¹H NMR (400 MHz, CDCl₃) δ 8.91 (s, 1H), 6.79 (s, 1H), 763 6.63 (s, 1H), 6.25 (dd, J = 23.9, 17.1 Hz, 2H), 5.63 (dd, J = 19.8, 10.3 Hz, 2H) 4.76 (s, 2H) 4.66 (s, 1H), 4.22 (dd, J = 15.1, 7.2 Hz, 3H), 4.4-4.10 (m, 1H), 3.97 (d, J = 2.0 Hz, 8H), 3.85 (d, J = 10.5 Hz, 3H), 3.75 (s, 1H), 2.00 (d, J = 9.2 Hz, 1H), 1.93 (s, 1H). Example 7.0 49.4 60.4 ¹H NMR (400 MHz, CDCl₃) δ 8.78 (s, 1H), 6.84 (brs, 2H), 764 6.76 (s, 1H), 6.58 (t J = 7.9 Hz, 1H), 6.39 (brs, 1H), 6.08 (d J = 16.9 Hz, 1H), 5.93 (dd, J = 17.0, 10.2 Hz, 1H), 5.39 (d, J = 10.2 Hz, 1H), 4.81 (p, J = 6.6, 5.6 Hz, 2H), 4.15- 4.05 (m, 2H), 3.85-3.81 (m, 1H), 3.81 (s, 6H), 3.71 (dd, J = 9.2, 5.8 Hz, 1H), 3.08 (s, 3H). Example 158 420.8 656.5 ¹H NMR (400 MHz, CDCl₃) δ 8.93 (s, 1H), 6.80 (s, 1H), 765 6.64 (s, 1H), 6.23 (d, J = 16.9 Hz, 1H), 6.08-5.91 (m, 4H), 5.75 (s, 1H), 5.58 (d, J = 10.4 Hz, 1H), 4.89 (s, 2H), 4.24 (ddd, J = 23.7, 9.4, 5.9 Hz, 2H), 3.96 (s, 6H), 3.88 (dd, J = 9.8, 3.4 Hz, 1H), 3.76 (dd, J = 9.2, 5.5 Hz, 1H). Example 8.3 19.8 27.9 ¹H NMR (400 MHz, CDCl₃) δ 8.80 (s, 1H), 6.60 (s, 1H), 766 6.54 (s, 1H), 6.33 (brs, 1H), 6.12 (d, J = 16.9 Hz, 1H), 5.96 (dd, J = 17.0, 10.3 Hz, 1H), 5.48 (dd, J = 10.3, 1.4 Hz, 1H), 4.83-4.78 (m, 2H), 4.17-4.06 (m, 2H), 3.84-3.81 (m,1H), 3.71-3.68 (m, 1H). Example 7 23.9 45.1 ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 6.87 (s, 1H), 767 6.68 (t, J = 7.9 Hz, 1H), 6.60 (brs, 1H), 6.22 (s, 1H), 6.17 (s, 1H), 5.96 (dd, J = 16.9, 10.3 Hz, 1H), 5.80 (brs, 1H), 5.56 (d, J = 10.3 Hz, 1H), 4.94-4.83 (m, 2H), 4.30-4.18 (m, 2H), 3.91 (s, 6H), 3.88 (s, 1H), 3.75 (dd, J = 9.3, 5.9 Hz, 1H), 3.65 (s, 2H), 1.36 (t, J = 7.2 Hz, 3H). Example 4 9.9 12.5 ¹H NMR (400 MHz, CDCl₃) δ 8.95 (s, 1H), 7.09 (s, 1H), 768 6.69 (t, J = 7.9 Hz, 1H), 6.26 (dd, J = 17.0, 1.3 Hz, 1H), 6.14 (d, J = 7.4 Hz, 1H), 6.03 (dd, J = 17.0, 10.3 Hz, 1H), 5.75 (d, J = 7.1 Hz, 1H), 5.63 (dd, J = 10.3, 1.3 Hz, 1H), 4.89-4.83 (m, 1H), 4.82-4.72 (m, 5H), 4.23 (dd, J = 9.5, 6.2 Hz, 2H), 3.92 (s, 6H), 3.81 (ddd, J = 19.8, 9.5, 4.8 Hz, 2H). Example 3.7 8.4 10.0 ¹H NMR (400 MHz, CDCl₃) δ 8.94 (s, 1H), 7.04 (s, 1H), 769 6.69 (t, J = 7.8 Hz, 1H), 6.34 (brs, 1H), 6.22 (d, J = 16.9 Hz, 1H), 6.04 (dd, J = 17.1, 10.1 Hz, 1H), 5.60 (d, J = 10.2 Hz, 1H), 4.87-4.70 (m, 4H), 4.63 (d, J = 13.5 Hz, 2H), 4.30 (d, J = 13.6 Hz, 1H), 4.23-4.10 (m, 3H), 3.92 (s, 6H), 3.90-3.85 (m, 1H), 3.79-3.73 (m, 1H), 3.29-3.24 (m, 1H), 2.08-2.01 (m, 2H). Example 2413.9 >10000 >10000 ¹H NMR (400 MHz, CDCl₃) δ 8.90 (s, 1H), 7.78 (t, J = 7.5, 770 1H), 7.31 (s, 1H), 7.17 (t, J = 8.0 Hz, 1H), 6.96 (t, J = 8.0 Hz, 1H), 6.49 (m, 1H), 6.27 (brs, 1H), 6.18 (d, J = 16.9 Hz, 1H), 5.93 (dd, J = 17.0, 10.3 Hz, 1H), 5.84, (brs, 1H), 5.53 (d, J = 10.3 Hz, 1H), 4.91-4.88 (m, 2H), 4.31-4.13 (m, 2H), 3.94 (s, 3H), 3.94-3.88(m, 1H), 3.82-3.70 (m, 1H), 3.21 (t, J = 4.8 Hz, 3H). Example 7.9 25.5 32.3 ¹H NMR (400 MHz, CDCl₃) δ 8.88 (s, 1H), 6.67 (s, 1H), 771 6.63 (s, 1H), 6.22, (brs, 1H), 6.20 (dd, J = 17.0, 1.4 Hz, 1H), 5.97 (dd, J = 17.0, 10.3 Hz, 1H), 5.79 (brs, 1H), 5.55 (dd, J = 10.3, 1.5 Hz, 1H), 4.94-4.86 (m, 2H), 4.26-4.18 (m, 2H), 3.96 (s, 6H), 3.88 (dd, J = 9.8, 3.2 Hz, 1H), 3.81- 3.72 (m, 1H). Example 2.9 6.8 8.1 ¹H NMR (400 MHz, CDCl₃) δ 8.77 (s, 1H), 6.81 (s, 1H), 772 6.59 (s, 1H), 6.57(brs, 1H), 6.14 (d, J = 16.6 Hz, 1H), 5.96 (m, 1H), 5.85 (brs, 1H), 5.53 (d, J = 10.4 Hz, 1H), 4.87- 4.66 (m, 2H), 4.53-4.23 (m, 4H), 4.18-4.08 (m, 2H), 3.83 (s, 6H), 3.82-3.69 (m, 2H), 1.95-1.75 (m, 2H), 1.51 (s, 3H). Example 1.8 2.0 2.3 ¹H NMR (400 MHz, CDCl₃) δ 8.84 (s, 1H), 6.87 (d, J = 5.2 773 Hz, 1H), 6.66 (t, J = 8.1 Hz, 1H), 6.45 (brs, 1H), 6.14 (dd, J = 16.9, 12.4 Hz, 1H), 5.96 (dd, J = 16.9, 10.3 Hz, 1H), 5.82 (brs, 1H), 5.50 (d, J = 20.2, 10.3 Hz, 1H), 4.93-4.85 (m, 1H), 4.84-4.78 (m, 1H), 4.43-4.34 (m, 2H), 4.19-3.77 (m, 5H), 3.90 (s, 6H), 3.72-3.69 (m, 1H), 1.49 (d, J = 23.8 Hz, 3H). Example 3.2 6.9 8.8 ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 6.88 (s, 1H), 774 6.67 (t, J = 7.9 Hz, 1H), 6.52 (brs, 1H), 6.24 (dd, J = 17.0, 1.5 Hz, 1H), 6.08 (dd, J = 17.0, 10.2 Hz, 1H), 5.96 (brs, 1H), 5.61 (dd, J = 10.2, 1.4 Hz, 1H), 4.82-4.72 (m, 2H), 4.57 (brs, 4H), 4.26-4.16 (m, 2H), 3.91 (s, 6H), 3.85 (dd, J = 9.4, 3.9 Hz, 1H), 3.78 (dd, J = 9.4, 5.0 Hz, 1H), 2.42 (p, J = 7.6 Hz, 2H). Example 8.9 20.8 27.8 ¹H NMR (400 MHz, CDCl₃) δ 8.92 (s, 1H), 6.96 (s, 1H), 775 6.69 (t, J = 8.0 Hz, 1H), 6.65 (s, 1H), 6.25 (dd, J = 17.0, 1.4 Hz, 1H), 6.08 (s, 1H), 6.02 (dd, J = 16.9, 10.3 Hz, 1H), 5.60 (dd, J = 10.3, 1.4 Hz, 1H), 4.73 (brs, 1H, 4.56 (brs, 1H), 4.42 (d, J = 8.5 Hz, 1H), 4.39-4.22 (m, 4H), 4.05 (dd, J = 12.0, 4.5 Hz, 1H), 3.99 (d, J = 11.7 Hz, 1H), 3.92 (s, 6H), 3.75 (dd, J = 11.9, 1.6 Hz, 1H), 3.65-3.57 (m, 1H), 3.33 (s, 3H), 2.09-2.02 (m, 1H), 1.91-1.81 (m, 1H). Example 4.9 7.9 9.4 ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 6.92 (s, 1H), 776 6.67 (t, J = 7.9 Hz, 1H), 6.38 (brs, 1H), 6.23 (dd, J = 17.0, 1.4 Hz, 1H), 6.03 (dd, J = 16.9, 10.3 Hz, 1H), 5.80 (brs, 1H), 5.61 (dd, J = 10.3, 1.4 Hz, 1H), 4.86-4.77 (m, 2H), 4.27-4.19 (m, 6H), 3.91 (s, 6H), 3.89-3.86 (m, 1H), 3.76 (dd, J = 9.3, 5.7 Hz, 1H), 3.69-3.66 (m, 4H), 1.86 (t, J = 5.2 Hz, 4H). Example NT 650.8 660 ¹H NMR (400 MHz, CDCl₃) δ 8.80 (s, 1H), 6.86-6.81 (m, 777 3H), 6.45 (brs, 1H), 6.13 (d, J = 16.9 Hz, 1H), 6.06 (brs, 1H), 5.86 (dd J = 16.9 10.3 Hz, 1H), 5.67 (brs, 1H), 5.49 (d, J = 10.4 Hz, 1H), 4.98-4.68 (m, 2H), 4.28-4,07 (m, 2H), 3.84 (s, 3H), 3.84-3.71 (m, 1H), 3.67 (dd, J = 9.2, 6.0 Hz, 1H), 3.08 (d, J = 4.8 Hz, 3H). Example NT 9.5 11.2 ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 6.70 (s, 1H), 778 6.61 (s, 1H), 6.29 (brs, 1H), 6.11 (d, J = 17.1 Hz, 1H), 5.81 (m, 2H), 5.45 (d, J = 10.2 Hz, 1H), 5.07-4.84 (m, 2H), 4.55-4.40 (m, 1H), 4.22-4.15 (m, 2H), 4.05-3.75 (m, 3H), 3.95 (s, 6H), 3.91-3.71 (m, 2H), 2.05-1.96 (m, 2H), 1.44 (s, 3H). Example NT 7.5 8.6 ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 6.70 (s, 1H), 779 6.61 (s, 1H), 6.43 (brs, 1H), 6.11 (d, J = 17.1 Hz, 1H), 5.97 (dd, J = 16.9, 10.3 Hz, 1H,), 5.79 (brs, 1H), 5.45 (d, J = 10.2 Hz, 1H), 5.01-4.75 (m, 2H), 4.55-4.40 (m, 1H), 4.25-4.00 (m, 4H), 3.95 (s, 6H), 3.94-4.80 (m, 2H), 3.79-3.72 (m, 1H), 2.03-1.93 (m, 2H), 1.53 (s, 3H). Example 17.0 38.4 47.6 ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 6.86 (s, 1H), 786 6.68 (t, J = 7.9 Hz, 1H), 6.49 (s, 1H), 6.20 (dd, J = 16.9, 1.3 Hz, 1H), 6.11 (s, 1H), 6.02 (d, J = 8.6 Hz, 1H), 5.88 (dd, J = 17.0, 10.3 Hz 1H) 5.53 (dd, J = 10.4, 1.4 Hz, 1H), 4.73 (d, J = 8.5 Hz, 1H), 4.38-4.26 (m, 1H), 4.08 (d, J = 12.1 Hz, 1H), 3.99 (d, J = 12.1 Hz, 1H), 3.92 (s, 6H), 3.75 (dd, J = 12.0, 1.7 Hz, 1H), 3.61 (m, 1H), 3.13 (s, 3H), 1.91 (m, 2H). Example 45.0 86.0 102.8 ¹H NMR (400 MHz, Methanol-d₄) δ 8.89 (s, 1H), 6.90 (t, 787 J = 8.1 Hz, 1H), 6.81 (s, 1H), 6.13 (dd, J = 17.1, 1.9 Hz, 1H), 5.96 (dd, J = 17.0, 10.3 Hz, 1H), 5.47 (dd, J = 10.2, 1.9 Hz, 1H), 4.24 (dt, J = 12.4, 4.2 Hz, 1H), 4.07 (dd, J = 11.9, 4.4 Hz, 1H), 3.99-3.93 (m, 1H), 3.90 (s, 6H), 3.78 (dd, J = 12.0, 2.0 Hz, 1H), 3.67-3.52 (m, 2H), 3.47-3.33 (m, 1H), 2.06 (qd, J = 12.5, 4.8 Hz, 1H), 1.77-1.66 (m, 1H), 1.46-1.26 (m, 5H). Example 7.8 12.6 15.9 ¹H NMR (400 MHz, CDCl₃) δ 9.02 (s, 1H), 7.24 (s, 1H), 789 7.00 (brs, 1H), 6.70 (t, J = 8.0 Hz, 1H), 6.25 (dd, J = 16.9, 1.3 Hz, 1H), 6.02 (dd, J = 17.0, 10.3 Hz, 1H), 5.57 (d, J = 10.3 Hz, 1H), 4.50-4.30 (m, 2H), 4.19-3.76 (m, 11H), 3.97 (s, 6H), 3.63 (t, J = 10.2 Hz, 1H), 2.32-1.75(m, 2H). Example 8.5 11.4 13.6 ¹H NMR (400 MHz, CDCl₃) δ 8.93 (s, 1H), 6.97 (s, 1H), 790 6.68 (t, J = 7.9 Hz, 1H), 6.24 (dd, J = 17.1, 1.4 Hz, 1H), 6.04 (brs, 1H), 6.01 (dd, J = 16.9, 10.3 Hz, 1H), 5.63- 5.53 (m, 1H), 4.62-4.31 (m, 4H), 4.22-3.95 (m, 4H), 3.92 (s, 6H), 3.78-3.72 (m, 1H), 3.66-3.57 (m, 1H), 3.28 (s, 3H), 1.13-2.05 (m, 1H), 1.90-1.78 (m, 1H), 1.53 (s, 3H). Example 3.7 6.4 8.4 ¹H NMR (400 MHz, CDCl₃) δ 8.97 (s, 1H), 7.10 (s, 1H), 791 6.70 (t, J = 7.9 Hz, 1H), 6.48 (d, J = 7.2 Hz, 1H), 6.27 (dd, J = 17.0, 1.4 Hz, 1H), 6.18-6.08 (m, 1H), 5.98 (dd, J = 16.9, 10.3 Hz, 1H), 5.59 (dd, J = 10.3, 1.3 Hz, 1H), 4.80 (q, J = 12.0 Hz, 2H), 4.68 (q, J = 11.9 Hz, 2H), 4.44 (d, J = 10.0 Hz, 1H), 4.41-4.34 (m, 1H), 4.06 (dd, J = 11.9, 4.6 Hz, 1H), 3.99 (d, J = 11.8 Hz, 1H), 3.92 (s, 6H), 3.76 (dd, J = 11.9, 1.6 Hz, 1H), 3.62 (td, J = 12.0, 2.5 Hz, 1H), 2.02 (s, 1H), 1.92-1.81 (m, 1H). Example 3.1 4.8 6.2 ¹H NMR (400 MHz, CDCl₃) δ 8.91 (s, 1H), 6.92 (s, 1H), 792 6.83 (d, J = 6.8 Hz, 1H), 6.68 (t, J = 7.9 Hz, 1H), 6.26 (dd, J = 16.9, 1.5 Hz, 1H), 6.07 (dd, J = 17.0, 10.2 Hz, 1H), 6.02 (brs, 1H),, 5.61 (dd, J = 10.3, 1.5 Hz, 1H), 4.53 (s, 2H), 4.48-4.36 (m, 3H), 4.35-4.29 (m, 1H), 4.05 (dd, J = 11.9, 4.6 Hz, 1H), 3.99 (d, J = 11.7 Hz, 1H), 3.91 (s, 6H), 3.74 (dd, J = 11.8, 1.6 Hz, 1H), 3.61 (td, J = 12.0, 2.5 Hz, 1H), 2.41-2.32 (m, 2H), 2.12-2.04 (m, 1H), 1.91-1.80 (m, 1H). Example 5.3 7.9 9.9 ¹H NMR (400 MHz, CDCl₃) δ 8.92 (s, 1H), 6.97 (s, 1H), 793 6.67 (t, J = 7.9 Hz, 1H), 6.63 (brs, 1H), 6.23 (dd, J = 17.0, 1.3 Hz, 1H), 6.04 (d, J = 8.8 Hz, 1H), 5.99 (dd, J = 17.1, 10.4 Hz, 1H), 5.57 (dd, J = 10.2, 1.4 Hz, 1H), 4.51-4.39 (m, 3H), 4.38-4.31 (m, 1H), 4.30-4.20 (m, 2H), 4.07- 3.96 (m, 2H), 3.91 (s, 6H), 3.75 (dd, J = 11.8, 1.6 Hz, 1H), 3.65-3.56 (m, 1H), 2.05-1.98 (m, 1H), 1.91-1.80 (m, 1H), 1.56 (s, 3H). Example 4.8 5.5 6.9 ¹H NMR (400 MHz, CDCl₃) δ 8.90 (d, J = 3.0 Hz, 1H), 794 6.93 (d, J = 4.0 Hz, 1H), 6.68 (t, J = 7.9 Hz, 1H), 6.36 (brs, 1H), 6.26-6.15 (m, 1H), 6.05-5.90 (m, 2H), 5.60-5.50 (m, 1H), 4.50-4.30 (m, 2H), 3.92 (s, 6H), 4.23-3.80 (m, 7H), 3.70-3.65 (m, 1H), 3.60-3.55 (m, 1H), 3.34 (d, J = 7.0 Hz, 3H), 2.02-1.90 (m, 2H), 1.87-1.78 (m, 2H). Example 7.5 9.5 11.8 ¹H NMR (400 MHz, CDCl₃) δ 9.00 (s, 1H), 7.20 (s, 1H), 795 6.69 (t, J = 7.9 Hz, 1H), 6.22 (dd, J = 17.0, 1.5 Hz, 1H), 6.02 (dd, J = 17.0, 10.3 Hz, 1H), 5.55 (d, J = 10.8 Hz, 1H), 4.54-4.15 (m, 4H), 4.13-4.00 (m, 2H), 3.93 (s, 6H), 3.77 (d, J = 12.0 Hz, 1H), 3.70-3.57 (m, 1H), 3.52-3.38 (m, 3H), 3.37 (s, 3H), 2.07-1.85 (m, 2H), 1.65-1.46 (m, 4H). Example 23.0 38.0 47.8 ¹H NMR (400 MHz, CDCl₃) δ 8.95 (s, 1H), 7.04 (s, 1H), 796 6.68 (t, J = 7.9 Hz, 1H), 6.25 (s, 1H), 6.20 (dd, J = 17.0, 1.4 Hz, 1H), 6.07 (s, 1H), 5.93 (dd, J = 16.9, 10.3 Hz, 1H), 5.56 (dd, J = 10.2, 1.4 Hz, 1H), 4.71 (d, J = 6.4 Hz, 2H), 4.61 (d, J = 13.6 Hz, 1H), 4.55 (d, J = 13.6 Hz, 1H), 4.45 (d, J = 8.9 Hz, 1H), 4.41-4.34 (m, 1H), 4.17 (d, J = 13.7 Hz, 1H), 4.07 (d, J = 13.5 Hz, 2H), 3.99 (d, J = 11.9 Hz, 1H), 3.92 (s, 6H), 3.73 (d, J = 11.6 Hz, 1H), 3.67-3.64 (m, 1H), 3.59 (td, J = 11.9, 2.6 Hz, 1H), 3.22 (q, J = 7.1 Hz, 1H), 1.97 (d, J = 13.7 Hz, 1H), 1.92-1.81 (m, 1H). BLU-9931 24.7 549 1362 BLU-554  18.0 27 126 Note “NT”, i.e., “Not Tested”, means that the compound is not tested. BLU-9931 and BLU-554 are positive compounds.

It can be seen from the enzymatic activity data of the compounds of specific examples that the compounds of the present invention have a strong inhibitory effect on FGFR4 kinase activity. It can be seen from the cell activity data of the compounds of specific examples that the compounds of the present invention have a strong inhibitory effect on the proliferation activity of HuH-7 cells highly expressing FGFR4.

All documents mentioned in the present application are hereby incorporated by reference in their entirety, just as each document is cited separately as a reference. In addition, it should be understood that various modifications and changes may be made by those skilled in the art after reading the above teachings of the present invention and these equivalent forms also fall within the scope defined by the claims appended hereto. 

1.-22. (canceled)
 23. A method for inhibiting FGFR4 comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (IVa-1), a stereoisomer or pharmaceutically acceptable salt thereof:

wherein Z is

R₂, R₃, R₄ and R₅ are each independently selected from the group consisting of H, deuterium, Cl, F, hydroxyl, methyl, isopropyl, cyclopropyl, 3-oxacyclobutyl, trifluoromethyl, trideuteromethyl and —O—R₁₁, or R₂ and R₄, R₃ and R₅ are taken together with the directly attached carbon atoms to form a 5-8 membered heterocyclyl, the heteroatom is N or O; R₈ is selected from the group consisting of H, deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—P(O)(R₁₀)₂, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁, above groups are further more optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋ ₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁; X₁ is —CH— or N; R₁₀ is selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₁₋₈ haloalkyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, amino, mono-C₁₋₈ alkylamino, di-C₁₋₈ alkylamino and C₁₋₈ alkanoylamino; R₁₁ is selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl and 5-10 membered heteroaryl, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ alkylthio, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₁₋₈ alkylsulfonyl, C₁₋₈ alkylsulfonylamino, amino, mono-C₁₋₈ alkylamino, di-C₁₋₈ alkylamino, ═O or hydroxyl; R₁₂ is selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ alkoxy, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₅₋₁₀ aryloxy and 5-10 membered heteroaryloxy, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ alkylthio, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₁₋₈ alkylsulfonyl, C₁₋₈ alkylsulfonylamino, amino, mono-C₁₋₈ alkylamino, di-C₁₋₈ alkylamino, ═O or hydroxyl; R₁₃ and R₁₄ are each independently selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₁₋₈ alkylsulfonyl and C₁₋₈ alkanoyl, or R₁₃ and R₁₄ are taken together with the directly attached nitrogen atom to form a 4-10 membered heterocyclyl, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ alkylthio, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₁₋₈ alkylsulfonyl, C₁₋₈ alkylsulfonylamino, amino, mono-C₁₋₈ alkylamino, di-C₁₋₈ alkylamino, ═O or hydroxyl; r is 0, 1 or 2; wherein unless otherwise defined, the heterocyclyl is a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur, and the polycyclic cycloalkyl is a spiro, fused or bridged cycloalkyl, and the heteroaryl is a heteroaromatic system containing 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur.
 24. The method of claim 23, wherein R₈ is selected from the group consisting of H, deuterium, halogen, cyano, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—O—R₁₁, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁, above groups are further more optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋ ₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁.
 25. The method of claim 23, wherein the compound is selected from the group consisting of:


26. A method for treating FGFR4 related cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (IVa-1), a stereoisomer or pharmaceutically acceptable salt thereof:

wherein Z is or

R₂, R₃, R₄ and R₅ are each independently selected from the group consisting of H, deuterium, Cl, F, hydroxyl, methyl, isopropyl, cyclopropyl, 3-oxacyclobutyl, trifluoromethyl, trideuteromethyl and —O—R₁₁, or R₂ and R₄, R₃ and R₅ are taken together with the directly attached carbon atoms to form a 5-8 membered heterocyclyl, the heteroatom is N or O; R₈ is selected from the group consisting of H, deuterium, halogen, cyano, nitro, azido, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—S(O)_(r)R₁₀, —C₀₋₈—P(O)(R₁₀)₂, —C₀₋₈—O—R₁₁, —C₀₋₈—C(O)OR₁₁, —C₀₋₈—C(O)R₁₂, —C₀₋₈—O—C(O)R₁₂, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—C(O)NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁, above groups are further more optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋ ₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁; X₁ is —CH— or N; R₁₀ is selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₁₋₈ haloalkyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, amino, mono-C₁₋₈ alkylamino, di-C₁₋₈ alkylamino and C₁₋₈ alkanoylamino; R₁₁ is selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl and 5-10 membered heteroaryl, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ alkylthio, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₁₋₈ alkylsulfonyl, C₁₋₈ alkylsulfonylamino, amino, mono-C₁₋₈ alkylamino, di-C₁₋₈ alkylamino, ═O or hydroxyl; R₁₂ is selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ alkoxy, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₅₋₁₀ aryloxy and 5-10 membered heteroaryloxy, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ alkylthio, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₁₋₈ alkylsulfonyl, C₁₋₈ alkylsulfonylamino, amino, mono-C₁₋₈ alkylamino, di-C₁₋₈ alkylamino, ═O or hydroxyl; R₁₃ and R₁₄ are each independently selected from the group consisting of H, deuterium, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₁₋₈ alkylsulfonyl and C₁₋₈ alkanoyl, or R₁₃ and R₁₄ are taken together with the directly attached nitrogen atom to form a 4-10 membered heterocyclyl, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ alkylthio, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, C₁₋₈ alkylsulfonyl, C₁₋₈ alkylsulfonylamino, amino, mono-C₁₋₈ alkylamino, di-C₁₋₈ alkylamino, ═O or hydroxyl; r is 0, 1 or 2; wherein unless otherwise defined, the heterocyclyl is a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur, and the polycyclic cycloalkyl is a spiro, fused or bridged cycloalkyl, and the heteroaryl is a heteroaromatic system containing 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur.
 27. The method of claim 26, wherein the FGFR4 related cancer is prostate cancer, liver cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma.
 28. The method of claim 26, wherein R₈ is selected from the group consisting of H, deuterium, halogen, cyano, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, 3-10 membered heterocyclyl, C₅₋₁₀ aryl, 5-10 membered heteroaryl, —C₀₋₈—O—R₁₁, —C₀₋₈—NR₁₃R₁₄, —C₀₋₈—N(R₁₃)—C(O)R₁₂ and —C₀₋₈—N(R₁₃)—C(O)OR₁₁, above groups are further optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁, above groups are further more optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₃₋₄ cycloalkyl, 3-8 membered heterocyclyl, C₅₋₈ aryl, 5-8 membered heteroaryl, —C₀₋₄—S(O)_(r)R₁₀, —C₀₋₄—O—R₁₁, —C₀₋₄—C(O)OR₁₁, —C₀₋₄—C(O)R₁₂, —C₀₋₄—O—C(O)R₁₂, —C₀₋₄—NR₁₃R₁₄, —C₀₋ ₄—C(O)NR₁₃R₁₄, —C₀₋₄—N(R₁₃)—C(O)R₁₂ and —C₀₋₄—N(R₁₃)—C(O)OR₁₁.
 29. The method of claim 26, wherein the compound is selected from the group consisting of: 